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Abstract
Asthma is characterized using the spirometry measurement of the forced expiratory volume
in one second (FEV1). Simple and inexpensive, FEV1 provides a global estimate of lung
function but this metric cannot regionally identify airways responsible for airflow
limitation, asthma symptoms or control. Work that brought about an understanding that
airway abnormalities are heterogeneously distributed within the lung in asthma patients
has motivated the development of pulmonary imaging approaches, such as hyperpolarized
helium-3 (3He) and xenon-129 (129Xe) magnetic resonance imaging (MRI). These methods
provide a way to visualize and quantify lung regions accessed by gas during a breath-hold,
as well as those not accessed, referred to as “ventilation defects.” Despite the strong
foundation for the use of MRI in asthma clinical care, clinical translation has been inhibited
in part due to the current limited clinical and physiological understanding of ventilation
defects. Accordingly, our objective was to better understand the structural determinants
and clinical consequences of MRI ventilation defects observed in asthma and to provide a
foundation for imaging to guide clinical decisions and asthma therapy. We evaluated the
effect of gas properties on ventilation defects. In asthmatics, we compared hyperpolarized
3

He and 129Xe MRI before and after bronchodilator administration and showed greater gas

distribution abnormalities using

129

Xe compared to 3He before bronchodilation. The

temporal behavior of asthma ventilation defects was then investigated by generating
personalized temporal-spatial pulmonary function maps from 3He MR images acquired on
three occasions. Persistent and intermittent defects were visualized and quantified using
this tool and were recognized as potential intermediate endpoints or targets for treatment.
We then evaluated clinical and emerging computed tomography-derived airway
morphology measurements in asthmatics with and without defects. Ventilation defects
were observed in two-thirds of well-controlled asthmatics who had worse lung function,
increased airway inflammation, airway hyperresponsiveness and greater airway wall
thickness than asthmatics without ventilation defects. Acknowledging that asthma control
is the primary goal of asthma treatment, we investigated the relationship, and established a
link between worse ventilation and poor control.

These findings provide a better

understanding of asthma ventilation defects and strongly support their potential as a novel
treatment target.
i
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CHAPTER 1
Asthma is a chronic and phenotypically heterogeneous disease of intermittent respiratory
symptoms and airflow limitation triggered by various stimuli, and is characterized by
bronchial hyperresponsiveness and airways inflammation.1,2

1

INTRODUCTION

1.1

Motivation and Overview

Asthma is the most common chronic respiratory disease in Canada, accounting for
approximately 80% of chronic respiratory disease,3 affecting 8.1% or 2.4 million
Canadians in 2014 (Figure 1-1).4

Figure 1-1 Proportion of all respiratory diseases due to specific conditions in Canada.
Adapted from Life and Breath: Respiratory Disease in Canada 2008.5
Asthma is most common during childhood and affects more than 13% of Canadian
children. In 2014, 9.2% of females and 7.0% of males were diagnosed with asthma.4 In
2009, 228 asthma-related deaths were reported in Canada. Internationally, an estimated
300 million people currently have asthma and this is expected to increase to 400 million
by 2025.6 Asthma is estimated to account for one in 250 deaths worldwide.6 Due to its
high prevalence, asthma has an enormous economic and healthcare burden for the patient
and society, with high rates of healthcare resource utilization that vary widely with respect
to age and disease severity. Asthma is also a major cause of hospitalization and repeat
hospitalization in Canada (Figure 1-2). Annually, the number of patients hospitalized for
asthma is comparable to hospitalization due to chronic obstructive pulmonary disease
1

(COPD) and angina.7

However, in contrast to COPD and angina, asthma-related

hospitalizations are much more common under the age of 19, accounting for approximately
65% of all asthma admissions.7 Asthma was a contributing factor in approximately 10%
of hospital admissions for children under the age of 5 and 8% for those aged 5 to 14 years.5
In 1990, the estimated cost for asthma in Canada was $504 to $648 million, of which $306
million were direct costs.8 A study by Ismalia and colleagues indicated that the annual
direct cost per asthma patient in Canada ranges from $366 to $647.9

Figure 1-2 Repeat hospitalizations and hospitalization cases by age and condition in
Canada.
The left plot shows the number of patients with a single hospitalization, one repeat
hospitalization and two or more repeat hospitalization by condition at first admission. The
right plot shows the distribution of hospitalization cases by condition and age. Adapted
from the Canadian Institute for Health Information’s (CIHI) publication entitled Health
Indicators 2008.7
Despite decades of active research and the staggering societal burden of asthma described
above, the mechanism of disease and its distribution within the asthmatic lung are still not
fully understood. Imaging and post-mortem evidence allude to the possibility that airway
abnormalities in asthma are heterogeneously distributed within the lung.

Currently,

however, airways disease worsening and response to therapy in asthma are commonly
evaluated using the forced expiratory volume in one second (FEV1) – a simple and
inexpensive measurement of airflow obstruction. As a result, current and newly-developed
asthma therapies are mainly directed towards improvements in FEV1, but it is well-known
that this global measurement does not capture the regional heterogeneity of airway
abnormalities that may be responsible for asthma control and future risk of exacerbations
2

and lung function decline. In other words, using current clinical tools, there is no way to
measure regional lung abnormalities in asthma, making it difficult if not impossible to
develop, test and guide regional asthma therapies. Satisfying the uncertain notion that all
airways in asthma are equally abnormal and exhibit the same temporal behavior, current
therapies are geared to all airways.
Pulmonary functional magnetic resonance imaging (MRI), using inhaled helium-3 (3He)
and xenon-129 (129Xe) gas, provides a way to quantify gas distribution in vivo and it has
the advantage that it shows exactly where functional abnormalities, termed “ventilation
defects,” are located in the asthmatic lung. In spite of this potential, medical imaging has
played a very limited role in asthma research, treatment development and patient care, and
for a variety of reasons, the numerous advantages of imaging have not been translated to
clinical use. Regardless of the gas used for imaging, the exact etiology of ventilation
defects in asthma is poorly understood. A clear understanding of ventilation defects is
absolutely necessary prior to the clinical translation of hyperpolarized gas imaging
methods. Armed with such an understanding, there is the potential to use functional MRI
to guide asthma treatment, predict treatment outcomes, identify new treatment targets and
better understand the asthmatic lung regionally and its response to asthma treatment. With
the challenges impeding clinical translation in mind, the overarching objective of this thesis
was to better understand the underlying structural determinants and clinical consequences
of MRI ventilation defects observed in asthma and to provide a foundation for imaging to
guide clinical decisions and asthma therapy.
In this Chapter, the relevant background knowledge necessary to understand and motivate
the original research presented in Chapters 2 to 5 will be summarized. It will begin with a
general overview of the respiratory system’s structural and functional responsibilities (1.2)
before focusing on the pathophysiology and underlying disease mechanisms of asthma
(1.3).

Subsequently, standard clinical measurements of asthma (1.4), diagnosis and

classification schemas (1.5) and standard of care treatment regimens (1.6) will all be
introduced. The benefits and limitations of currently available imaging techniques will be
discussed with respect to their influence on better understanding the asthmatic lung and
contribution of imaging biomarkers that can be used to guide asthma treatment (1.7).
Finally, the specific hypotheses and objectives of this thesis will be introduced (1.8).
3

1.2

The Respiratory System: Structure and Function

Similar to all organ systems, the functions of the respiratory system are multifaceted and
range from protection against inhaled pathogens to gas exchange. While the respiratory
system includes the oral and nasal cavities, the lungs, the airways and the muscles
responsible for facilitating breathing, here I will elaborate on the structure and function of
the airways and the alveoli. The airways are a pipeline which connect the external
environment with the alveoli where gas exchange can occur across the blood-gas interface.
By the process of ventilation, the main function of the airways and the alveoli is to deliver
oxygen and remove carbon dioxide from the blood to maintain normal partial pressure of
oxygen and carbon dioxide levels in the arterial blood.

1.2.1

The Airways: Conducting and Respiratory Zones

Inhaled air enters the respiratory system via the nasal or oral passages which converge on
the pharynx followed by the larynx. Beyond the upper airways, as shown in Figure 1-3,
the lower airways are divided into the conducting zone and the respiratory zone based on
their structural and functional characteristics. The conducting zone is responsible for
carrying inhaled air to the respiratory zone where gas exchange can occur.
Conducting Zone
The conducting zone consists of the first sixteen airway generations, beginning with the
trachea (generation zero) and ending with the terminal bronchioles (generation 16).10 It is
important to emphasize that conducting zone airways do not directly participate in gas
exchange, but instead their sole function is to conduct and humidify air. Due to its function,
this zone is considered anatomic deadspace - approximately 150 mL of air resides here.10
The trachea is a long, cartilaginous and muscular conduit that follows the larynx that
directly supplies air to lungs and bifurcates asymmetrically into the left and right main
bronchi that supply the left and right lung respectively. Subsequently, the main bronchi
divide into the lobar bronchi that supply the five lobes of the lung, three of which are in
the right lung (upper, middle and lower) and two of which are in the left lung (upper and
lower). The lobar bronchi then divide into the segmental bronchi that supply air to their
corresponding bronchopulmonary segment that is structurally and functionally
independent. Bronchi are not individually named distal to the segmental bronchi where
4

they become narrower, shorter and more numerous as they branch dichotomously to reach
all areas of the lung. Secondary lobules or lung sub-segments are supplied by the small
bronchi. It is at this point where important structural changes occur. Beyond the small
bronchi, the air passages no longer contain cartilage but become embedded in the lung
parenchyma for structural support. Terminal bronchioles are the smallest category of air
passages without alveoli and are the final conduit of the conducting zone.

Figure 1-3 Characteristics of the air passages.
Adapted from Lumb A. Nunn’s Applied Respiratory Physiology, Fifth edition.11
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Respiratory Zone
The respiratory zone is the last seven generations (generations 17-23) of the airway tree.10
In contrast to the conducting zone, the air passages of the respiratory zone contain alveoli
which facilitate gas exchange. As shown in Figure 1-3, the respiratory bronchioles begin
the respiratory zone and have an increasing number of alveoli budding from their muscular
walls before giving rise to the alveolar ducts which precede the alveolar sacs that are
completely lined with alveoli. A pulmonary acinus is considered a single anatomical unit
consisting of a terminal bronchiole and its subsequent respiratory bronchioles, alveolar
ducts and sacs.

The average human lung contains 30,000 acini,12 each containing

approximately 10,000 alveoli which together make up most of the lung volume, ranging
from approximately 2.5 to 3 L at rest.10

1.2.2

Site of Gas Exchange: The Alveoli

The alveoli are the site of gas exchange and are the terminal ends of the airway tree found
on the respiratory bronchioles, alveolar ducts and alveolar sacs. It has been estimated that
480 million (range: 274-790 million) alveoli exist in the average human lung and that the
average size of a single alveolus is 4.2x106 µm3 (range: 3.3-4.8 µm3) or 200 µm in
diameter.13 The blood-gas interface of the alveoli is comprised of two layers: the alveolar
epithelium and the capillary endothelium, which facilitates the movement of oxygen and
carbon dioxide between the alveolar airspace and capillary plasma. This interface is
extremely thin (0.2-0.3 µm) with a large surface area (50-100 m2), making it well-suited
for efficient exchange of oxygen and carbon dioxide by passive diffusion, according to the
principles of Fick’s law.

1.2.3

Ventilation

Gas reaches the blood-gas interface by the process of ventilation, which is the exchange of
air between the external environment and the alveoli by bulk flow.10 During ventilation,
air flows because of pressure gradients that exist between the atmosphere and alveoli.
Inspiration occurs when the inspiratory muscles actively contract and alveolar pressure
decreases; whereas expiration occurs when the inspiratory muscles passively relax and
alveolar pressure increases. The total amount of air that enters the lungs and resides in the
6

conducting and respiratory zones upon inspiration is termed tidal volume (VT) and is
approximately 0.5 L. As shown in Equation 1-1, total ventilation is the total volume of
air leaving the lungs each minute and is calculated as the ventilation rate multiplied by VT.
Equation 1-1
Total ventilation [L/minute] = Ventilation rate × VT
As discussed above, with each exhalation, approximately 0.15 L of “stale” air from the
respiratory zone remains in the conducting airways and is first to commute back to the
alveoli upon subsequent inspiration. As shown in Equation 1-2, alveolar ventilation
represents the amount of “fresh” air that reaches the alveoli to participate in gas exchange
and it is therefore used to more accurately quantify ventilation efficiency by taking into
account the dead space volume (VD).
Equation 1-2
Alveolar ventilation [L/minute] = Ventilation rate × (VT − VD )
For a healthy adult, the ventilation rate, VT and VD are 12-20 breaths/minute, 0.5 L and
0.15 L respectively.14 At 15 breaths/minute, the total ventilation is 7.50 L/minute and the
alveolar ventilation is 5.25 L/minute. This means that although 7.5 L of fresh air enters
the respiratory system, only 5.25 L actually reach the alveoli.

1.3 Pathophysiology of Asthma
The word “asthma” originated from the Greek word aazein, meaning “to breathe with open
mouth or to pant” generalizing that any patient experiencing dyspnea was asthmatic.15
Given that asthma is as old as antiquity, it is not surprising that the definition and our
understanding of the disease has evolved significantly from initial accounts as evidenced
by the quotes below. Today, with nearly 300 million asthmatics globally, confusion and
controversy continue to surround the definition of asthma.16
“Asthma is the inability to breathe without making noise.”
Aulus Cornelius, 1st Century BC
“If from running, gymnastic exercises, or any other work, the breathing becomes difficult,
it is called Asthma.”
Aretaeus the Cappodocian, 2nd Century AD

7

“Asthma is paroxysmal dyspnea of a peculiar character, generally periodic, with intervals
of healthy respiration between attacks.”
Henry Hyde Salter, 1860
“Asthma is a special form of inflammation of the small bronchioles.”
Sir William Osler, 1892
“Asthma is a disease characterized by an increased responsiveness of the trachea and
bronchi to various stimuli and manifested by widespread narrowing of the airways that
changes in severity either spontaneously or as a result of therapy.
American Thoracic Society, 1962

1.3.1

Definition of Asthma

In the 2015 Global Initiative for Asthma (GINA) report, the Global Strategy for Asthma
Management and Prevention,1 asthma is defined as: “A heterogeneous disease usually
characterized by chronic airway inflammation. It is defined by a history of respiratory
symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over
time and in intensity, together with variable expiratory airflow limitation.” This definition
consists of four components: symptoms, variable airflow obstruction, airway
hyperresponsiveness and airway inflammation.17 As described in the literature, this
relatively broad and non-specific definition encompasses many different asthma
phenotypes identified according to environmental triggers, inflammatory processes and
clinical features. In a recent review highlighting the heterogeneity of asthma, common
clinical phenotypes were classified as trigger-induced phenotypes (occupational asthma,
cigarette smoke induced asthma, air pollution induced asthma and exercise induced
asthma), symptom-based phenotypes (exacerbation-prone, persistent airflow limitation,
cough-variant, adult-onset and the obese asthma) and biomarker-based phenotypes
(eosinophilic and neutrophilic asthma).18

Phenotyping of asthma is becoming more

important than ever due to the development of targeted and phenotype specific approaches
to asthma therapy.

1.3.2

Causes and Risk

There is no single gene or environmental exposure that causes asthma,19 although the onset
most commonly begins in childhood.

Instead, it is widely accepted that host and

environmental factors interact to cause asthma.19 Unfortunately this interplay is complex
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and poorly understood. Numerous host factors have been identified that influence the risk
of asthma; these include genetic polymorphisms,20,21 family history of asthma,22 sex,23
race24 and obesity.25 Similarly, numerous environmental factors have been identified that
influence the risk of asthma; these include aeroallergen sensitization,26 respiratory
viruses,27,28 early life microbial exposures,29,30 cigarette smoke,31 air pollution,32 vitamin D
deficiency,33 antioxidants34 and stress.35

1.3.3

The Asthmatic Lung

Asthma is considered a chronic disorder that is confined to the airways and involves a
complex interaction of airflow obstruction, airway hyperresponsiveness and inflammation
that results in symptoms.2 As shown in Figure 1-4, as compared to a healthy airway, the
airway lumen of an asthmatic is narrowed and obstructed, restricting airflow into and out
of the lungs. Characteristic structural abnormalities throughout the airway walls of
asthmatics include goblet cell hyperplasia,36 subepithelial layer thickening,37 smooth
muscle hyperplasia and hypertrophy,38 submucosal gland hyperplasia and hypersecretion39
and angiogenesis.40

Together, these structural abnormalities, in conjunction with

inflammatory changes, lead to bronchial thickening and edema as well as increased mucus
production and bronchoconstriction, all of which contribute to the airflow obstruction
typically found in asthma. The mechanisms that are responsible for airflow obstruction in
asthma include bronchoconstriction by airway smooth muscle; luminal obstruction by
mucus and debris; and inflammation and remodeling of the airway wall.
Bronchoconstriction occurs due to smooth muscle contraction, which results in a reduction
in airway caliber by epithelial folding, ultimately increasing airflow resistance.
Bronchoconstriction may occur in response to various stimuli that include allergens or
irritants such as exercise and cold air. Airway hyperresponsiveness is an “exaggerated”
bronchoconstrictor response to various stimuli such as those mentioned above. While
airways throughout the bronchial tree can be involved, the magnitude of airway narrowing
and resultant airflow obstruction is temporally intermittent but may become persistent.41
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Figure 1-4 Airway pathology in a healthy and an asthmatic airway.
Histological (sectioned and stained using Movat’s pentachrome stain) and corresponding
schematic representation of airway structures in healthy and asthmatic airways. The
asthmatic airway has structural remodeling, including goblet cell hyperplasia, subepithelial
fibrosis and increased smooth muscle.
Adapted from JV Fahy Nature Reviews 2015.42
Airway inflammation has a fundamental role in the pathophysiology of asthma and
involves the interaction of many cell types and mediators.

Although the cellular

mechanisms behind airway inflammation are beyond the scope of this thesis, important
inflammatory cells include lymphocytes, mast cells, eosinophils, neutrophils, dendritic
cells, macrophages and epithelial cells. Additionally, important inflammatory mediators
include chemokines, cytokines, cysteinyl-leukotrienes and nitric oxide. Immunoglobulin
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E (IgE) is the antibody responsible for activation of allergic reactions and is important in
the development of persistent inflammation.

1.4 Clinical Measurements of Asthma
Clinical measurements of asthma play an important role in diagnosis, categorizing disease
severity and evaluating the effectiveness of medications to manage disease. Currently, no
single clinical tool can be used to adequately diagnose and manage asthma. Instead, an
integrated approach is employed which combines objective measurements of pulmonary
function, bronchial responsiveness, airway inflammation and subjective symptom and
quality-of-life questionnaires.

1.4.1

Global Measurements of Pulmonary Function

In a physician’s office and hospital pulmonary function laboratory, various aspects of lung
function can be evaluated by performing cost-effective pulmonary function testing. Global
spirometry measurements and lung volumes play an important role in the diagnosis and
management of asthma. It is important to acknowledge that pulmonary function tests are
dependent on patient effort, limiting their use in children and cognitively impaired
populations. With appropriate coaching by a trained pulmonary function technologist, the
majority of patients can perform adequate pulmonary function manoeuvres for which
acceptability and reproducibility criteria have been published.

1.4.1.1 Spirometry
Spirometry, the gold standard measurement of lung function, is an important diagnostic
and disease monitoring test that measures volume and flow of air during inhalation and
exhalation manoeuvres. As shown in Figure 1-5, spirometry is often performed using a
hand-held spirometer (Figure 1-5A) and the most commonly performed manoeuvre is the
forced exhalation manoeuvre (Figure 1-5B). This is performed by having a participant
breathe normally and then inspire fully, filling their lungs completely, followed by a hard
and fast forced exhalation. It is important that the participant exhale as hard and as fast as
they can and that they continue exhaling until they cannot expel any more air. At this point,
the end of test criteria has been met. The duration of exhalation may extend well beyond
15 seconds, depending on the severity of the participants airflow obstruction. The most
11

widely reported indices derived from the forced exhalation manoeuvre are the forced vital
capacity (FVC), the FEV1 and the ratio of FEV1 to FVC (FEV1/FVC). As shown in Figure
1-5B, FVC is a measure of the total volume of air that can be forcefully exhaled from full
inspiration, whereas FEV1 is a measure of the maximum volume of air that can be forcefully
exhaled in the first second of the manoeuvre. Both FVC and FEV1 are measured in litres
and are also commonly expressed as a percentage of the reference value based on the
patient’s age, height, sex and ethnicity. Extensive spirometry standardization criteria have
been compiled by the ATS/ERS Task Force and are now widely applied.43

Figure 1-5 Handheld spirometer and typical volume-time spirogram tracing.
FEV1=forced expiratory volume in one second; FVC=forced vital capacity.

1.4.1.2 Lung Volumes and Capacities
Static lung volumes and capacities are identified on a typical volume-time spirogram
tracing as shown in Figure 1-6B. While the majority of these can be directly measured by
spirometry (tidal volume (TV), inspiratory reserve volume (IRV), expiratory reserve
volume (ERV), vital capacity (VC) and inspiratory capacity (IC)), this tes0t cannot
determine the functional residual capacity (FRC), residual volume (RV) or total lung
capacity (TLC). All lung volumes are defined as follows: TV is the volume of gas
exchanged at mouth during a normal inhalation or exhalation during tidal breathing; IRV
is the volume of gas that can be inhaled from the end of a normal inhalation during tidal
12

breathing; ERV is the volume of gas that can be exhaled from the end of a normal
exhalation during tidal breathing; VC is the volume of gas exchanged at the mouth between
a full inspiration and full exhalation; IC is the volume of gas that can be inhaled from the
end of a normal exhalation while tidal breathing; FRC is the volume of gas remaining in
the lungs at the end of a normal exhalation while tidal breathing; RV is the volume of gas
remaining in the lungs at the end of a full exhalation; and TLC is the volume of gas in the
lungs at the end of a full inhalation.
As previously alluded to, alternative nitrogen washout, gas dilution or body
plethysmography techniques are required to measure FRC, from which RV and TLC can
subsequently be derived by performing “linked” spirometry manoeuvres.44 As shown in
Figure 1-6A, a body plethysmograph is an airtight chamber that can accommodate the
patient comfortably inside. Briefly, the linked manoeuvre is performed by having the
participant breathe normally and then perform a series of gentle pants against a closed
shutter initiated at FRC. After sufficient panting has been achieved the shutter will open
and the participant can then resume tidal breathing followed by a full inhalation and slow
full exhalation from which ERV and IVC can be measured. FRC is obtained by applying
the principles of Boyle’s law relating pressure and volume in an isothermal environment.44
RV can then be calculated as FRC minus ERV, and TLC can be calculated as the sum of
FRC and IC.
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Figure 1-6 Body plethysmograph and typical volume-time spirogram tracing identifying
lung volumes.
TV=tidal volume; IRV=inspiratory reserve volume; ERV=expiratory reserve volume;
VC=vital capacity; IC=inspiratory capacity; FRC=functional residual capacity;
RV=residual volume; TLC=total lung capacity.

1.4.1.3 Airway Resistance
Airway resistance (Raw) is a measure of the resistance to flow within the airways and is
defined in Equation 1-3 as the ratio of the driving force of airflow (difference in alveolar
and mouth pressure) to the flow rate (measured at the mouth) and can be quantified using
several techniques. Raw is influenced by resistance in the mouth, pharynx, larynx, large
airways and small airways11 and is most commonly indirectly quantified using whole body
plethysmography.45 Raw can be derived from the specific airway resistance (sRaw) and
FRC as shown in Equation 1-4, both of which can be directly measured using
plethysmography. sRaw is a corrected index that describes airway resistance regardless of
lung volume.46 Following open shutter panting, the inverse slope of the plot of flow rate
versus box pressure is sRaw.

In healthy adults, Raw typically falls within 0.6-2.4

cmH2O·s·L-1.47 Both Raw and sRaw are increased in the presence of inflammation, mucus
secretion, and bronchoconstriction.47
Equation 1-3
Airway resistance (Raw) [cmH2 O·s·L-1]=

Alveolar pressure - Mouth pressure [cmH2 O]
Flow rate (V̇ ) [L·s-1]
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Equation 1-4
Airway resistance (Raw) [cmH2 O·s·L-1]=

Specific airway resistance (sRaw) [cmH2 O·s]
Functional residual capacity (FRC) [L]

1.4.1.4 Inert Gas Washout
Single-breath48 and multiple-breath49 inert gas washout techniques (SBW and MBW,
respectively) were first employed more than 65 years ago to measure lung volumes and
ventilation heterogeneity. Although both tests are relatively simple, the MBW test is more
informative and has been more commonly used. MBW involves measuring the washout
concentration of an inert tracer gas from the lungs during normal tidal breathing. The tracer
gas can be endogenous, such as nitrogen (N2), and washed-out of lungs by breathing 100%
oxygen. Alternatively, if the tracer gas is exogenous, such as sulfur hexafluoride (SF6) or
helium (He), it must be washed-in prior to being washed out of the lung by breathing room
air. As shown in Figure 1-7, with each tidal breath of the washout phase, there is a decrease
in the concentration of the exhaled tracer gas (N2 in this example) and when the gas
concentration has decreased to 1/40th of the starting concentration, the test is complete.
The manoeuvre is generally completed with the participant sitting upright and breathing
through a mouthpiece while wearing nose clips.

Figure 1-7 Example of a typical inert gas washout machine and inert gas multiple breath
washout tracing.
The MBW tracings display tidal volume (lower plot) and the corresponding nitrogen gas
(N2) concentration (upper plot). With each breath there is a decrease in the peak expiratory
N2 concentration.
15

The most commonly reported MBW derived measurement is the lung clearance index
(LCI), which is thought to be representative of whole lung ventilation heterogeneity.50 LCI
is the number of FRC lung turnovers needed to clear the lungs of the inert marker gas and
it is calculated as the cumulative expired gas volume (CEV) divided by FRC.51 Additional
metrics that reflect ventilation heterogeneity in the conductive and acinar lung zones
(Scond and Sacin, respectively) can be derived using sophisticated phase III slope analysis
of the MBW tracing.52 Additional outcomes include FRC, trapped gas volume and closing
capacity.
Inert gas washout measurements are becoming particularly attractive due to their feasibility
in the pediatric population53,54 and increased sensitivity to early disease changes55,56 while
offering complementary information to standard pulmonary function tests. Taken together,
MBW indices of ventilation heterogeneity in asthmatics are elevated in comparison to
healthy controls;57-59 are independent determinants of airway hyperresponsiveness;60
improve with bronchodilation57,61 and inhaled corticosteroids;62,63 and worsen during
exacerbations.64 Unfortunately, these measurements cannot regionally localize the site of
functional abnormalities.

1.4.2

Bronchial Responsiveness

Reversibility of airflow obstruction and bronchial hyperresponsiveness are features of
asthma airway pathophysiology that can be objectively evaluated. The assessment of these
disease characteristics are important for diagnosing asthma, categorizing disease severity
and evaluating the effectiveness of asthma medications to manage disease.

1.4.2.1 Assessing Bronchodilator Reversibility
Evidence of reversible airflow obstruction is a key consideration when establishing a
diagnosis of asthma. The primary objective of reversibility testing is to determine whether
a participant’s lung function is improved following bronchodilation, assessed by
performing spirometry pre- and post-bronchodilator administration. Baseline spirometry
is performed after the participant has withheld their medications for an appropriate duration
as advised by the ATS/ERS Task Force.43 Subsequently, an inhaled short-acting betaagonist (four 100μg doses of albuterol/salbutamol) is delivered to the participant prior to
performing post-bronchodilator spirometry 15 minutes later. Reversibility is commonly
16

expressed as the absolute change in FEV1 and FVC or as a percent of the pre-bronchodilator
value, as shown in Equation 1-5. It is generally accepted that a clinically-relevant positive
bronchodilator response is warranted when the post-bronchodilator increase in FVC and/or
FEV1 is ≥ 12% and 200mL from baseline.65
Equation 1-5
(Post-bronchodilator value) − (Pre-bronchodilator value)
% reversibility= [
] × 100
(Pre-bronchodilator value)

1.4.2.2 Assessing Airway Hyperresponsiveness
In addition to bronchodilator reversibility, airway hyperresponsiveness is another defining
characteristic of asthma.66 Methacholine and exercise challenge testing are two of the most
widely used methods to assess airway hyperresponsiveness for which standardized
guidelines have been published.67
Methacholine Challenge
Methacholine induces bronchoconstriction by acting on airway smooth muscle receptors.
Similar to reversibility testing, a methacholine test (MCT) should be performed after the
participant has withheld their medications for an appropriate duration as advised by ATS
guidelines.67

Aerosolized methacholine is inhaled through a nebulizer and the MCT is

completed according to the established two-minute tidal breathing or five-breath dosimeter
protocol described in detail by ATS.67 Briefly, baseline spirometry is first performed to
assess pre-MCT FEV1 and subsequently the diluent or first dose of methacholine
(0.03mg/mL) is administered. After the nebulization has been completed, spirometry is
repeated. If FEV1 has not declined by 20%, the next highest concentration of methacholine
should be delivered.

This procedure is repeated with increasing concentrations of

methacholine until FEV1 has declined by more than 20% of baseline or until the highest
concentration of methacholine (16mg/mL) has been reached.
The primary outcome measure for the MCT is the provocative concentration of
methacholine that causes a 20% decrease in FEV1 (PC20), from which the degree of airway
hyperresponsiveness can be interpreted clinically. Calculated according to Equation 1-6,
PC20 ≥16mg/mL is indicative of normal airway hyperresponsiveness, whereas a PC20
17

≤4mg/mL is indicative of abnormal airway hyperresponsiveness.67 Intermediate values (<
16 and >4 mg/mL) indicate borderline airway hyperresponsiveness and should be
interpreted with caution.67
Equation 1-6
PC20 [mg/mL]=antilog [logC1 +

(logC2 -logC1 )(20-R1 )
]
R2 -R1

C1 = second-to-last methacholine concentration; C2 = last methacholine concentration;
R1 = percent fall in FEV1 after C1; R2 = percent fall in FEV1 after C2.

Exercise Challenge
Exercise induces bronchoconstriction in approximately 80% of asthmatics.68 In contrast
to methacholine, exercise is an indirect activator of smooth muscle constriction induced by
airway dehydration and subsequent mediator release.69 Exercise challenge testing is
preferentially performed using a treadmill or cycle ergometer as described in detail by
ATS, although the protocols are not well standardized or uniformly implemented.67
Briefly, 6-8 minutes of exercise (4-6 minutes at a pre-determined target intensity) should
be completed while breathing cool (<25ºC) dry air. The primary outcome measure for an
exercise challenge is FEV1. A post-exercise decreased in FEV1 >10% is considered
abnormal and a decrease >15% is indicative of exercise-induced bronchoconstriction.

1.4.3
1.4.3.1

Inflammation
FeNO

Nitric oxide (NO) is produced in the lungs and can be detected in the exhaled breath of
humans, as first described in 1991.70 Although the exact pathophysiological role of NO in
the lung is complex and poorly understood, its production increases in the presence of
inflammation.71 The relationship between NO and eosinophilic airway inflammation has
been extensively studied and has been correlated with blood eosinophils and eosinophils
present in induced sputum, bronchoalveolar lavage and biopsies.72-77 Fractional exhaled
nitric oxide (FeNO) is a well-established, simple, noninvasive and highly reproducible
quantitative biomarker of eosinophilic airway inflammation that is ideally suited for serial
monitoring of patients with airways disease.
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Among the most important clinical

applications of FeNO are its ability to aid in the diagnosis of eosinophilic asthma and to
predict corticosteroids-responsiveness. Asthmatics have higher levels of NO in their
exhaled breath as compared to healthy controls.78,79 Although not all asthmatics have
eosinophilic inflammation, those who do tend to have elevated FeNO levels and are much
more likely to benefit from inhaled corticosteroid (ICS) therapy than those with normal
FeNO levels.80 According to the 2011 ATS recommendations, FeNO < 25 ppb indicates
that eosinophilic inflammation and responsiveness to corticosteroids are unlikely, whereas
FeNO > 50 ppb indicates that eosinophilic inflammation and responsiveness to
corticosteroids is likely.81 Intermediate values (≥ 25 and ≤ 50 ppb) should be interpreted
with caution. Currently, a clinically important difference in FeNO levels has not been
determined. Standardized for clinical use, ATS/ERS guidelines for the measurement of
FeNO have been published.82,83

1.4.4

Validated Questionnaires

1.4.4.1 Asthma Control Questionnaire
The Asthma Control Questionnaire (ACQ)84 was designed to measure asthma control and
the change in asthma control over time or in response to treatment. It has been widely
adopted as a clinical trial endpoint.85-87 The questionnaire evaluates control during the
previous week and contains five symptom-related questions (night awakenings by
symptoms, symptoms on waking, activity limitation, dyspnea and wheeze), prebronchodilator FEV1%pred and daily rescue bronchodilator use, each scored on a sevenpoint scale. The ACQ score is calculated as the mean of five, six or seven questions to
generate the ACQ-5 score (pre-bronchodilator FEV1%pred and daily rescue bronchodilator
use omitted), ACQ-6 score (pre-bronchodilator FEV1%pred omitted) and ACQ-7 score
respectively. Scores range from zero (totally controlled) to six (severely uncontrolled).
Asthmatics whose score ranges from 0.0 to 0.75 are considered well-controlled and those
whose score is >1.5 are poorly-controlled.88 The cross-over point between well-controlled
and poorly-controlled asthma is near 1.0, therefore asthmatics whose score ranges from
0.75 to 1.5 fall into a ‘grey zone’ and should be interpreted with caution.88 The minimum
clinically-important difference is 0.5.89

19

In addition to the ACQ, there are numerous additional questionnaires used to evaluate
asthma control. Some of the more common questionnaires are the Asthma Control Test
(ACT), the Asthma Control Scoring System (ACSS), the Asthma Therapy Assessment
Questionnaire (ATAQ), the 30-Second Asthma Test and Lara Asthma Symptom Scale
(LASS).

1.4.4.2 Standardized Asthma Quality of Life Questionnaire
The Standardized Asthma Quality-of-Life Questionnaire (AQLQ(S))90 was designed to
measure asthma-related quality-of-life. The questionnaire evaluates quality-of-life during
the previous two weeks and consists of 32 questions encompassing four subscore domains
(12 questions on symptoms; 11 questions on activity limitation; 5 questions on emotional
function and 4 questions on exposure to environmental stimuli). A range of matters are
assessed including activity limitation, amount of discomfort due to chest tightness, concern
about having asthma, fear of not having access to asthma medication and symptoms from
exposure to cigarette smoke. Four different seven-point Likert-type response scales are
used, ranging from one (totally limited/a very great deal/all of the time/severely limited,
most not done) to seven (not at all limited/none/none of the time/not limited, have done
all). The AQLQ total score is calculated as the mean of all 32 questions and the domain
subscores are the mean of the questions in the domain. The minimum clinically-important
difference is 0.5,91 although the validity of this threshold is still being discussed.
Importantly, the AQLQ(S) has been widely adopted as a clinical trial endpoint.92
The AQLQ preceded the AQLQ(S) and there are now additional variations including the
Mini Asthma Quality of Life Questionnaire (Mini AQLQ) and Acute Asthma Quality of
Life Questionnaire (Acute AQLQ). In addition to the various AQLQ instruments, there
are numerous additional questionnaires used to evaluate asthma-related quality-of-life.
Some of the more common questionnaires are the Asthma Bother Profile (ABP), Asthma
Impact Survey (AIS-6), Living with Asthma Questionnaire (LWAQ), Modified Asthma
Quality of Life-Marks (M-AQLQ-Marks), Asthma Short Form (ASF), St. George’s
Respiratory Questionnaire (SGRQ) and Airways Questionnaire-20 (AQ-20).
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1.4.4.3 Dyspnea
Dyspnea is a common symptom of asthma and the Modified Medical Research Council
(mMRC)93 and Borg dyspnea scales94 are commonly used to assess it severity. The
Modified Medical Research Council dyspnea scale is one of the most commonly used
questionnaires to assess dyspnea. It uses a simple five-point scale which assesses the
impact or burden of dyspnea on the patient. Scores range from zero (breathless with
strenuous exercise) to four (too breathless to leave the house, or breathless when dressing).
Similarly, the modified 0-10 Borg dyspnea scale assesses how patients perceive their
severity of dyspnea using a simple 10-point scale, with scores ranging from zero (nothing
at all) to ten (maximal).

1.5 Diagnosis and Classification of Asthma
Asthma is particularly challenging to diagnose and classify due to its multiple overlapping
pathologies that are heterogeneous between individuals (Figure 1-8).95

Although

spirometry is most often employed to diagnose asthma, it is difficult to use spirometry to
further classify asthma into respective phenotypic categories. With the advent of novel
biomarkers, such as FeNO, accurate classification of asthma sub-phenotypes is possible.95
As depicted schematically in Figure 1-8, a multifaceted approach and a gamut of
biomarkers is required to accurately diagnose and subsequently classify asthma.96

Figure 1-8 Asthma is a heterogeneous disease consisting of several overlapping pathologies
necessitating multiple biomarkers to accurately diagnose and phenotype patients.
Adapted from SJ Wadsworth, J Asthma Allergy 2011.
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1.5.1

Asthma Diagnosis

A history of variable respiratory symptoms, the presence of airflow obstruction or
hyperresponsiveness, reversibility of obstruction and exclusion of alternative diagnoses
constitutes a positive diagnosis of asthma.1,2 Respiratory symptoms indicative of asthma
include a combination of wheeze, dyspnea, chest tightness and cough that are temporally
intermittent and tend to worsen at night.1,2 In reality, asthma is still commonly diagnosed
on the basis of symptoms alone. In Ontario, Canada, only 43% of asthmatics diagnosed
by a physician performed spirometry.97 Failure to include objective assessments in the
diagnostic process is likely contributing to overdiagnosis; evidence of this was observed
in a longitudinal study across eight Canadian cities that concluded approximately 33% of
individuals with a physician diagnosis of asthma did not have asthma when objectively
assessed.98 Ideally, a diagnosis should be rendered through evaluation of the patient’s
respiratory symptoms, medical history, physical examination and spirometry.1,2
Independently, symptoms, medical history and physical exams cannot accurately exclude
and/or confirm a diagnosis of asthma. Spirometry is absolutely required to objectively
assess airflow obstruction, its severity and reversibility.96 Accordingly, spirometry should
be performed prior to and following inhalation of a short-acting bronchodilator to indicate
the degree of obstruction and reversibility according to ATS/ERS standards.65
Common differential diagnoses include chronic obstructive pulmonary disease, alternative
upper airway diseases (e.g. rhinitis) and obstructions involving the large (e.g. vocal cord
dysfunction) and small airways (e.g. bronchiolitis).2

1.5.2

Asthma Control

Asthma control refers to the extent that symptoms of asthma can been reduced or removed
by treatment.17 Control encompasses two domains: current clinical control and future risk
of exacerbations and lung function decline.17 Symptom control is gauged by evaluating
the frequency of day-time symptoms, night-time symptoms, short-acting beta-agonist
(SABA) use and activity limitation. Risk is gauged by evaluating the frequency and
severity of previous exacerbations. Taken together, a patient’s asthma is considered to be
well-controlled if he/she is symptom free without activity limitation or exacerbations and
does not experience variable lung function. As described above, multiple standardized
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questionnaires have been designed to assess the degree of asthma control. Some of the
most commonly used questionnaires are the ACQ and ACT. There is no general consensus
between national and international guidelines regarding degrees of asthma control. For
example, the GINA report of 2015 used categories of “well-controlled,” “partlycontrolled” and “uncontrolled;”1 whereas the National Heart, Lung, and Blood Institute
(NHLBI) ERP3 used “well-controlled,” “not well-controlled” and “very poorlycontrolled.”2 Regardless, the primary goal of asthma treatment is the achievement and
maintenance of disease control.

1.5.3

Asthma Severity

Asthma severity can be defined by the intensity of treatment required to control asthma.17,99
Severity can be classified as intermittent, mild, moderate and severe according to the lowest
level of treatment required to achieve asthma control. Shown below in Table 1-1,
intermittent, mild, moderate and severe asthma is asthma that is well-controlled while
receiving the indicated treatment regimen. The indicated treatment regimens can be
extrapolated to reflect the six-step and five-step treatment strategies proposed by the
NHLBI100 and GINA,1 respectively. Severe asthma is defined as asthma which requires
treatment with high dose ICS and LABA (and/or OCS) to achieve asthma control, or
asthma that remains uncontrolled despite maximum therapy.101

As defined, asthma

severity can only be assessed after a patient has been on regular controller treatment for
several months.
Table 1-1 Classification of asthma severity.
Intermittent
Mild
Moderate
Severe
Lowest level of
SABA as
Low-dose ICS or Low- to moderate- High dose ICS
treatment required
needed
other low intensity
dose ICS and
and LABA ±
to achieve control
treatment
LABA
OCS
Treatment strategy Step Allocation
NHLBI EPR3100
1
2
3 or 4
5 or 6
GINA1
1 or 2
3
4 or 5
NHLB, Expert Panel Report 3 of the National Heart, Lung and Blood Institute; GINA,
Global Initiative for Asthma; ICS, inhaled corticosteroids; LABA, long acting betaagonists; OCS, oral corticosteroids. Adapted from DR Taylor, Eur Respir J 2008.99
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1.6 Treating Asthma
Similar to the majority of chronic lung diseases, no existing asthma treatments are
preventative or curative.

Accordingly, the primary goal of asthma treatment is the

achievement and maintenance of disease control while minimizing the risk of future
exacerbations or lung function decline. The majority of asthma can be well-controlled
using a SABA for rescue during acute onset bronchoconstriction and ICS for chronic
control. However, as asthma severity is increased, treatment becomes more complex and
requires personalized, phenotype-specific additive therapies.
Towards the goal of asthma treatment, evidence-based stepwise approaches have been
developed by the NHLBI100 and GINA1 (Figure 1-9) to guide treatment decisions. Both
guidelines suggest that a continuous control-based management cycle (Figure 1-9),
consisting of iterative patient assessment, treatment and review is necessary to ensure
asthma is adequately treated. Following each assessment, treatment can be “stepped-up”
when asthma in not well-controlled and “stepped-down” when asthma is wellcontrolled.102 The breadth of asthma medications can be categorized as controllers,
relievers and add-on therapies.

Corticosteroids, beta-agonist bronchodilators,

theophylline, leukotriene receptor antagonists, immunomodulators and bronchial
thermoplasty are briefly described below.
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Figure 1-9 2015 GINA stepwise approach to asthma treatment.
ICS, inhaled corticosteroids; SABA, short-acting beta2-agonists; LABA, long-acting betaagonists; OCS, oral corticosteroids; anti-IgE, anti-immunoglobin E therapy; theoph,
theophylline; LTRA, leukotriene receptor antagonists.
Adapted from GINA Global Strategy for Asthma Management and Prevention, 2015.1

1.6.1

Controller & Reliever Treatment

1.6.1.1 Corticosteroids
Corticosteroid anti-inflammatory therapy is the most effective therapy for asthma.1,2
Corticosteroids block various inflammatory pathways, suppressing cytokine production,
recruitment of eosinophils and the release of inflammatory mediators.41 In the 1990s, their
efficacy was evidenced by their ability to safely reduce airflow obstruction, symptoms,
emergency department visits, hospitalizations and asthma-related deaths, to improve
asthma control and quality-of-life and to decrease airway hyperresponsiveness and
exacerbation frequency.103-107 Response to this treatment is variable between asthmatics
and is related to the type of underlying inflammation. Asthmatics with neutrophilic
predominant inflammation are commonly corticosteroid-resistant;108 whereas asthmatics
with eosinophilic predominant inflammation are predominantly corticosteroid-responsive.
As an independent controller medication, ICS demonstrate superiority over other controller
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medications in placebo-controlled trials.109,110

Commonly used ICS include

beclomethasone, budesonide, ciclesonide, fluticasone, mometasone and triamcinalone.
As many as 30% of severe asthmatics require daily oral systemic corticosteroids (OCS) as
additive maintenance therapy, with 50% requiring more than three bursts of OCS
annually.111 Due to the well-documented negative side-effects of chronic OCS use, they
are only recommended as an add-on treatment for severe asthmatics who remain poorly
controlled despite high-dose ICS and long-acting beta-agonists (LABA).1,2 OCS are more
commonly used in short bursts (3-7 days) during an exacerbation to gain control of
symptoms as they speed the resolution and prevent relapse of exacerbations.112,113

1.6.1.2 Beta-agonist Bronchodilators
Short-acting and long-acting beta-agonists (SABA and LABA, respectively) are the most
commonly used bronchodilators for treating asthma. SABAs, such as salbutamol, are a
highly-effective reliever of acute bronchoconstriction in mild, moderate and severe asthma.
LABAs, salmeterol and formoterol, cause bronchodilation for greater than 12 hours114 and
are used in combination with ICS for long-term control in moderate and severe asthma.
The clinical benefit of monotherapy therapy with SABA and LABAs is inferior to that of
ICS and has been linked to adverse outcomes,115 accordingly LABAs are rarely used
independently. When used in combination with ICS, LABAs have an additive effect,
improving lung function and symptom control.116,117 The effects of beta-agonists are the
result of their binding to beta-adrenoceptors, present on airway smooth muscle, epithelial
and inflammatory cells.

Its major mechanism of action is initiated when beta-

adrenoceptors on the airway smooth muscle are stimulated, increasing cyclic AMP, which
causes the smooth muscle to relax. The variable rate of onset and the duration of effect
between SABAs and LABAs is due to their hydrophilic and lipophilic characteristics that
govern their interaction with beta-adrenoceptors.114

1.6.2

Add-on Treatments

1.6.2.1 Theophylline
Low-dose theophylline, is a relatively weak bronchodilator that may have an antiinflammatory and immunomodulatory effect.41 Due to the availability of safer and more
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effective treatments, such as ICS and beta-agonists, theophylline is considered an
alternative controller option or add-on treatment.1,2,118 The clinical benefit of adding
theophylline to ICS treatment was found to only minimally improve lung function.119 The
clinical utility of theophylline is complicated due to its toxicity and associated side-effects
at effective doses, which is particularly problematic as its bronchodilator effect is dosedependent. Despite guideline recommendations, theophylline is one of the most prescribed
medications for asthma internationally because of its low cost. This relates to its use in
developing nations where access to superior and more expensive alternatives is limited.

1.6.2.2 Leukotriene Receptor Antagonists (LTRAs)
LTRAs reduce bronchoconstriction and inflammation in response to various stimuli; they
are considered an alternative first-line therapy, but are most commonly used as add-on
treatment.1,2 Leukotrienes are biochemical mediators that are released from inflammatory
cells such as mast cells, eosinophils and macrophages in response to various stimuli.41,120
Binding of cysteinyl-leukotrienes to cysteinyl-leukotrienes receptors results in smooth
muscle constriction, mucus secretion, edema and inflammation.41,120 For the treatment of
asthma, montelukast (Singulair) is the most commonly used LTRA, blocking the effect of
cysteinyl-leukotrienes receptors. LTRAs are considered an alternative first-line therapy as
they are less effective than ICS when used independently.121 In a multicentre, randomized,
double-blind, placebo-controlled trial, montelukast improved airway obstruction,
exacerbations, control and blood eosinophils in stable asthma.122 In a subsequent trial, the
clinical benefit of adding montelukast to ICS treatment was found to be as effective as
doubling the ICS dose.123 Multiple studies have concluded that adding LTRA to ICS
results in comparable124 or worse outcomes125,126 than achieved by adding LABA to ICS.127

1.6.2.3 Anticholinergic bronchodilators
Anticholinergic bronchodilators are considered a clinically valuable add-on treatment for
the treatment of asthma. Anticholinergic agents inhibit cholinergic activity by competing
with acetylcholine at muscarinic receptors to permit dilation of the airways.41
Acetylcholine, which acts through muscarinic receptors, is a key player in the regulation
of airway smooth muscle tone and mucus gland secretion.128 Studies evaluating the
efficacy of Tiotropium Bromide (Spiriva), a long-acting muscarinic antagonist, reported
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improved lung function and symptoms, reduced frequency of SABA use and reduced risk
of future exacerbations in asthmatics taking ICSs and LABAs.129-131

1.6.2.4 Immunomodulators
Immunomodulator is an umbrella term used to encompass many different pharmaceutical
agents aimed at modulating cell signalling and the immunologic responses in asthma.
Omalizumab, a monoclonal antibody that interrupts the allergic cascade by binding free
immunoglobulin E (IgE), is considered a phenotype-guided add-on treatment for allergic
asthma that cannot be well-controlled with ICS.1,2 In patients with moderate-to-severe
allergic asthma, large-scale clinical trials have proven omalizumab reduces exacerbations
and symptoms, improves quality-of-life and has a steroid-sparing effect.132-135

In

subsequent trials, adding omalizumab to ICS treatment was proven clinically beneficial
due to further improved lung function and a reduction in exacerbations. While omalizumab
is the only immunomodulator currently integrated into treatment guidelines, numerous
clinical trials have emerged to evaluate novel pharmaceutical agents engineered to target
various pathways important to the pathogenesis of asthma. Potential new treatments
include: anti-interleukin 5 (IL-5) antibodies, mepolizumab136 and reslizumab;87 anti-IL-13
antibodies, lebrikizumab137 and tralokinumab;138 anti-TNF-α antibody, golimumab;139
tyrosine kinase inhibitor, masitinib;140 IL-2Rα antibody, daclizumab;141 and CXCR2
antagonist, SCH527123.142

1.6.2.5 Bronchial Thermoplasty
Bronchial thermoplasty is a novel nonpharmacological outpatient treatment procedure for
severe asthma. During three bronchoscopy sessions, radiofrequency energy is delivered to
all of the bronchopulmonary segments to disrupt bronchial smooth muscle.143 The effect
of this procedure is a reduction in airway smooth muscle mass in the treated airways,
resulting in a reduced potential for bronchoconstriction.144,145 The safety and efficacy of
bronchial thermoplasty have been evaluated in numerous clinical trials, including a multicentre, randomized, double-blinded, sham-controlled trial, that together demonstrated
improved asthma control, quality-of-life, and decreased exacerbation frequency,
hospitalizations and ED visits following treatment.86,146,147 The long-term effectiveness
was recently evaluated and reduced hospitalizations and exacerbation frequency were
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shown to persist five years after treatment.148,149 Despite its excellent safety and efficacy
profile, the worldwide literature consists of only about 200 patients who have received this
treatment.

1.7 Imaging Asthma
Currently, the clinical use of imaging in asthma is minimal and largely confined to chest
radiography and x-ray computed tomography (CT). Through research initiatives, novel
imaging biomarkers of lung structure and function have been developed, many of which
have the potential to impact asthma diagnosis, management and evaluation of treatment
effect. X-ray CT, single photon emission computed tomography (SPECT), positron
emission tomography (PET) and MRI based techniques can be used to non-invasively
evaluate regional ventilation. Imaging has provided valuable insight into the underlying
disease mechanisms of asthma, and will be discussed below.

1.7.1

Plain X-ray

The chest radiograph (Figure 1-10) is the oldest and most common type of image used to
evaluate the lung as it is relatively inexpensive and fast. Unfortunately, the utility of chest
radiographs is limited as they are two-dimensional projection images of the threedimensional anatomy and are therefore limited by tissue superimposition. A posterioranterior chest radiograph is obtained with the patient standing upright, with the x-ray
source positioned behind them so that the x-ray beam enters from the posterior side and
exits the anterior side of the patient.150 Different anatomical structures absorb x-rays to
different extents and this is termed attenuation, the principle behind the contrast in an xray image.150 Highly attenuating tissues such as bone absorb many x-rays and appear white
on an x-ray image. In contrast, low attenuating tissues such as lung parenchyma absorb
very few x-rays and therefore appear black on an x-ray image. The radiation dose
associated with a typical posterior-anterior chest radiograph is 0.01 mSv,151 approximately
equivalent to 0.6% of the annual background radiation in Toronto, Canada (1.6 mSv).
Chest radiographs are rarely useful in the diagnosis and management of asthma as they are
often normal. However, their strength lies in the ability to reveal complications or
alternative causes of “asthma-like symptoms.”

A study by Paganin and colleagues

concluded that only 38% of chest radiographs were abnormal in adults with chronic
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asthma.152 Radiographic findings associated with asthma are generally subtle and they
include increased lung volume, increased lung lucency and bronchial wall thickening.153
Increased lung volume or hyperinflation is the most common radiographic observation and
is seen as increased lung length and flattening of the diaphragm (Figure 1-10).41 The
prevalence of bronchial wall thickening identified on chest radiographs has been related to
asthma severity.152

Figure 1-10 Representative posterior-anterior chest radiograph of a healthy volunteer and
an asthmatic subject.
In asthma, diaphragm flattening is indicative of hyperinflation. Healthy case courtesy of
Dr. Usman Bashir, Radiopaedia.org, rID: 18394; Asthma case courtesy of Dr. Garth
Kruger, Radiopaedia.org, rID: 21812.

1.7.2

X-ray Computed Tomography

Since its advent in the 1970s, x-ray CT has become the imaging modality of choice for the
evaluation of pulmonary disease. Through technological advancements, the entire lung
volume can now be captured with sub-millimetre isotropic spatial resolution in a single
breath-hold using multiple-row detector CT scanners.154 This increased spatial resolution
and the potential for isotropic voxels permit multi-planar and three-dimensional
reconstructions.155 Similar to plain radiography, the attenuation properties of tissues
govern image contrast in x-ray CT. In CT however, attenuation values are measured in
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Hounsfield units (HU) and range from -1000 HU for air, 0 HU for water and to
approximately 700 HU for bone.155
CT of asthmatic subjects have shown abnormal findings such as bronchial wall thickening,
bronchial wall dilation, luminal narrowing, bronchiectasis, mosaic lung attenuation, mucus
plugging and atelectasis (Figure 1-11).152,156 In asthma research studies, CT has been used
extensively to directly evaluate the large airways and to indirectly evaluate the small
airways (<2mm). As detailed below, CT-derived metrics are correlated with clinical
symptoms and are highly sensitive to treatment response. Gupta and colleagues used CT
to evaluate 185 severe asthmatics and reported that abnormalities were present in 80% of
study participants.157

Figure 1-11 Axial CT of the right lower lobe in two representative asthmatics.
At baseline (panel A), after inhalation of methacholine (panel B) and then salbutamol
(panel C) there are visually obvious variations in bronchial lumen diameters (highlighted
by white arrow) consistent with bronchoconstriction and subsequent bronchodilation.158 In
a separate asthmatic (panel D) mosaic attenuation due to air-trapping is observed.159
Reproduced with permission from Beigelman-aubry et al (2002)158 and Sung et al
(2007).159
The architecture of the large airways is assessed by quantifying metrics similar to those
employed in histological studies such as the airway wall area percent (Equation 1-7),
airway wall thickness percent (Equation 1-8) and airway lumen area. Initial airway
quantification techniques relied on manual tracing; however, due to the obvious limitations
of this approach, semi-automated and automated computer-based approaches have since
been developed. Three-dimensional approaches enable up to ten generations of the airway
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tree to be segmented, and reliable quantification can be achieved for first to sixth generation
airways.154,160

Furthermore, automated three-dimensional approaches allow for the

identification of airways using standardized clinical nomenclature, as demonstrated in
Figure 1-12.160 Awadh and colleagues were the first to quantify airway wall thickness in
the segmental and sub-segmental airways of asthmatics and healthy controls using a
manual approach. They reported that asthmatics had a greater airway wall thickness as
compared to controls and that wall thickness was increased with increasing asthma
severity.161 Subsequent investigations have compared airway measurements in normal and
asthmatic subjects using various quantification techniques and their results support the
initial findings by Awadh et al.162-167 Furthermore, CT airway measurements have been
correlated with asthma severity,167-169 airflow obstruction,162,164,167,168,170 airway
hyperresponsiveness163,168,171 and pathology.168 Following interventions such as deep
inspiration,172 methacholine challenge166 and ICS therapy,165,173,174 the airways have been
shown to behave in the expected direction.
Equation 1-7
Wall Area Percent [%] =

Airway wall area
×100
Total airway area

Equation 1-8
Wall Thickness Percent [%] =

Airway wall thickness
×100
Airway outer diameter

Figure 1-12 Three-dimensional quantitative CT of the lungs and airways in asthma.
Coronal CT (left panel) and the corresponding three-dimensional rendering of the lung and
airway tree using Pulmonary Workstation 2.0 (VIDA) (middle panel). The trachea, left
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main bronchus and left upper lobe bronchus pathway is highlighted (in blue) and the
segmental LB3 airway is quantified (right panel). In cross-section, the pathway and LB3
airway boundaries are outlined in red.
The small airways (<2mm) cannot be directly evaluated using CT as they are beyond the
current spatial resolution limit of the technique. However, air trapping in asthma is thought
to be an indirect measure of small airway obstruction and can be visualized as
heterogeneous regions of low attenuation on CT (Figure 1-11). As expected, regions of
low attenuation are more apparent on expiratory as compared to inspiratory scans. Various
metrics have been used to quantify the extent of air trapping on CT and these include
scoring systems, threshold and percentile techniques and lung density expiratory to
inspiratory ratios. Threshold techniques use a specific threshold of HU (e.g. -950 HU, 910 HU, -856 HU) and the percentage of the lung less than this threshold is calculated.175
Percentile techniques require a specific percentile point (e.g. lowest 15th percentile) to be
selected and the HU value for the corresponding percentile is determined.175 Using various
CT-derived gas trapping metrics, investigators have observed significantly elevated gas
trapping in asthmatics over healthy controls.158,176 Other investigators correlated CT
measurements

of

gas

trapping

in

asthma

with

asthma

severity,177

airflow

obstruction,170,176,178 airway hyperresponsiveness and disease duration.178 Zeidler and
colleagues performed a double-blinded, cross-over study to compare the effect of
montelukast versus placebo on small airway function in mild-to-moderate asthma.
Compared to placebo, montelukast resulted in significantly less air trapping on CT.179
Moreover, other interventional studies have shown that air trapping on CT worsens
following methacholine158 and improves following treatment with ICS.180,181 These studies
similarly concluded that CT is a more sensitive method to assess treatment response in the
small airways than conventional lung function tests.
In addition to providing rich qualitative and quantitative structural information regarding
the airways and lung parenchyma, functional assessments of ventilation and perfusion are
also possible with novel CT techniques. Introduced in the late 1980s, xenon ventilation
CT182 is a technique used to non-invasively measure regional pulmonary ventilation in lung
diseases. CT is performed after the participant inhales radiodense xenon and ventilation
can in turn be assessed because the airspaces that contain xenon have increased CT density
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in comparison to those that do not.183 However, this technique is limited as xenon
enhancement is poor and this has motivated xenon ventilation imaging using a dual-energy
CT based approach. Using dual-energy CT, Chea and colleagues observed ventilation
defects in 80% of stable asthmatics who had significantly worse airflow obstruction and
thicker airway walls than asthmatics without defects.183 Using the same approach, another
group of investigators observed an increase in xenon ventilation defects following
methacholine that resolved following salbutamol inhalation.184
Despite the rich qualitative and quantitative structural and functional information that CT
can provide, it is disadvantaged due to its use of ionizing radiation. The radiation dose
associated a clinical chest CT is approximately 8 mSv,151 equivalent to roughly five years
of background radiation in Toronto, Canada (1.6 mSv) or 400 plain chest radiographs. This
becomes a major concern in asthma research and patient care as serial imaging capabilities
are necessary for disease management and the evaluation of response to treatment or
intervention.

1.7.3

Nuclear Medicine

Gamma Scintigraphy & Single Photon Emission Computed Tomography (SPECT)
Scintigraphy and SPECT can be used to regionally evaluate perfusion and ventilation in
the lungs. Following the injection or inhalation of a radionuclide tracer, gamma radiation
is used to form an image of radioactivity within the body. Radionuclide tracers emit
gamma rays at a specific energy that can be detected by a gamma camera that converts
absorbed energy into an electrical signal that can be displayed as an image. Accordingly,
regions of high radionuclide concentration appear as hot spots on the image. Similar to
how x-ray CT compares to plain x-ray, SPECT compares to scintigraphy.185 Scintigraphy
uses gamma radiation to form two-dimensional images of radioactivity within the body,
whereas SPECT offers a three-dimensional image.
A tracer that is radioactive itself or labelled with a radionuclide is required.185 For regional
imaging of ventilation, radioactive gases, radioactively-labelled aerosols and Technegas
can be used.185 The most commonly used radioactive gases are xenon-133 (133Xe) and
krypton-81m (81mKr).

The radionuclide technetium-99m (99mTc) is used as
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99m

Tc-

diethylene-triamine pentaacetate (DTPA) aerosol and Technegas.185

The inhaled

deposition of Technegas has been shown to be similar to the distribution of inhaled

133

Xe

gas, and is preferred as its deposition within the lungs remains unchanged for more than 20
minutes.186
Scintigraphy using inhaled 133Xe gas was the first method to identify regional ventilation
abnormities in asthma.187,188 Engel and colleagues were the first investigators to show the
effect of methacholine-induced bronchoconstriction on regional ventilation.189 Nearly ten
years later, the effect of histamine-induced bronchoconstriction on ventilation was
observed.190 In the late 1990s, King and colleagues began to measure ventilation in asthma
using SPECT and an inhaled bolus of Technegas. As hypothesized based on previous
scintigraphy studies, ventilation was compromised in asthmatics compared to healthy
controls.191 Using the same technique, the investigators subsequently observed increased
ventilation abnormalities following methacholine challenge in asthma.192 Importantly, the
team demonstrated a link between ventilation defects and peripheral airways disease
measured by MBNW.192 Not necessarily representative of ventilation, SPECT has been
used extensively in research to investigate the regional deposition of inhaled aerosols when
labelled with the radionuclide 99mTc.193,194
Similar to x-ray based imaging methods, an obvious limitation of SPECT is its
radionuclide-dependent radiation exposure. A lung ventilation-perfusion study using
99m

Tc exposes the subject to an effective dose of 2-3mSv.185 Furthermore, SPECT suffers

from poor spatial resolution (~15mm) and motion artifact due to long acquisition times.
Positron Emission Tomography (PET)
Similar to SPECT, PET offers three-dimensional images of radioactivity and requires the
injection or inhalation of a positron-emitting radioisotope. As the radioisotope decays
within the patient, positrons are emitted and then quickly annihilated when they come into
contact with an electron. As a result, two photons are emitted approximately 180º to one
another.195

The emitted photons can be detected and a three-dimensional map of

radioactivity can be reconstructed to generate a PET image.195
Regional ventilation, perfusion and ventilation/perfusion matching can be assessed with
nitrogen-13 (13NN) PET following bolus injection or inhalation of 13NN.
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13

NN has a half-

life of ten minutes and is not soluble in blood or tissue.195 The bolus injection technique is
used to deliver

13

NN to the lung via the bloodstream. Accordingly, unventilated lung

regions, termed ventilation defects, retain the tracer due to gas trapping whereas the tracer
is quickly washed out of ventilated lung regions. Conversely, when the alternative
inhalation technique is used, the tracer does not reach poorly-ventilated regions of the
lungs. Intravenous bolus injection of 13NN was used by Venegas and colleagues in a study
evaluating the effect of methacholine-induced bronchoconstriction on regional ventilation
in mild-to-moderate asthmatics.196

Following bronchoconstriction, the investigators

observed regions of poor ventilation.196 Using the same technique, similar results were
observed in mild asthmatics but in a subsequent study, lung perfusion was shown to
redistribute away from ventilation defects.197 The effect of omalizumab treatment on
ventilation and ventilation/perfusion matching metrics was assessed in a small group of
uncontrolled allergic asthmatics but no effect was observed.198
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F-fluorodeoxyglucose (FDG) is the most commonly used PET tracer in clinical practice

due to its high uptake by metabolically active cells, such as cancer cells.154 Interest has
surrounded the utility of FDG-PET as a biomarker of eosinophilic and neutrophilic
inflammation in the lungs of asthmatics.199,200 Future work is required to determine the
utility of this approach in asthma.

1.7.4

Magnetic Resonance Imaging

MRI does not require ionizing radiation and, due to this obvious advantage, the past 25
years have seen an accelerated development of pulmonary MRI. However, conventional
1

H MRI has numerous inherent limitations that have motivated the development of

alternative inhaled gas contrast methods since the 1990s. Oxygen-enhanced, fluorinated
gas and hyperpolarized gas MRI are capable of imaging lung structure and function. Of
these techniques, hyperpolarized gas MRI has been most widely applied in pulmonary
research; however, despite its utility, clinical translation has been slow.

1.7.4.1 Conventional 1H MRI
Conventional 1H MRI is challenging due to the lung’s inherent properties. Primarily
consisting of air, the density of the human lung is approximately 0.1 g/cm3, making it the
least dense organ in the body201. Accordingly, the lungs inherently low 1H density
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translates to low 1H MRI signal intensity. Furthermore, the lung consists of millions of
alveoli or air-tissue interfaces. These numerous air-tissue interfaces create significant local
magnetic field inhomogeneities referred to as susceptibility artifacts, further inducing 1H
MRI signal loss.201 Finally, due to cardiac and respiratory motion, the images are highly
susceptible to motion artifacts. Due to these limitations, as shown in Figure 1-13, the lungs
appear as black holes and resultantly healthy and asthmatic lungs are relatively
indistinguishable using conventional 1H MRI sequences.

Figure 1-13 Representative coronal conventional 1H MRI of a healthy volunteer and an
asthmatic subject.
Due to the low 1H density within the lung, 1H MRI cannot visually distinguish structural
abnormalities inherent to the asthmatic lung.
Despite these shortcomings, alternative and potentially more sensitive 1H MRI techniques
such as ultra-short echo time (UTE),202 oxygen-enhanced203 and Fourier decomposition204
methods have been developed.

Advantageously, both oxygen-enhanced and Fourier

decompositions methods provide functional information, offering insight into ventilation
and perfusion characteristics. Even with the advent of these alternative techniques, the
application of 1H MRI in asthma has been limited. Static and dynamic oxygen-enhanced
MRI methods have been used to assess oxygen delivery, uptake and washout in asthma.205208

Oxygen-enhanced MRI metrics are sensitive to asthma severity205-207 and correlate with
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FEV1.207 Most recently, the oxygen transfer function has been shown to decrease in asthma
subjects after a segmental endobronchial allergen challenge and was correlated with
bronchoalveolar lavage eosinophil counts.208 Although yet to be evaluated in asthma,
Fourier decomposition MRI allows lung perfusion and ventilation to be assessed, and
preliminary studies have demonstrated excellent feasibility and reproducibility in healthy
volunteers and subjects with respiratory disease.204,209-211 Similarly, UTE methods have
not been evaluated in subjects with asthma. However, in a murine asthma model UTE 1H
MRI was used to quantify peribronchial eosinophilic inflammation that correlated with
lung function parameters.212

1.7.4.2 Inhaled Gas MRI
Over the past two decades, MRI using inhaled hyperpolarized and fluorinated gases has
been used to investigate lung function and structure in healthy volunteers and subjects with
pulmonary disease. Thus far, the field of inhaled gas MRI has been dominated by
hyperpolarized gas techniques, using

129

Xe and 3He.

Unlike conventional 1H MRI,

specialized polarizer equipment and multinuclear radio-frequency hardware are necessary.
Furthermore, this approach requires the subject to inhale an anoxic gas mixture and
perform a short breath-hold (8-14 seconds) during image acquisition. The field slowly
began to take shape following the seminal investigation by Albert and colleagues who
produced the first hyperpolarized 129Xe MR images of excised mouse lungs.213 Using spinexchange optical pumping, Albert and colleagues recognized that the longitudinal
polarization of 3He and

129

Xe gas nuclei could be increased by approximately 100,000

times.214 This strong signal makes it possible to acquire data from the hyperpolarized gas
itself once inhaled by the patient.
The process of polarization is achieved by spin-exchange optical pumping, circularly
polarized light bombards a glass cell housing rubidium and a noble gas situated within a
helmholtz coil.215 The circularly polarized light is absorbed by the rubidium atoms,
resulting in spin-polarization of its valence electrons. Subsequent collisions between the
noble gas and polarized rubidium atoms result in the transfer of angular momentum from
rubidium electrons to the noble gas nucleus, thereby increasing its nuclear-spin
polarization.215
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While initial investigations used hyperpolarized 129Xe gas, the field quickly transitioned to
hyperpolarized 3He gas due to its three-fold higher nuclear gyromagnetic ratio (129Xe:
11.78 MHz/T; 3He: 33.43 MHz/T) and greater achievable polarization (129Xe: 8-25%; 3He:
30-40%) – both of which contribute to the greater MRI signal achieved with 3He than 129Xe
gas.215 More recently, the limited quantity and resultant high cost of 3He gas has motivated
the field to shift its focus back towards

129

Xe gas as it is widely available and a less

expensive alternative.216,217 Notably, advances in polarizer technology have resulted in
improved 129Xe polarization that has improved the overall MRI signal. It is important to
acknowledge that excellent safety and tolerability of both 3He and

129

Xe MRI has been

demonstrated in healthy volunteers and subjects with pulmonary disease.218,219 Studies
have shown no clinically significant adverse effects of 3He or 129Xe inhalation.218,219 With
this method, regional ventilation, lung microstructure and gas exchange have been
qualitatively and quantitatively evaluated in clinical research.
Ventilation Imaging
Spin density imaging of hyperpolarized 3He or 129Xe, acquired during breath-hold, provides
an opportunity to visualize with high spatial resolution those areas of the lung that
participate in gas distribution and those that do not. As shown in Figure 1-14, in healthy
young adults, inhalation of hyperpolarized gas results in homogeneous signal suggesting
that all areas of the lung are participating equally in ventilation. In contrast, characteristic
regions of signal void are observed in asthma (Figure 1-14), corresponding to areas of the
lungs that are not ventilated within the time-course of a breath-hold scan. Regions of signal
void, termed ventilation defects, have also been observed in cystic fibrosis, COPD,
bronchiectasis, lung cancer and the healthy elderly.
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Figure 1-14 Representative coronal centre slice hyperpolarized 3He MRI of a healthy
volunteer and an asthmatic subject.
3
He MRI gas distribution (in blue) registered to the 1H MRI of the thorax (in grey-scale).
Unlike the representative healthy volunteer, the asthmatic subject has visually obvious
ventilation defects.
The presence of ventilation abnormalities were initially quantified using visual scoring and
manual segmentation, but semi-automated220,221 and automated222 segmentation
approaches are now more commonly employed. Quantitative MRI-derived metrics include
the ventilation defect volume,223,224 ventilated volume,225 ventilation coefficient of
variation226,227 and the ventilation defect percent (VDP).

VDP is a measure of the

ventilation defect volume normalized to the thoracic cavity volume, as shown in Equation
1-9. VDP is now a widely disseminated biomarker220,221,225 due to its demonstrated
reproducibility,220 relation to standard measurements of lung function228 and its sensitivity
to disease severity and treatment response.229
Equation 1-9
Ventilation Defect Percent (VDP) [%]=

Ventilation defect volume
×100
Thoracic cavity volume

Many clinical research studies using hyperpolarized gas MRI have been performed in
asthma to evaluate ventilation heterogeneity.224,226,230-239 In 2001, Altes and colleagues
were the first to observe heterogeneous ventilation in non-symptomatic asthmatic adults
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with normal lung function using hyperpolarized 3He MRI.235 In addition to this seminal
study, numerous others have observed worse ventilation in asthmatics compared to healthy
controls (Figure 1-14).226,233,235,237 While the majority of investigational studies to date
have evaluated adults, a recent study by Cadmen and colleagues imaged asthmatic children
for the first time.239 Similar to previous observations in adults, a greater number and larger
size of ventilation defects were observed in children with asthma than those without
asthma.239 In one of the largest studies evaluating 58 asthmatics with varying disease
severity, ventilation worsened with the increase of disease severity.233 With respect to lung
function, the number of ventilation defects224,236 and the number of ventilation defects per
slice232,233 were inversely correlated with FEV1, but not ventilation volume234 or VDP.237
VDP was, however, correlated with airways resistance, FeNO and dyspnea.237
Without ionizing radiation, there is enormous potential for serial and longitudinal treatment
evaluation studies using hyperpolarized gas MRI. Accordingly, and for obvious reasons,
interest has surrounded the temporal variability of focal MRI ventilation defects in asthma.
In a 30-minute scan-rescan study, all defects were found to be persistent.235 Another study
concluded that approximately 75% of defects remained in the same location when
evaluated twice in the same day.231 Over longer periods of time (7-476 days) many
ventilation defects were persistent or reoccurred in the same location.230-232 Similarly,
following repeat bronchoconstriction on separate days, the majority of defects were also
induced in the same locations.232 With methacholine226,232,236,237 and exercise230,236 induced
bronchoconstriction, numerous new ventilation defects and more heterogeneous
ventilation

patterns

have

been

observed.

Alternatively,

salbutamol-induced

bronchodilation has been shown to improve, but not completely reverse, induced
ventilation abnormalities.232,234,236,237 Figure 1-15 shows the ventilation distribution for a
representative asthmatic at baseline, post-methacholine challenge and post-salbutamol
inhalation. A double-blinded, placebo-controlled, multi-institutional study assessed the
response of

3

He MRI ventilation to montelukast therapy in exercise-induced

bronchoconstriction.234

Following exercise, the authors observed a larger drop in

ventilation volume while receiving placebo than while receiving treatment.234 These
studies demonstrate the sensitivity of MRI ventilation to bronchoconstriction and
treatment.
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Figure 1-15 Representative coronal centre slice hyperpolarized 3He MRI of an asthmatic
subject at baseline, post-methacholine and post-salbutamol.
3
He MRI gas distribution (in blue) registered to the 1H MRI of the thorax (in grey-scale).
Ventilation abnormalities are present at baseline that become worse following
methacholine-induced bronchoconstriction. Post-salbutamol, ventilation is improved but
abnormalities are not completely resolved.
It is probable that ventilation defects in asthma are the result of gas trapping and airway
obstruction, although their etiology remains to be investigated. In an attempt to evaluate
the structural determinants of ventilation defects in asthma, Fain and colleagues evaluated
3

He MRI in conjunction with CT and bronchoalveolar lavage.224 It was concluded that

global metrics of ventilation volume were not related to inflammatory markers. However,
subsequent regional analysis suggested that ventilation defects may be associated with
abnormal inflammation as poorly-ventilated lobes had elevated neutrophils as compared to
well-ventilated lobes in the same patient. 224 Furthermore, in the same asthmatics, a spatial
relationship between ventilation defects and CT hyperlucency was observed.224
Taken together, these studies suggest that in asthma, ventilation defects are related to
airways disease, are regionally heterogeneous, temporally variable and responsive to
therapy and provocation. MRI ventilation defects vary in size, ranging from tiny focal
hypo-ventilated spots to lobar in nature, and are often observed in asthmatics despite
normal lung function. Most importantly, these studies suggest that asthma is a disease that
involves selected airways focally rather than diffusely, a concept that could revolutionize
asthma management and treatment. With the field’s imminent transition to
asthma has yet to be evaluated using this alternative approach.
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129

Xe MRI,

While it can be

hypothesized that the knowledge gained from 3He MRI investigations will be transferable,
direct comparisons are required.
Diffusion-weighted Imaging
Another type of hyperpolarized gas MR image that has been commonly acquired uses
diffusion-weighted MRI, providing a sensitive and rapid approach for evaluating the lung
microstructure.240

Within the lungs, movement of gas atoms is restricted by tissue

boundaries. Therefore, a quantitative apparent diffusion coefficient (ADC) map can be
generated that is representative of airspace size.241 While both 3He and

129

Xe ADC

measurements have been obtained in the lung, 3He ADC has been more extensively studied
demonstrating high reproducibility242-244 and correlation with histology measurements of
airspace size.245 For obvious reasons, ADC studies have been most commonly employed
in COPD, while to date there have only been a few investigations in asthma.237,239,246,247
While heterogeneous gas diffusion coefficients have been observed throughout the
asthmatic lung, contradiction surrounds the differences in whole lung microstructure
between asthmatics and healthy controls. One study has shown increased gas diffusion
coefficients in asthma compared to healthy controls,246 whereas another study observed no
difference.237 In the only study evaluating gas diffusion in asthmatic children, Cadmen and
colleagues reported a greater degree of restricted diffusion in children with asthma
compared to children without asthma.239 In the only treatment study, ADC in asthma was
quantified at baseline, post-methacholine challenge and following salbutamol inhalation.237
An increased ADC was observed following methacholine, indicative of gas trapping, which
was subsequently reduced followed salbutamol inhalation.237 A recent study indicated
ADC in asthma is related to the acinar component of ventilation heterogeneity due to its
relationship with the MBNW derived metric Scond. The same authors also observed that
ADC was strongly related to FVC and a CT marker of gas trapping.247

1.8

Thesis Hypotheses and Objectives

The overarching objective of this thesis was to develop and apply novel pulmonary imaging
methods to better understand asthma and to provide a foundation for functional imaging to
guide clinical decisions and treatment in patients with asthma. The specific objectives and
hypotheses tested in each chapter of this thesis are introduced below.
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In Chapter 2, our objective was to quantitatively compare hyperpolarized 3He and

129

Xe

MRI within a five-minute period before and after bronchodilator administration in a small
group of well-controlled asthmatic adults. We wanted to understand the effect of the gas
physical properties on ventilation defects in asthma. The transition from 3He to 129Xe gas
is a necessary step to facilitate broad clinical integration of hyperpolarized gas MRI. Due
to the higher density and viscosity of

129

Xe gas, we hypothesized that

129

Xe MRI would

reveal more ventilation abnormalities pre-bronchodilator than 3He MRI and that these
differences would be diminished post-bronchodilator.
In Chapter 3, our objective was to exploit the inherent temporal and spatial pulmonary
function information provided by hyperpolarized 3He MRI and develop image processing
methods to regionally identify temporally persistent and intermittent ventilation defects
that could be used to measure, optimize and guide asthma treatment. In this proof-ofconcept study, seven asthmatic subjects underwent MR imaging at three timepoints over a
two-week period.

We hypothesized that patient-specific temporal-spatial pulmonary

function maps could be generated from 3He MRI to visualize and quantify temporally
persistent and intermittent ventilation defects.
In Chapter 4, our objective was to determine the underlying structural and clinical
determinants of asthma ventilation defects by evaluating well-established clinical and
emerging imaging (hyperpolarized 3He MRI and CT) measurements in healthy volunteers
and subjects with well-controlled asthma. In addition to evaluating the relationship
between airway structure and lung function, we asked the question: Are asthmatics with
ventilation defects different from asthmatics without ventilation defects? We hypothesized
that there would be a quantitative and spatial relationship between MRI ventilation defects
and abnormal airways and that ventilation defects would be related to well-established
clinical measurements of asthma.
In Chapter 5, our objective was to evaluate the relationship between MBNW and MRI
measurements of ventilation, and to better understand their link to asthma control.
Multiple-breath gas washout studies have previously demonstrated a link between poor
asthma control and increased ventilation abnormalities, and this led to the questions: What
is the relationship between in vivo ventilation defects quantified using MRI and asthma
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control? Can ventilation defects serve as an intermediate endpoint of outcomes like
exacerbations, quality-of-life and asthma control?

We wanted to understand this

relationship because the primary goal of asthma treatment is the achievement and
maintenance of disease control. Accordingly, we hypothesized that MRI and MBNW
measurements of ventilation would be related, and contribute to poor asthma control.
In Chapter 6, an overview and summary of the important findings and conclusions of
Chapters 2-5 will be provided. The study specific limitations as well as general limitations
of the hyperpolarized gas MRI studies presented will be discussed, and some potential
solutions will be offered. The thesis ends with a roadmap for future studies that could build
on the foundation of knowledge generated by this work.
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CHAPTER 2
To better understand ventilation defects in asthma, here we quantitatively compared
hyperpolarized 3He and 129Xe MRI in a small group of well-controlled asthmatics before
and after bronchodilator administration.
The contents of this chapter were previously published in the Journal of Magnetic
Resonance Imaging: S Svenningsen, M Kirby, D Starr, D Leary, A Wheatley, G Maksym,
DG McCormack and G Parraga. Hyperpolarized 3He and 129Xe Magnetic Resonance
Imaging Differences in Asthma prior to Bronchodilation. J Magn Reson Imaging 2013;
38(6):1521-1530. Permission to reproduce this article was granted by John Wiley & Sons
and is provided in Appendix A.

2

HYPERPOLARIZED 3HE AND 129XE MRI: DIFFERENCES IN
ASTHMA BEFORE BRONCHODILATION

2.1

Introduction

Asthma – a chronic inflammatory disease of the airways is characterized by acute
intermittent attacks of airflow limitation resulting in symptoms of dyspnea, cough, chest
tightness, and wheeze.1,2 Reversible airflow obstruction occurs in response to external
stimuli that trigger acute effects such as bronchoconstriction, plasma exudation, edema and
mucus hypersecretion. It is believed that untreated chronic airway inflammation leads to
airway remodeling, resulting in numerous physiological and functional consequences
including airflow limitation and ventilation abnormalities.3,4 The diagnosis and monitoring
of asthma are commonly performed using the spirometry measurement5,6 of the forced
expiratory volume in 1s (FEV1) -a global measure of airflow limitation that is relatively
insensitive to changes in small airway structure and function.7,8
Multiple-breath-nitrogen washout (MBNW) studies have clearly shown that ventilation is
heterogeneous in asthma9,10 and that this heterogeneity is likely related to airway hyperresponsiveness,11 although similar to FEV1, MBNW measurements cannot provide
regional information.

Imaging studies including those using nuclear medicine

scintigraphy,12-14 positron emission tomography15 and x-ray computed tomography (CT)1618

have provided a regional picture of heterogeneous ventilation abnormalities in asthma.

Additionally, at our site19 and other centres,20-25 magnetic resonance imaging (MRI) using
hyperpolarized helium-3 (3He) has shown regional ventilation heterogeneity20,21,25 and the
surprising spatial-temporal persistence of ventilation abnormalities or defects22,23 in
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asthma. Moreover, in asthma, hyperpolarized 3He ventilation defects have been correlated
with disease severity21 and ventilation defects become larger and/or more numerous after
methacholine challenge and exercise.19,24,25
Hyperpolarized 3He MRI remains a specialized imaging research tool, primarily because
the restricted quantity and unpredictable cost of 3He gas26 has limited uptake in pulmonary
medicine. These issues do not pertain to hyperpolarized 129Xe MRI, an alternative contrast
agent27 that was used to obtain the first reported MR ventilation images.28,29 With recent
advances in polarization physics,30-33

129

Xe MRI has been further developed to provide

high resolution measurements of both 129Xe pulmonary ventilation and diffusion.28,29,32,3441

The safety and tolerability38,42 of

129

Xe MRI was recently evaluated and a direct

quantitative comparison with 3He MRI was reported in COPD and healthy subjects.43 This
previous work showed significantly greater

129

Xe as compared to 3He ventilation defects

in COPD subjects, although in healthy volunteers there were no differences observed.43
Similarly, previous work qualitatively compared 3He and

129

subjects with cystic fibrosis (CF) and showed 3He and

Xe ventilation defects were in

129

good agreement for some subjects, but in other subjects,

129

Xe MRI gas distribution in

Xe ventilation defects were

larger and/or more numerous.44 Although it is unclear what the structural determinants or
mechanisms are behind the differences between 3He and

129

Xe gas distribution, such

differences are believed to reflect differences in the physical properties of the inspired
gases and their interaction with pulmonary abnormalities that are not present in healthy
volunteers. A potential mechanism responsible for the differences in 3He and

129

Xe gas

distribution is the effect of gas density and viscosity on flow resistance in the airways,
which is dependent on airway lumen dimensions.45 Structural narrowing of the airway
lumen is a common feature in asthma and COPD, resulting in increased resistance to flow
in the airways. Thus, the higher density and viscosity of

129

Xe gas may result in greater

resistance to flow through narrowed airways, contributing to greater

129

Xe MRI as

compared to 3He MRI ventilation defects.
To our knowledge, the direct comparison of 129Xe and 3He MRI has not been performed in
asthmatics. Accordingly, here we quantitatively compared hyperpolarized 3He and 129Xe
MRI within a short 5-minute period before and 25-30 minutes after salbutamol
administration in a small group of well-controlled asthmatic adults.
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2.2
2.2.1

Materials and Methods
Subjects and Study Design

All subjects provided written informed consent to the study protocol approved by the local
research ethics board and Health Canada, and the study was compliant with the Personal
Information Protection and Electronic Documents Act (PIPEDA, Canada) and the Health
Insurance Portability and Accountability Act (HIPAA, USA).

Seven subjects were

enrolled between the ages of 18 and 60 years of age (mean age=47±7 years; n=4 males)
with a physician diagnosis of asthma and FEV1 ≥ 60%pred (Table 2-1). Before salbutamol
administration, vital signs were recorded, pulmonary function tests completed, and MRI
was performed.

Post-bronchodilator imaging and pulmonary function tests were

performed 25-30 minutes after administration of 200µg salbutamol (Apo-Salvent CRC
Free Inhalation Aerosol; Apotex, Toronto, Ontario, Canada) delivered through a
pressurized metered dose inhaler and AeroChamber Plus valved holding chamber (Trudell
Medical International, London, Canada).
Spirometry and plethysmography were performed pre- and post-salbutamol using a
MedGraphics Elite Series plethysmograph (MedGraphics, St. Paul, MN, USA). All
manoeuvres were performed according to the American Thoracic Society (ATS)
guidelines.46 All subjects also underwent a previous imaging session 326±199 days prior
to this study. At this time, hyperpolarized 3He MRI and thoracic CT were performed prior
to methacholine challenge and 3He MRI was repeated following methacholine, as
previously described.19

2.2.2

Image Acquisition

MRI was performed on a whole body 3.0 Tesla Discovery 750MR (General Electric Health
Care, Milwaukee, WI, USA) MRI system with broadband imaging capability as previously
described.47 Subjects were instructed to inhale a gas mixture from a 1.0L Tedlar ® bag
(Jensen Inert Products, Coral Springs, FL, USA) from functional residual capacity (FRC),
and image acquisition was performed in 8-15s under breath-hold conditions. To minimize
the potential for differences or bias in the levels of inspiration between 3He and 129Xe MRI,
extensive coaching was performed and the order of 3He and
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129

Xe MRI acquisition was

randomized. Conventional 1H MRI was performed prior to hyperpolarized 3He and 129Xe
MRI with subjects scanned during 1.0L breath-hold of ultrahigh purity, medical grade
nitrogen (N2) (Spectra Gases, Alpha, NJ) using the whole body radiofrequency (RF) coil
and 1H fast spoiled gradient-recalled-echo sequence (10s data acquisition, TR = 4.3ms, TE
= 1.2ms, flip angle = 20 degrees, field of view (FOV) = 40cm x 40cm; matrix, 128 x 128;
14-17 slices; slice thickness = 15mm, 0mm gap) as previously described.47
Hyperpolarized 3He MRI was enabled using a linear bird-cage transmit/receive chest coil
(RAPID Biomedical GmbH, Wuerzburg Germany). A turn-key system (HeliSpin™) was
used to polarize 3He gas to 30—40% and doses (5mL/kg body weight) were administered
in 1.0L Tedlar® bags diluted with N2.

3

He MRI coronal static ventilation images were

acquired using a fast gradient-recalled echo method (9s data acquisition, TR = 3.8ms, TE
= 1ms, flip angle = 1 degree, FOV = 40cm x 40cm; matrix, 128 x 128; 14-17 slices; slice
thickness = 15mm, 0mm gap) as previously described.47
Hyperpolarized

129

Xe MRI was enabled using a custom-made, unshielded quadrature-

asymmetric bird-cage coil model tuned to 35.34MHz, as previously described.48,49

129

Xe

gas (86% enriched) was polarized to 10—60% using a turn-key polarizer (XeBox-E10,
Xemed LLC, New Hampshire, USA). Doses of hyperpolarized 129Xe gas were dispensed
directly into the pre-rinsed 1.0L Tedlar® bags pre-filled with 4He to generate a 50/50
mixture.

129

Xe MRI coronal static ventilation images were acquired using a 3D fast

gradient-recalled-echo sequence with centric phase-encoding ordering in the y direction
and normal sampling in the z direction during a breath-hold of the 1.0L 129Xe/4He mixture
(14s data acquisition, TR = 6.7ms, TE = 1.5ms, flip angle = variable, FOV = 40cm × 40cm;
matrix, 128 x 128; 14-17 slices; 15mm slice thickness, 0 gap) as previously described.43
Thoracic CT was performed using a 64-slice Lightspeed VCT scanner (GEHC, Milwaukee,
WI USA) using a detector configuration of 64×0.625mm, 120 kVp, 100 effective mA, tube
rotation time of 500ms and a pitch of 1.0. In order to reduce the radiation dose delivered
to each subject, CT images were acquired for 56 (versus a total of 400 possible) 1.25mm
thick slices in a region-of-interest (ROI) spatially identified by 3He MRI to contain
ventilation defects. In order to spatially register CT and 3He MRI breath-hold volumes and
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anatomy, CT was acquired similar to MRI with subjects in breath-hold after inhalation of
a 1.0L Tedlar® bag of N2 from FRC.

2.2.3
3

Image Analysis

He and 129Xe MRI semi-automated segmentation was performed to quantify lung volumes

using custom software generated using MATLAB R2007b (The Mathworks Inc., Natick,
MA, USA), as previously described.50 To compare the distribution of both 3He and 129Xe
gases within the lung, we segmented the 3He and

129

Xe images based on pixel signal

intensity. Briefly, 3He and 129Xe static ventilation images were segmented using a K-means
approach that classified voxel intensity values into five clusters ranging from signal void
(cluster 1 (C1) or ventilation defect volume (VDV)) and hypo-intense (cluster 2 (C2)) to
hyper-intense signal (cluster 5 (C5)), and therefore generating a gas distribution clustermap. For delineation of the ventilation defect boundaries, a seeded region-growing
algorithm51 was used to segment the 1H MRI thoracic cavity for registration to the clustermap. 3He and

129

Xe VDP were generated using VDV normalized to the thoracic cavity

volume. Similarly, for the remaining ventilation clusters, the segmented 1H thoracic cavity
volume was used to generate a cluster percentage representing a normalized cluster volume
for the lung. All measurements were performed by the same observer (S.S.) with two years
of experience performing semi-automated

3

He MR image segmentation.

The

reproducibility of the semi-automated method was previously determined50 on the basis of
intra-observer variability of five repeated 3He MRI VDP measurements for five asthmatic
subjects.
The signal-to-noise ratio (SNR) was calculated for each 3He and

129

Xe static ventilation

slice and then averaged to obtain a single SNR value for each subject image. Briefly, SNR
was determined by calculating the mean voxel value within a 5 x 5 cm2 voxel region of
interest (ROI) for four representative ROI within the lung parenchyma, and dividing by the
standard deviation of the voxel values for four representative ROI of the same size in the
image background where there was no lung structure, as previously described.43
Ventilation heterogeneity was estimated according to previously described methods25
using the coefficient of variation (COV). Briefly, a ventilated lung ROI was defined as gas
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distribution cluster-map clusters C2-C5. For each voxel within the ventilated lung ROI a
local ventilation heterogeneity value was calculated by computing the coefficient of
variation of the signal intensity in the voxels 5 x 5 neighborhood. Mean COV for each
slice was calculated for each 3He and

129

Xe static ventilation slice and then averaged to

obtain a single COV value for each subject.
Partial CT image analysis was performed using software (Pulmonary Workstation 2.0,
VIDA Diagnostics; Iowa City, IA, USA) to generate wall area percent (WA%) and lumen
area (LA). An automated airway tree segmentation algorithm (VIDA) was applied,
however, a manual component was introduced to the algorithm if the trachea and main
bronchus were not present in the image. Seed-points were manually placed within the
lumen of the airway of interest to initiate manual segmentation of the airway. To confirm
the spatial relationship between a ventilation defect and the corresponding airway of
interest, the partial CT was manually registered to the corresponding MR image using 3D
Slicer manual registration software (http://www.slicer.org).52

2.2.4

Statistical Analysis

In order to determine the statistical significance of the difference between pulmonary
function tests and MRI measurements pre- and post-salbutamol we performed a
multivariate analysis of variance (MANOVA) and repeated measures analysis of variance
(ANOVA) using SPSS 20.0 (IBM, Armonk, NY, USA).

Furthermore, in order to

determine if the change observed following salbutamol inhalation using

129

Xe MRI was

significantly greater than the change observed using 3He MRI, we performed a three-way
mixed-design repeated measures ANOVA, using SPSS 20.0. In this analysis subject was
treated as a between-subjects factor, and treatment (pre- and post-salbutamol) and gas (3He
and

129

Xe) was treated as a within-subjects factor. Finally, because 3He MRI often has

higher SNR than

129

Xe MRI, there is the potential for regions of reduced signal intensity

to appear as ventilation defects in low SNR 129Xe images. Therefore, Pearson correlations
(r) were performed to determine the relationship between the difference in 3He and 129Xe
VDP with the difference between 3He and 129Xe SNR using GraphPad Prism version 4.00
(Graphpad Software Inc, San Diego, CA, USA). In all statistical analyses, results were
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considered statistically significant when the probability of making a Type I error was less
than 5% (p < 0.05).

2.3

Results

Table 2-1 shows demographic characteristics, pulmonary function, and MRI
measurements for seven mild-to-moderate asthma subjects (four males) pre- and postsalbutamol. For all subjects, mean age was 47±7 years and mean body mass index was
27±4 kg/m2.

Pre-bronchodilator mean FEV1 was 76±6%pred and mean FVC was

91±12%pred.

All subjects were considered to be well-controlled with ≤ 1 asthma

exacerbation resulting in hospitalization in the calendar year prior to the study visit.
Table 2-1 Subject demographic characteristics, pulmonary function and MRI
measurements.
Pre-Salbutamol
Post-Salbutamol
Significance of
(n=7)
(n=7)
Difference (p)*
Subject Demographics
Age yrs (±SD)
47 (7)
Male Sex
4
2
BMI kg/m (±SD)
27 (4)
Pulmonary Function Test
FEV1 %pred (±SD)
76 (6)
83 (10)
0.01
FVC %pred (±SD)
91 (12)
93 (13)
0.35
FEV1/FVC % (±SD)
67 (7)
71 (6)
0.01
TLC %pred (±SD)
104 (8)
103 (10)
0.41
RV %pred (±SD)
136 (16)
123 (12)
0.17
RV/TLC (%)(±SD)
40 (8)
37 (6)
0.15
IC %pred (±SD)
101 (16)
112 (18)
0.02
FRC %pred (±SD)
108 (17)
95 (16)
0.003
Raw %pred (±SD)
184 (72)
133 (56)
0.04
MRI Measurements
3
He VDP % (±SD)
6 (5)
4 (3)
0.001
129
Xe VDP % (±SD)
8 (5)
5 (4)
<0.0001
3
He COV (±SD)
0.282 (0.018)
0.269 (0.024)
<0.0001
129
Xe COV (±SD)
0.309 (0.028)
0.296 (0.036)
0.002
SD=Standard Deviation, BMI=Body Mass Index, FEV1=Forced Expiratory Volume in
1s, %pred=Percent Predicted, FVC=Forced Vital Capacity, TLC=Total Lung Capacity,
RV=Residual Volume, IC=Inspiratory Capacity, FRC=Functional Residual Capacity,
Raw=Airway resistance, VDP=Ventilation Defect Percent, COV=Coefficient of
Variation.
*Significance of difference (p<.05) determined using a multivariate analysis of variance.
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Figure 2-1 shows for two representative asthmatics (subject A and B), 3He and 129Xe MRI
coronal slices before and after bronchodilator administration as well as signal intensity
cluster maps and COV maps. For both subjects, there were visibly obvious regional
ventilation abnormalities in the MRI and cluster maps. As shown,

129

Xe gas distribution

was qualitatively more heterogeneous (COV maps) compared to 3He MRI, with regions of
patchy signal void (cluster and COV maps). As shown in Figure 2-1, following salbutamol
administration, for both

129

Xe and 3He MRI, some ventilation abnormalities disappeared

whereas others persisted.
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Figure 2-1 3He and 129Xe MRI pre- and post-salbutamol.
Hyperpolarized 3He and 129Xe MRI for two representative subjects (Subjects A and B) preand post-salbutamol. Static ventilation MRI, corresponding cluster maps and coefficient
of variation (COV) maps are shown for:
A) 43 yr old male, baseline FEV1=82%pred, baseline FEV1/FVC=69%;
B) 50 yr old female, baseline FEV1=71%pred, baseline FEV1/FVC=68%.
C1 = cluster 1, C2 = cluster 2, C3 = cluster 3, C4 = cluster 4, and C5 = cluster 5.
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As shown in Table 2-1, for all subjects there was a significant improvement in mean
FEV1%pred (p=0.01), FEV1/FVC (p=0.01), IC %pred (p=0.02), FRC %pred (p=0.003), and
airways resistance (Raw %pred p=0.04) after the administration of salbutamol.
bronchodilator

129

Pre-

Xe VDP (8 ± 5%) was significantly greater than 3He VDP (6 ± 5%,

p=0.003); post-bronchodilator 3He (4 ± 3%) and 129Xe VDP (5 ± 4%) were not significantly
different. SNR was significantly lower for
(3He: 46±21,

129

129

Xe MRI compared to 3He MRI both pre-

Xe: 22±8, p=0.02) and post-bronchodilator (3He: 36±16,

p=0.005), importantly however, the difference between 3He and

129

129

Xe: 22±10,

Xe VDP pre-

bronchodilator (r=0.02, p=0.96) was not related to image SNR. The COV for 129Xe MRI
ventilation was significantly greater than for 3He MRI ventilation, both pre- (p<0.0001)
and post-bronchodilator (p<0.0001).
In Table 2-1 and shown in more detail in Figure 2-2, there was a significant improvement
post-salbutamol for 3He (p=0.001) and 129Xe MRI VDP (p<0.0001) with the improvement
in

129

Xe MRI VDP significantly greater than for 3He MRI VDP (p=0.008).

Post-

salbutamol, both 3He (p<0.0001) and 129Xe (p=0.002) COV were significantly decreased.
There was no relationship for the difference in VDP post-salbutamol with SNR (3He MRI,
r=-0.30, p=0.51; 129Xe MRI, r=-0.32, p=0.49). A subject listing of all MRI measurements
is provided in Table 2-2.

Figure 2-2 Bronchodilator response using hyperpolarized 3He and 129Xe MRI.
Mean hyperpolarized 3He and 129Xe ventilation defect percent (VDP) and ventilation
coefficient of variation (COV) pre- (white) and post-salbutamol (grey). Values are means
for all subject slices, and error bars are ± SD. *p ≤ 0.01, **p ≤ 0.001, ***p ≤ 0.0001.
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Table 2-2 Pre- and post-salbutamol hyperpolarized 3He and 129Xe MRI measurements.
Pre – Salbutamol
He MRI
C2
C3
C4
C5
VDP
(%)
(%)
(%)
(%)
(%)
12
40
29
16
4
10
37
33
19
3
11
32
26
15
18
12
39
29
15
8
12
37
35
10
7
12
40
29
12
7
11
40
30
14
8
11 (1) 38 (3) 30 (3) 14 (3)
8 (5)
Post – Salbutamol
3
He MRI
C2
C3
C4
C5
VDP
(%)
(%)
(%)
(%)
(%)
10
44
30
14
2
10
41
30
18
1
12
31
31
14
13
10
35
32
19
4
9
40
33
14
4
12
42
28
12
8
11
39
31
15
4
11(1) 39(4)
31(2)
15(2)
5 (4)
3

Subject
1‡
2
3§
4*
5†
6
7
Mean (±SD)

Subject
1‡
2
3§
4*
5†
6
7
Mean(±SD)

VDP
(%)
3
1
17
6
6
6
5
6 (5)

VDP
(%)
2
1
12
4
3
6
4
4 (3)

129

Xe MRI
C3
C4
(%)
(%)
35
36
28
40
26
28
19
36
35
34
33
34
30
38
29 (6) 35 (4)

C2
(%)
9
9
9
15
11
13
11
11 (2)

C5
(%)
16
21
20
23
14
14
14
17 (4)

129

C2
(%)
9
6
12
10
9
17
14
11(4)

Xe MRI
C3
(%)
32
17
21
27
31
25
29
26(5)

C4
(%)
40
45
34
37
38
35
42
39(4)

C5
(%)
17
31
20
23
18
15
12
19(6)

VDP=ventilation defect percent (C1=Cluster 1), C2 =Cluster 2, C3=Cluster 3,
C4=Cluster 4, C5=Cluster 5, SD=standard deviation. † Subject A, ‡ Subject B, § Subject
C, * Subject D

To further investigate the difference in 3He and

129

Xe gas distribution detected prior to

salbutamol inhalation we evaluated the spatial relationship of airways and ventilation
defects using thoracic CT. All subjects underwent a previous imaging session, 326±199
days prior to this study when hyperpolarized 3He MRI and thoracic CT were acquired as
previously described.19 In Figure 2-3, we show the centre coronal slice 3He and 129Xe MRI
and the corresponding centre slice 3He MRI following methacholine challenge19 for 2
subjects: Subject C, a 41yr old male, FEV1=75% pred; and Subject D, a 36 year old female,
FEV1=86%pred. As shown with arrows in Figure 2-3, for Subject C, a large sub-segmental
ventilation defect distal to the apical bronchus of the right upper lobe (RB1) was visualized
using 129Xe MRI and also using 3He MRI but only after provocation with methacholine, at
the PC20. Thoracic CT for this subject revealed a 4th generation apical sub-segmental
bronchus of the right upper lobe as the airway that was spatially proximal to this specific
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ventilation defect. The CT-derived WA% and LA for this 4th generation airway were 78%
and 2.9 mm2 respectively, both of which are worse than previously reported values for a
group of older asthmatic men (WA%=55-80% and LA=5-15mm2).53 For Subject D, there
was no evidence of a right upper lobe ventilation abnormality and CT-derived
measurements WA% and LA were 69% and 3.8 mm2 respectively for the same 4th
generation apical sub-segmental bronchus.

Figure 2-3 MRI and CT for two asthmatic subjects.
Hyperpolarized 3He and 129Xe MRI and post-methacholine 3He MRI for two subjects (C
and D)
C) 41 yr old male, FEV1=75%pred, FEV1/FVC=66%. White arrows identify a right upper
lobe ventilation defect visible using 129Xe MRI, and for 3He MRI, only post-methacholine
at PC20. Regional CT is shown with the apical segmental bronchus of the right upper lobe
in red which is proximal to the 129Xe and 3He post-methacholine ventilation defect. The
cross-sectional slice of the airway is shown and the airway of interest is identified in a
schematic of the bronchial tree.
D) 36 yr old female, FEV1=86%pred, FEV1/FVC=73% with no ventilation defect in the right
upper lobe.
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2.4

Discussion

Hyperpolarized 3He MRI of asthma has been performed over the last 2 decades19-25,54,55
and across numerous studies, asthma ventilation defects have been shown to be spatially
and temporally persistent,22,23 and some of these ventilation defects partially or fully
resolve following inhaled or systemic therapy.19,20,24,25 Unfortunately, we still do not have
a full understanding of the structural or physiological determinants of such asthma
ventilation abnormalities,56 although armed with such an understanding there is the
potential to use functional MRI to guide asthma therapy, to identify new therapeutic targets
or at least, better understand regional pulmonary response to asthma therapy. A recent
pilot study that compared 3He and 129Xe MRI in older healthy and COPD subjects43 showed
greater

129

Xe MRI ventilation defects in COPD suggesting that

129

Xe MRI may provide

enhanced sensitivity to airway abnormalities in obstructive lung disease. In COPD there
are multiple mechanisms that may be responsible for 3He and 129Xe ventilation differences
including increased airways resistance and the presence of emphysema and the effects of
collateral ventilation.43,57 To try to get a better understanding of the structure-function
relationships in the asthmatic lung, and to tease out the different contributing etiological
factors that result in ventilation defects in asthma, here we directly compared
hyperpolarized 3He and

129

Xe MRI ventilation defects before and after salbutamol

inhalation. We made a number of important observations: 1)

129

Xe VDP and COV were

significantly greater than 3He MRI VDP and COV before salbutamol inhalation, 2) there
were significantly greater post-salbutamol improvements in 129Xe MRI VDP such that 3He
and 129Xe MRI were not significantly different post-salbutamol, and, 3) a remodeled subsegmental airway was shown to be spatially related to a sub-segmental

129

Xe MRI

ventilation defect that was not visible using 3He MRI, except at PC20, after methacholine
administration.
First, we directly compared hyperpolarized

3

He and

129

approximately five minutes of one another and observed that

Xe MRI acquired within
129

Xe MRI VDP and COV

were both qualitatively and quantitatively greater than 3He MRI-derived VDP and COV.
We note that in this study, the differences between 3He and 129Xe MRI VDP were not large
– much smaller in fact than previously reported in COPD.43 Although VDP was not large,
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qualitatively, there certainly was evidence of increased

129

Xe ventilation heterogeneity

compared to 3He and these differences were quantified using the 3He and 129Xe ventilation
COV. We note that SNR was lower for 129Xe as compared to 3He MRI, and therefore there
is the potential for regions of the lung with reduced signal intensity to appear as ventilation
defects in low SNR 129Xe images. However, we observed that the difference between 3He
and 129Xe SNR was not significantly correlated with the difference between 3He and 129Xe
VDP. Therefore, VDP and COV differences might well reflect other differences in the
physical properties of the inspired gases and perhaps their interactions with airway
abnormalities present in the asthmatic lung. For example, in asthma, like COPD, the small
airways (<2mm) are the major site of airflow obstruction and are believed to result in
increased airways resistance.58

129

Xe gas has both a greater density and viscosity than 3He

(pure 129Xe gas has approximately 40 times greater density and 1.5 times greater viscosity
than pure 3He gas)57 and this has an effect on resistance to both turbulent and laminar flow
in the airways, as previously described.45 Importantly, we have previously estimated the
density and viscosity of the inspired 3He-N2 (40/60) and 129Xe-4He gas mixtures (50/50).57
The estimated density of the inspired 3He-N2 gas mixture and 129Xe-4He gas mixture was
0.61kg/m3 and 2.65kg/m3, respectively, and the estimated viscosity of the 3He-N2 mixture
and

129

Xe-4He mixture was 1.99x10-4P and 2.55x10-4P, respectively.57 The increased

density of 129Xe gas would tend to increase the gas Reynold’s number, thereby increasing
the probability for turbulent flow with higher airflow resistance; laminar flow resistance
would also increase proportionately to the change in viscosity according to Poiseulle’s
equation.45 The increased density and viscosity of 129Xe gas could lead to slower filling or
decreased access to lung units distal to narrowed or obstructed airways, amplifying
ventilation differences arising from airway abnormalities between the gases.
In COPD, emphysema may be an additional factor responsible for the differences in 3He
and

129

Xe MRI ventilation and may account for the larger

129

Xe/3He MRI differences

previously observed in COPD43 compared to asthma. In emphysematous lung tissue,
resistance to flow through collateral channels is low whereas in normal lung tissue, flow
resistance through collateral channels is very high.59 Regardless, the results observed here
in asthma support further interrogation using dynamic imaging approaches such as recently
reported in COPD.60 It is also important to note that previous work has also shown that the
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mixture of

129

Xe/4He gas administered during image acquisition performed here better

approximates the self-diffusion coefficient of room air in the lung,43 as compared to 3He/N2
or 3He/4He gas mixtures, supporting the notion that 129Xe gas distribution might provide a
better estimate of “ground truth” ventilation abnormalities.
Second, and as might be expected, we observed a significant regional improvement in both
3

He and

129

Xe MRI VDP following salbutamol administration, with the

129

Xe MRI

improvement significantly greater than 3He MRI. Regional improvements in ventilation
have previously been reported following salbutamol inhalation using xenon-enhanced
dual-energy CT in asthma.61 However, to our knowledge this is the first study to report a
change in 129Xe MRI ventilation abnormalities following inhaled salbutamol. Beta-2 (β2)
adrenergic receptor agonists promote smooth muscle relaxation and dilation, increasing
airway caliber with concomitant decreased resistance to flow. Post-salbutamol, for all
subjects, the global measurement of airways resistance was significantly decreased and this
may have resulted in the improved and more similar regional distribution of 3He and 129Xe
gas post-salbutamol. This suggests that increased airway caliber following bronchodilator
administration allows for similar access of 3He and

129

Xe to lung regions, as previously

reported in healthy subjects.43
Finally, in a single asthmatic, we showed that a relatively large sub-segmental ventilation
defect that was visualized using 129Xe MRI, was also visible using 3He MRI, but only after
methacholine challenge at the PC20. Thoracic CT acquired within a year of this study and
contemporaneous to the methacholine challenge was used to locate the airway proximal to
this defect. A 4th generation apical segmental bronchus of the right upper lobe was
identified as the significantly remodeled airway that was spatially related to this ventilation
defect. Furthermore, in another asthmatic with a normally ventilated right upper lobe, the
same 4th generation airway showed more “normal” airway morphology. It is clear that
airway diameters and wall thicknesses vary among individuals and we acknowledge that
we do not believe that one defect in one subject confirms our hypothesis. However, these
results support the hypothesis that in asthma, 3He gas may penetrate lung regions through
partially obstructed airways that

129

Xe gas cannot access during a short breath-hold scan;

in other words 3He MRI may mask clinically relevant airway abnormalities in asthma. This
interesting finding warrants further investigation in a larger group of asthmatic subjects to
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determine whether there is indeed a relationship between abnormal airway
pathophysiology and the differences between 3He and 129Xe gas distribution.
We acknowledge that this work was limited by the small number of subjects evaluated and
therefore caution should be exercised in generalizing these results to a more general asthma
population. Indeed, the reported VDP in this small group of asthmatics was low and may
be related to the nearly normal FVC for these subjects, reflecting the fact that these subjects
(who were enrolled from a tertiary care asthma centre) were receiving optimal asthma
therapy. The low baseline VDP also suggests that the differences in 3He and 129Xe VDP
reported here might provide a conservative estimate of the differences that would be
observed in a larger, less specialized asthma subject group. What is clear though, is that
salbutamol effectively negated the differences observed between 3He and

129

Xe VDP.

Future studies should aim to evaluate a large group of healthy volunteers and asthmatic
subjects with varying disease severity. Additionally, clinical tests such as dyspnea scores
and measurements of exercise performance should be performed. The clinical relevance
of the difference in 3He and

129

Xe gas distribution detected could then be determined by

direct comparison with established measures that are patient-centred and clinically
relevant.
Over the last two decades, an international imaging physics research effort has been
undertaken to develop non-invasive MRI methods, with the promise of direct and serial
structure-function measurements of the lung without radiation burden or risk. Yet, the
treatment and monitoring of patients with asthma is still mainly based on spirometry and
some emerging inflammatory biomarkers.62

Certainly, low accessibility and the

high/unpredictable cost of 3He gas has also limited its development and use.26 It is
important to note that the relatively low and predictable cost of

129

Xe gas provides the

potential for greater accessibility of pulmonary functional imaging for research and patient
care. One advantage of 129Xe gas is that it is capable of passive transmembrane diffusion
and it is soluble in tissues and blood. Hyperpolarized 129Xe MRI dissolved phase imaging
has shown good spatial agreement with the corresponding ventilation image.34. The
differences between 3He and

129

Xe MRI gas distribution shown here are unlikely to be

related to transmembrane diffusion of 129Xe gas as it has been estimated that only 1-2% of
the inhaled 129Xe gas dose is dissolved in the tissues and blood, during the 10-15s breath87

hold.21

Regardless of the gas used for imaging, we think that the lack of a clear

understanding of the clinical or physiological meaning of MRI ventilation defects will also
impede its development as a clinical tool, necessitating more detailed physiological and
modeling studies. In this study, we observed small but significant differences between
129

Xe and 3He MRI VDP before salbutamol inhalation that suggested

129

Xe MRI may be

more sensitive to airflow obstruction in asthma that is responsive to salbutamol. It is not
clear which one of the currently available pulmonary functional MRI methods (including
oxygen-enhanced MRI)63,64 provides ventilation estimates that are closest to ground truth
(ie. ventilation that occurs with molecular oxygen mixed in air).

The availability of

oxygen-enhanced and 129Xe MRI will certainly facilitate the research that still needs to be
done to investigate the fundamental anatomical and morphological determinants that
govern the occurrence and location of a ventilation defect, including bronchoscopy with
biopsy and histological assessment. MRI can be considered complementary to CT and
endobronchial biopsy because the anatomical determinants of small airway ventilation
defects may be beyond the resolution of CT and perhaps the reach of an endoscope or
optical coherence tomography probe65 as well.
In conclusion, we evaluated hyperpolarized 3He and

129

Xe MRI ventilation defects in a

small group of asthmatics before and after salbutamol inhalation and reported significantly
greater (worse)

129

Xe compared to 3He VDP and COV pre-salbutamol. We identified a

remodeled airway that was spatially related to a sub-segmental ventilation defect visualized
only with 129Xe MRI. These results suggest that the higher density and viscosity of 129Xe
gas (which is more similar to molecular oxygen in air than 3He gas) may help reveal
ventilation abnormalities prior to bronchodilation that are not observed using 3He MRI.
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CHAPTER 3
Hyperpolarized 3He MRI previously revealed the temporal and spatial heterogeneity of
ventilation defects in asthmatics, but these findings have not been used in treatment studies
or to guide personalized treatment. Accordingly, here we generated personalized 3He MRI
temporal-spatial pulmonary function maps to regionally identify temporally persistent and
intermittent ventilation defects that may be used to optimize, evaluate and guide asthma
treatment.
The contents of this chapter were previously published in Academic Radiology: S
Svenningsen, F Guo, M Kirby, S Choy, A Wheatley, DG McCormack and G Parraga.
Pulmonary Functional Magnetic Resonance Imaging: Asthma Temporal-spatial Maps.
Acad Radiol 2014; 21(11):1402-1410. Permission to reproduce this article was granted
by Elsevier and is provided in Appendix A.

3

PULMONARY FUNCTIONAL MAGNETIC RESONANCE
IMAGING: ASTHMA TEMPORAL-SPATIAL MAPS

3.1

Introduction

Asthma is a chronic pulmonary disease1 characterized by acute and predominantly
reversible episodes of airflow limitation and airway hyperresponsiveness that leads to
airway remodeling2,3 Currently used asthma measurements are largely dependent on
spirometry measurements of airflow limitation made at the mouth. Such measurements
tend to over-estimate large airway constriction and under-estimate small airways disease4
and these measurements cannot regionally identify the airways responsible for airflow
limitation, asthma symptoms or control.
Currently, pulmonary imaging techniques play a minor role in the clinical diagnosis and
management of asthma, although quantitative measurements of regional structural and
functional pulmonary abnormalities5 can be derived using a number of imaging methods.
For example, x-ray computed tomography (CT) has been used to show airway remodeling
and evidence of gas trapping in asthmatics.6,7

Single-photon emission computed

tomography8,9 and positron-emission tomography10 have revealed the spatial distribution
and extent of airway remodeling in asthmatics at rest and during exacerbations.
Hyperpolarized noble gas magnetic resonance imaging (MRI), using either 3He or 129Xe,
also provides a way to visualize and quantify lung regions that participate in ventilation
and those that do not.11,12 Longitudinal and interventional 3He MRI studies have revealed
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the regional and temporal nature of ventilation defects in asthma before and after
provocation (exercise and methacholine) and therapy.13-15 Previous work also showed that
in asthma, ventilation defects are related to disease severity,16 CT measurements of gas
trapping17 and airway morphological abnormalities.18

Taken together, these studies

suggest that in asthma, ventilation defects are related to airways disease, are regionally
heterogeneous, temporally variable and responsive to therapy and provocation.19-22
Asthma ventilation defects may be considered as therapy targets or intermediate endpoints
as they are present in older asthmatics with more advanced or severe disease, increased
indices of inflammation and more severely remodeled airways.18
There is enormous potential for imaging methods to improve the efficacy or costeffectiveness of asthma therapy.

However until now, the presence, location and/or

variability of such defects has not yet been used to guide or interpret the efficacy of asthma
therapy. The purpose of this proof-of-concept study, therefore, was to exploit the inherent
temporal and spatial pulmonary function information provided by hyperpolarized 3He MRI
to identify temporally persistent and intermittent ventilation defects as potential targets for
therapy.

3.2

Materials and Methods

3.2.1

Study Design

Subjects who were 18-55 years of age, with a physician diagnosis of asthma and forced
expiratory volume in one second (FEV1) ≥ 60%pred were recruited from a tertiary care
asthma clinic. All subjects provided written informed consent to a study protocol that was
in compliance with the Health Insurance Portability and Accountability Act and approved
by the local Research Ethics Board and Health Canada. All subjects consented to three
study visits, each 5±2 days apart, that took place between May 2007 and May 2008. At
each visit, pre- and post-exercise challenge, spirometry was performed followed by 1H and
3

He MRI.

Spirometry was performed using an ndd EasyOne spirometer (ndd

Medizintechnik AG, Zurich, Switzerland) and FEV1, forced vital capacity (FVC) and
FEV1/FVC were obtained according to the American Thoracic Society guidelines.23 The
exercise challenge was performed according to American Thoracic Society guidelines.24
Briefly the subject exercised (after a 2-minute warm-up) for 6 minutes on a treadmill, while
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inhaling compressed, room temperature dry air, at a workload which increased the heart
rate to 80-90% of the individual’s age predicted maximum.

3.2.2

Magnetic Resonance Imaging

Following spirometry, MRI was performed using a whole body 3.0 Tesla Excite 12.0 MR
system (GE Healthcare, Milwaukee, WI, USA), as previously described.25 Subjects were
in the supine position and all image acquisitions were performed under breath-hold
conditions (15 sec) following inspiration of a 1.0 L gas mixture from functional residual
capacity (FRC). To minimize the potential for differences in the level of inspiration
between imaging sessions, extensive coaching was performed prior to and during each
imaging session. To ensure that each inhalation was performed from FRC, subjects were
instructed to take two tidal breaths before inhaling the gas mixture from the 1.0 L Tedlar®
bag (Jensen Inert Products, Coral Springs, FL, USA).
Hyperpolarized 3He MRI static ventilation imaging was enabled using a single-channel,
rigid, transmit-receive elliptical chest coil (RAPID Biomedical GmbH, Wuerzburg, DEU)
as previously described.25 Hyperpolarized 3He gas (30-40% polarization) was provided by
a turnkey system (HeliSpinTM, GE Healthcare, Durham, NC, USA) and administered to
subjects (dose: 5mL/kg of body weight) in a 3He/N2 mixture.25 Hyperpolarized 3He MRI
static ventilation images were acquired following inspiration of the hyperpolarized 3He/N2
gas mixture using a fast two-dimensional gradient echo sequence with the following
parameters: repetition time, 4.3 msec; echo time, 1.4 msec; flip angle, 7○; field of view, 44
x 44 cm; matrix size, 128 x 128; slice gap, 0 mm; 14 contiguous slices; and slice thickness,
15 mm. Subsequent to hyperpolarized 3He MRI, conventional 1H MRI was performed
during a 1.0 L breath-hold of 4He/N2 to mimic the 3He MRI breath-hold manoeuvre. For
1

H imaging, a fast spoiled gradient recalled echo sequence was applied with the following

parameters: repetition time, 4.7 msec; echo time, 1.2 msec; flip angle, 30○; field of view,
44 x 44 cm; matrix size, 256 x 256; slice gap, 0 mm; 14 contiguous slices; and slice
thickness, 15 mm.
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3.2.3

Image Analysis

3.2.3.1 Overview of Pipeline
Figure 3-1 provides a summary of the registration and segmentation pipeline used to
generate whole lung, two-dimensional, temporal-spatial pulmonary function maps. The
inputs to the pipeline are N 3He images acquired at visits i  1,2..., N  , where N  2 , and
an associated 1H MR image acquired at an arbitrary visit j , j  1,2..., N . The pipeline
consists of four steps: 1) Registration, 2) 1H MRI Segmentation26, 3) 3He MRI
Segmentation26 and, 4) Temporal Map Generation and was developed using 3D Slicer 4.2
open source platform (http://www.slicer.org, Boston, MA, USA) and MATLAB R2013A
(The Mathworks Inc. Natick, MA, USA). In this proof-of-concept demonstration, 3He MR
images were acquired at three visits ( N  3 ), and an associated 1H MR image was
arbitrarily chosen at visit 2 ( j  2 ).

Figure 3-1 Pipeline to generate whole lung, two-dimensional, hyperpolarized 3He MRI
temporal-spatial pulmonary function maps.
The pipeline is divided into four steps: 1) Registration, 2) 1H MRI Segmentation, 3) 3He
MRI Segmentation and, 4) Temporal Map Generation. The inputs to the pipeline are N
3
He MR images acquired at visits i  1,2..., N  , where N  2 , and an associated 1H MR
image acquired at an arbitrary visit j , j  1,2..., N .

3.2.3.2 Step 1: Registration
As shown in Figure 3-1, using 3D Slicer, 3He MR images acquired at each visit i, 3Hevisiti,
i  1,2..., N  ,

and the 1H MR image acquired at visit j, are co-registered to 3Hevisiti=j to

generate temporal-spatial pulmonary function maps. 3Hevisiti=j, corresponding to the same
visit at which the 1H MR image was acquired, is used as the fixed image for each inter99

visit 3Hevisiti-3Hevisiti=j and intra-visit 1Hvisitj-3Hevisiti=j registration.
3

Inter-visit 3Hevisiti-

Hevisiti=j registration is required to correct for misalignment between two 3He MRI scans

acquired at visit i and j due to inter-visit patient position variability on the scanner bed.
3

Hevisiti-3Hevisiti=j co-registration is performed using an automated non-rigid deformable (B-

spline) registration method. Intra-visit 1Hvisitj-3Hevisiti=j co-registration is employed using
landmark-based affine registration with 4-7 corresponding anatomical fiducial markers,
such the carina, trachea, primary bronchi and the diaphragm.

3.2.3.3 Step 2: 1H MRI Segmentation
The thoracic cavity mask, which identifies the lung boundary and intern the thoracic cavity
volume (TCV), is generated by segmenting 1Hvisitj using a seeded-region growing
algorithm,27 as previously described.26 There is a subsequent manual editing option
implemented to permit user modification of the automatically generated mask.

3.2.3.4 Step 3: 3He MRI Segmentation
For each visit i, automated 3Hevisiti ventilation segmentation is achieved using a hierarchical
K-means clustering method, as previously described.26 The resulting 3He cluster maps
consist of five clusters that represent signal intensity classes ranging from no signal (cluster
1 (C1), or ventilation defect volume (VDV)), hypo-intense signal (C2) to hyper-intense
signal (C5). Subsequently, 3He clusters C2-C5 are merged and thoracic cavity masking
was performed to generate corresponding 3He ventilation masks (VM).

3

He MRI

ventilation defect percent (VDP) was quantified by normalizing VDV to the TCV, as
previously described.28

3.2.3.5 Step 4: Temporal Map Generation
To convey the short-term temporal behavior of 3He gas distribution, temporal-spatial
pulmonary function maps are generated from N 3He ventilation masks and consist of three
clusters: 1) persistent defect, 2) intermittent defect, and 3) persistent ventilation. Temporalspatial pulmonary function map voxels are deemed as “persistent defect” if the
corresponding 3He MRI ventilation mask voxels were ventilation defect (C1) at each visit.
Similarly, a voxel is deemed persistently ventilated if the corresponding ventilation mask
voxels were ventilated (C2-C5) at each visit. A voxel is deemed as “intermittent defect” if
the corresponding voxels were not consistently ventilation (C2-C5) or ventilation defect
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(C1) at each visit. Persistent ventilation defect percent (VDPP), intermittent ventilation
defect percent (VDPI) and persistent ventilation percent (PVP) were generated as the ratio
of each volume to the 1H MRI TCV.

3.2.4

Registration Performance Evaluation

Registration accuracy was estimated using the target registration error (TRE),29 defined as
the distance between corresponding fiducial points in the fixed image and the moving
images after registration. Distinguishing anatomical landmarks that were readily apparent
to the human observer, including the carina, trachea, primary bronchi and the diaphragm,
were used as fiducials.

3.2.5

Statistical Analysis

Repeated-measures analysis of variance (ANOVA) were performed to evaluate changes in
spirometry measurements, 3He polarization, 3He dose and 3He MRI VDP across timepoints
using IBM SPSS Statistics version 21.00 (SPSS Inc., Chicago, IL, USA). Paired two-tailed
t-tests were used for statistical comparison of temporal-spatial pulmonary function map
(VDPP and VDPI) anterior-centre-posterior (AP) and superior-middle-inferior (SI)
differences, as previously described,20 using GraphPad Prism version 6.02 (GraphPad
Software, Inc., San Diego, CA, USA). Relationships between temporal-spatial pulmonary
function maps (VDPP and VDPI) and spirometry were evaluated using Spearman
correlation coefficients (r) and linear regressions (r2) generated using GraphPad Prism. The
mean of all spirometric measurements, acquired at visit 1, 2 and 3, were used to assess
relationships. Results were considered statistically significant when the probability of
making a Type I error was less than 5% (p < 0.05).

3.3

Results

Subject demographic characteristics are shown in Table 3-1 for seven adults with asthma
(n=4 males, mean age=28±9 years), all of whom completed three imaging sessions with a
mean inter-visit interval of 5±2 days. In total there were 8 adverse events in 6 subjects.
All adverse events were related to hypoxia, defined as a temporary decrease in SpO2 below
88%, and these were temporally related to MRI breath-hold manoeuvres. Table 3-2 shows
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mean spirometry and hyperpolarized 3He measurements acquired at each visit and Table
3-3 provides a subject listing of all measurements.
Table 3-1 Subject demographic characteristics.
Asthma (n=7)
(±SD) [range]
Parameter
Age years
28 (9) [21-47]
Male/Female
4/3
BMI kg/m-2
26 (4) [21-33]
SaO2
97 (2) [94-98]
FEV1 %pred
88 (11) [65-99]
FVC %pred
104 (10) [89-120]
FEV1/FVC %
72 (8) [61-81]
SD=Standard Deviation; BMI=Body Mass Index; SaO2=Arterial Oxygen Saturation;
FEV1=Forced Expiratory Volume in 1s; %pred= Percent Predicted; FVC=Forced Vital
Capacity.

Table 3-2 Repeated spirometry and hyperpolarized 3He measurements.
Time-point (n=7)
(±SD)
Sig of Diff (p)*
Parameter
Visit 1
Visit 2
Visit 3
Spirometry
FEV1 %pred
88 (11)
86 (12)
84 (12)
0.22
FVC %pred
104 (10)
101 (15)
99 (14)
0.18
FEV1/FVC %
72 (8)
71 (7)
72 (8)
0.76
Hyperpolarized 3He
Dose mL
386 (70)
380 (76)
386 (95)
0.74
Polarization %
13 (2)
12 (2)
12 (2)
0.31
MRI VDP %
4 (2)
4 (3)
4 (3)
0.93
Sig of Diff=Significance of difference; SD=Standard Deviation; FEV1=Forced
Expiratory Volume in 1s; %pred=Percent Predicted; FVC=Forced Vital Capacity;
MRI=Magnetic Resonance Imaging; VDP=Ventilation Defect Percent.
*
Significance of difference (p<0.05) determined using a repeated-measures analysis of
variance.
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Table 3-3 Subject listing of demographic, spirometry and hyperpolarized 3He MRI
measurements.

V1=Visit 1; V2=Visit 2; V3=Visit 3; FEV1=Forced Expiratory Volume in 1s;
%pred=Percent Predicted; FVC=Forced Vital Capacity; VDP=Ventilation Defect Percent;
VDPP=Persistent Ventilation Defect Percent; VDPI=Intermittent Ventilation Defect
Percent; PVP=Persistent Ventilation Percent.

Figure 3-2 shows representative coronal hyperpolarized 3He MRI slices, acquired at each
visit, for each subject. All asthmatics evaluated had visually obvious 3He MRI gas
distribution abnormalities at one or more of their imaging timepoints and qualitative
differences in the distribution of 3He gas were observed between visits, as shown in Figure
3-2. However, despite regional gas distribution differences, as shown in Table 3-2,
spirometry (FEV1%pred, p=0.22; FVC%pred, p=0.18; FEV1/FVC%, p=0.76) and whole lung
3

He MRI VDP (p=0.93) were not significantly different between visits. Additionally, 3He

dose (p=0.74) and polarization (p=0.31) was not different between imaging sessions.
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Figure 3-2 3He MRI co-registered to the corresponding 1H MRI acquired at visit 1-3, and
the corresponding temporal-spatial pulmonary function maps for seven asthmatic subjects.
Regional differences in the spatial distribution of 3He MRI ventilation defects are visually
apparent between visits for each subject. This short-term temporal 3He ventilation defect
behaviour is shown in the corresponding two-dimensional temporal-spatial map for each
subject.
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3.3.1

Temporal-Spatial Pulmonary Function Maps

Temporal-spatial pulmonary function maps were generated from 3He MR images acquired
at three visits ( N  3 ), and an associated 1H MR image was arbitrarily chosen at visit 2 (
j  2 ).

3.3.1.1 Target Registration Error
Four corresponding fiducials were marked on each image volume (3Hevisit1, 3Hevisit2,
3

Hevisit3 and 1Hvisit2), for a total of 168 fiducials (24 per subject). The mean distance between

corresponding fiducials in the 3He-3He and 1H-3He image sets was 22±12mm and
19±10mm, respectively. For inter-visit 3He-3He registration, the mean TRE value for all
112 fiducials (56 pairs) was 7±5mm (range: 1mm-29mm).

For intra-visit 1H-3He

registration, the mean TRE for all 56 fiducials (28 pairs) was 6±3mm (range: 2mm-14mm).

3.3.1.2 Ventilation Defect Temporal Behavior
Figure 3-2 shows temporal-spatial pulmonary function maps for each subject and these
spatially quantified the short-term temporal behavior of 3He MRI ventilation defects. Lung
regions with persistent (black) and intermittent ventilation defects (blue) were identified,
the remaining regions were persistently ventilated (cyan). For all subjects evaluated, the
mean persistent ventilation defect percent was low (mean VDPP=0.2±0.2%) as was mean
intermittent ventilation defect percent (VDPI=4±2%). Mean persistent ventilation percent
was high (PVP=95±3%) across the three imaging sessions.

3.3.1.3 Anatomic Differences
As qualitatively shown in Figure 3-3 and quantitatively described in Figure 3-4, VDPP
and VDPI were evaluated in the AP and SI regions of interest. VDPI was significantly
greater in the posterior as compared to the centre (p=0.02) and anterior (p=0.04) lung
regions but VDPP was not different. In the inferior lung region, VDPI was significantly
greater (p=0.04) than the superior lung region, while VDPP was not different.
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Figure 3-3 Three-dimensional 3He MRI temporal-spatial pulmonary function maps for
three representative asthmatic subjects.
3D 3He MRI in the coronal, axial and sagittal view to qualitatively evaluate persistent and
intermittent ventilation defects. Both persistent and intermittent ventilation defects are
prominent in the gravity-dependent posterior and inferior lung regions.
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Figure 3-4 3He MRI intermittent ventilation defect percent (VDPI) and persistent
ventilation defect percent (VDPP) anatomical differences.
Plots show anatomical differences in VDPI and VDPP for regions of interest in the anteriorcentre-posterior (A, B) and superior-middle-inferior directions (C, D). Box and whisker
plots represent: minimum, 25th percentile, median, 75th percentile, and maximum.
Statistically significant differences between regions of interest are shown.

3.3.1.4 Relationships with Spirometry
Figure 3-5 shows correlations for VDPP and VDPI with baseline and post-exercise
FEV1/FVC. Both VDPP and VDPI were negatively correlated with baseline (VDPP: r=0.87, p=0.01; VDPI: r=-0.96, p=0.0008) and post-exercise FEV1/FVC (VDPP: r=-0.79,
p=0.04; VDPI: r=-0.96, p=0.003). There were no significant correlations for VDPP or VDPI
with FEV1%pred or FVC%pred.

107

Figure 3-5 Relationship of 3He MRI temporal-spatial pulmonary function with airflow
obstruction at baseline and following exercise challenge.
Baseline FEV1/FVC was significantly correlated with intermittent ventilation defect
percent (VDPI) (r=-0.96, p=0.0008) (A), and persistent ventilation defect percent (VDPP)
(r=-0.87, p=0.01) (B). Post-exercise FEV1/FVC was significantly correlated with VDPI
(r=-0.96, p=0.003) (C), and VDPP (r=-0.79, p=0.04) (D). Dotted lines indicate the 95%
limits of agreement.

3.4

Discussion

We aimed to exploit 3He MRI ventilation measurements to generate asthma temporalspatial pulmonary function maps in acknowledgement of the paucity of real-time
visualization/quantification tools available to identify temporal changes in regional
ventilation, especially in response to therapy. Therefore, here we developed a registrationsegmentation pipeline to generate 3He MRI temporal maps in mild-to-moderate asthmatics
in order to spatially quantify temporally persistent and intermittent ventilation defects.
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First, we acquired 3He MRI in seven asthmatic subjects, in whom there were no changes
in pulmonary function tests or 3He MRI VDP during a three-week data acquisition period.
For most subjects however, there were visually obvious differences in the regional
distribution of 3He ventilation defects over the three-week time period. Previous studies
have evaluated 3He MRI ventilation defects following bronchoconstriction13,20,21,30 and
bronchodilation,20,22 and these studies quantitatively described changes in the size and
number of ventilation defects. Other studies13,14,30 have evaluated ventilation defect
reproducibility prior to and following bronchoconstriction and bronchodilation. These
studies suggested that the location and the temporal occurrence of ventilation defects prior
to broncho-provocation were heterogeneous.30 We think that this important information
can be quantified and simplified using multiple 3He MRI time-points and that using a single
snapshot in time would likely be insufficient to quantify the complex interactions between
space, time and airway hyperresponsiveness. Persistent ventilation defects represented
regions that were always abnormal, perhaps due to remodeled, narrowed and/or collapsed
airways that altered the time constants for lung filling beyond the timeframe for MRI
acquisition (15 sec). Intermittent defects may be related to a number of underlying
physiological airway abnormalities such as variable airway lumen diameter, exposure to
triggers of hyperresponsiveness or mucus plugging.
MRI temporal-spatial pulmonary function maps may be used to regionally locate the
specific airways that are proximal to persistent or intermittent ventilation abnormalities as
potential targets for localized airway treatment such as bronchial thermoplasty.31 For
example, as shown in Figure 3-2 and Figure 3-3, for subject 3, the map provides evidence
of highly localized disease. For this subject, measurements of response to therapy to
localize treatment should be directed to the lower left lobe, and can avoid the upper left
lobe and the right lung.
Second, we observed that intermittent ventilation defects and persistently ventilated lung
showed regional differences or biases. All subjects were imaged in the supine position,
and in the gravity-dependent lung regions (posterior and inferior) VDP I was increased.
This suggests that ventilation defects are more variable over time in dependent lung
regions, a finding which must be further investigated. This finding is supported by
previous quantitative findings in both asthmatic and healthy subjects20 that VDP is greater
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in the dependent lung regions. Although the physiological mechanism responsible for this
observation is not known, airway collapse may be a plausible explanation.
Finally, we observed correlations for airflow obstruction (FEV1/FVC) with VDPI and
VDPP at baseline and following exercise-induced bronchoconstriction. Due to an increased
sensitivity of asthmatic airways to a range of constrictor agonists, bronchial
hyperresponsiveness is often referred to as the “hallmark” of asthma. Accordingly,
intermittent defects were identified in an attempt to spatially identify hyperresponsive
airways as potential therapy targets. We hypothesized that asthmatics with intermittent
defects would show greater response to broncho-provocation and interestingly, we did
observe a strong relationship between intermittent defects and post-exercise FEV1/FVC
(r=-0.96, p=0.003) in these seven asthmatics. This lends support to the notion that
temporal-spatial measurements may be identifying hyper-responsive lung regions or ROI
that are more likely to constrict during an exacerbation.
Although this preliminary demonstration provides promising proof-of-concept results, we
must acknowledge several limitations. Importantly, a sample size of seven is small,
therefore, our feasibility results should be considered a conservative estimate of VDPP and
VDPI. In fact, the immediate application of our method may be better-suited to poorlycontrolled and more severe asthma. Additionally, the maps generated here captured weekto-week lung function variability and not long-term ventilation defect persistence or
disease progression. The temporal persistence of ventilation defects was previously shown
to decrease with time,14 therefore a longer inter-visit interval than used here might yield
fewer persistent defect ROIs. Additionally, we recognize the importance of potential
registration errors and the effect this has on map interpretation – especially on the lung
periphery where sub-segmental defects tend to appear. In our experience, most registration
errors are derived from scan-to-scan variability/differences in lung inflation levels,
potentially due to gas trapping, and we therefore implemented a deformable registration
method to minimize this. If the methodology developed here was extended to generate
maps to display transient ROI in response to methacholine and/or salbutamol, the
application of the non-rigid registration algorithm presented here would be even more
essential to account for larger changes in lung volumes and shape. Finally, we must
consider our approach as a precursor to temporal-spatial pulmonary function maps
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generated using hyperpolarized

129

Xe gas22 as these will certainly play a more prominent

role in the future.32 Clearly, prior to the clinical application of this potential pulmonary
image-guidance tool extensive efficacy evaluations are required.

Specifically, a

randomized two-arm evaluation comparing the efficacy of conventional and image-guided
treatment will be necessary to determine if similar changes in asthma control and qualityof-life can be achieved as those obtained following conventional therapy.
By “seeing” the disease and its variability over time, we can potentially help improve
asthma treatments and outcomes, amounting to enormous clinical value. Therefore, this
work must be viewed as a first necessary step towards the development of high resolution
image-guidance maps to help target specific airway abnormalities in asthmatics who
undergo localized asthma therapies, such as bronchial thermoplasty, that currently are not
guided by imaging to abnormally functioning lung. In conclusion, personalized asthma
temporal-spatial pulmonary function maps were generated from thoracic 3He MRI to
visualize and quantify regional ventilation defects observed over time.
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CHAPTER 4
Towards the goal of understanding the structural determinants and clinical consequences
of MRI ventilation defects in asthma, we evaluated well-established clinical and emerging
CT-derived airway morphology measurements in healthy volunteers and asthmatics with
and without ventilation defects.
The contents of this chapter were previously published in the journal Thorax: S
Svenningsen, M Kirby, D Starr, HO Coxson, NA Paterson, DG McCormack and G
Parraga. What are Ventilation Defects in Asthma? Thorax 2014; 69(1):63-71. Permission
to reproduce this article was granted by BMJ Publishing Group Ltd and is provided in
Appendix A.

4

WHAT ARE VENTILATION DEFECTS IN ASTHMA?

4.1

Introduction

Asthma is typically diagnosed and characterized using the spirometry measurement1,2 of
the forced expiratory volume in 1 second (FEV1).

Although relatively simple and

inexpensive, spirometry measurements provide a global estimate of the morphological
changes in the small and medium-sized airways that are believed to be related to luminal
inflammation, airway remodeling and constriction. We now realize using multiple breath
nitrogen washout studies3,4 and pulmonary imaging methods, that functional abnormalities
in asthma are in fact regionally heterogeneous,5-7 temporally persistent8-10 and that these
abnormalities regionally respond to broncho-provocation7,11,12 and to bronchodilator
therapy.11,13 Thoracic x-ray computed tomography (CT) has been used for over a decade
as a non-invasive method to investigate structure-function relationships of asthmatic
airways and has shown strong relationships between CT-derived airway measurements
with inflammation,14,15 spirometry14-21 and disease severity.14,16,20,22 However, while these
CT data are encouraging, they are still somewhat limited because it is well recognized that
CT cannot resolve or measure airways beyond the 5th or 6th generation. Moreover, even
using new lower dose and iterative reconstruction methods,23 CT is not recommended for
longitudinal studies and studies of young adults and children because of the potential risks
associated with exposure to ionizing radiation. Other pulmonary imaging methods such as
nuclear medicine scintigraphy24-26 and positron emission tomography (PET)27 are also
limited clinically because of inherently low spatial resolution.
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Hyperpolarized 3He magnetic resonance imaging (MRI) has been previously used to
visualize heterogeneous and abnormal gas distribution in asthma. Regions of signal void
or ventilation defects have been shown to be temporally persistent8-10 and to correlate
significantly with spirometry,6,28,29 disease severity6 and CT measurements of gas
trapping.28

In addition, 3He MRI also provides a way to perform intensive serial

measurements due in part to its excellent safety profile,30 and the speed with which imaging
can be performed. More specifically, 3He MRI ventilation defects have been shown to
increase from baseline following both methacholine7,11,12 and exercise12 challenge, and
decrease from baseline following salbutamol administration.13 In asthma, the relationship
between ventilation defects and patient outcomes such as exacerbation frequency and
severity has not yet been evaluated, however this has been evaluated in chronic obstructive
pulmonary disease (COPD).31 Recently, there has been growing interest in the clinical
application of hyperpolarized gas MRI to assess treatment efficacy and furthermore to
guide localized airway treatments in asthma. Preliminary work in severe asthma has shown
improved 3He gas distribution following localized bronchial thermoplasty treatment.32
While these results provide a strong foundation for the use of MRI in asthma research and
patient care, a major drawback has been that we do not clearly understand the etiology of
MRI ventilation defects.33 It has been speculated that MRI ventilation defects reflect
regional airway narrowing that may be the consequence of airway remodeling;34 however,
to our knowledge, the direct spatial and quantitative relationship between MRI ventilation
defects and CT airway measurements has not been reported in asthmatics. Therefore, our
objective was to determine the underlying structural and clinical determinants of asthma
ventilation abnormalities by evaluating well-established clinical and emerging imaging
(hyperpolarized 3He MRI and CT) measurements in healthy volunteers and subjects with
asthma.

4.2

Methods

4.2.1

Study Subjects

All subjects provided written informed consent to a study protocol approved by the local
research ethics board, and the study was compliant with the Personal Information
Protection and Electronic Documents Act (PIPEDA, Canada) and the Health Insurance
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Portability and Accountability Act (HIPAA, USA). Subjects were enrolled between 18
and 60 years of age, including mild-to-moderate35 asthmatics, and healthy subjects with no
history or diagnosis of asthma or any other chronic or current acute respiratory illness.
Asthmatic subjects were phenotyped from health records based on disease severity and
symptoms from a tertiary care centre (interdisciplinary Allergy and Respirology asthma
care centre); all asthma subjects had a current physician diagnosis of asthma, were
currently under treatment for asthma and had a positive methacholine challenge within the
past five years. At a single visit, spirometry, plethysmography, fractional exhaled nitric
oxide (FeNO) breath analysis and pulmonary CT was performed within 30 minutes of MRI.

4.2.2

Pulmonary Function Tests

Spirometry and plethysmography were performed according to American Thoracic Society
Guidelines36 using an ndd EasyOne spirometer (ndd Medizintechnik AG, Zurich,
Switzerland) and a MedGraphics Elite Series plethysmograph (MedGraphics, St. Paul,
MN, USA), respectively. FeNO was measured using a Niox Mino (Aerocrine Inc. USA,
New Providence, NJ, USA).

Methacholine challenge was performed as previously

described 11 and the provocative concentration causing a 20% decrease in FEV1 (PC20) was
determined. Borg and modified Medical Research Council (mMRC) dyspnea scores were
recorded.

4.2.3

Magnetic Resonance Imaging

MRI was performed on a whole body 3.0 Tesla Discovery 750MR (General Electric Health
Care, Milwaukee, WI, USA) system with broadband imaging capability, as previously
described.37 Subjects were instructed to inhale a gas mixture from a 1.0L Tedlar ® bag
(Jensen Inert Products, Coral Springs, FL, USA) from functional residual capacity (FRC),
and image acquisition was performed in 8-15s under breath-hold conditions. Conventional
1

H MRI was performed prior to hyperpolarized 3He MRI, both methods are previously

described.37
3

He MR images were qualitatively and quantitatively evaluated for ventilation

abnormalities by a single trained observer. Upon qualitative inspection, asthmatic subjects
were classified into two groups, 1) asthmatics with no ventilation defects (ND) and
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asthmatics with ventilation defects (AD). If 3He gas was homogenously distributed
throughout the lung and there were no visible ventilation defects the subject was classified
as belonging to the ND group. In contrast, if 3He gas was heterogeneously distributed
throughout the lung and/or there were visually obvious ventilation defects, the subject was
classified as belonging to the AD group.

Quantitative evaluation of 3He MRI was

performed to estimate ventilation defect percent (VDP) and ventilation heterogeneity using
the coefficient of variation (COV). 3He MRI semi-automated segmentation was performed
to quantify lung volumes using custom software generated using MATLAB R2007b (The
Mathworks Inc., Natick, MA, USA), as previously described.38 As shown in Figure 4-1,
3

He static ventilation images were segmented using a K-means approach that classified

voxel intensity values into five clusters ranging from signal void (cluster 1 (C1) or
ventilation defect volume (VDV)) to hyper-intense signal (cluster 5 (C5)) to create a gas
distribution cluster-map.

3

He MRI VDP was generated using VDV normalized to the

thoracic cavity volume. Whole lung and regional VDP specific to the CT region-of-interest
(ROI) were generated for each subject. Ventilation heterogeneity was estimated according
to previously described methods7 using the COV. Briefly, a ventilated lung ROI was
defined as gas distribution cluster-map clusters C2-C5.

For each voxel within the

ventilated lung ROI a local ventilation heterogeneity value was calculated by computing
the COV of the signal intensity in the voxels 5 x 5 neighborhood. Mean COV for each
slice was calculated for each 3He static ventilation slice and then averaged to obtain a single
COV value for each subject.

4.2.4

Computed Tomography

Following 3He MRI, thoracic CT was performed with the same inhalation breath-hold
volume and manoeuvre used for MRI, in order to match CT and MRI lung volume and
anatomy. CT imaging was performed in the supine position using a 64-slice Lightspeed
VCT scanner (GEHC, Milwaukee, WI USA) using a detector configuration of 64×0.625
mm, 120 kVp, 100 mA, 0.5 second gantry rotation, and a pitch of 1.25. To reduce the
radiation dose, CT was obtained for a 4cm axial ROI where there were visually obvious
MRI ventilation defects. In the case where there were no visually obvious ventilation
defects, the CT volume was acquired in the superior region of the lung. This approach
119

resulted in CT volumes consisting of 32-80 slices and a total effective dose ranging from
0.37 mSv to 0.14 mSv, (generated using the CT parameters and algorithm at
www.impactscan.org).
CT image analysis was performed using Pulmonary Workstation 2.0, (VIDA Diagnostics;
Iowa City, IA, USA) to generate bronchial wall area percent, wall thickness percent and
lumen area for all 3rd-5th generation segmental bronchi analyzed and lumen area was
normalized to body surface area.39 As shown in Figure 4-1, an automated airway tree
segmentation algorithm was applied with a manual seed-point in the airway lumen
introduced if the trachea and main bronchus were not present in the image. For each
subject, all airway segment measurements were averaged to report whole lung means. To
identify potential spatial relationships between

3

He MRI ventilation defects and

corresponding airways, CT-MRI co-registration was performed using 3D Slicer
registration software (http://www.slicer.org).40
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Figure 4-1 Schematic for 3He MRI – Regional CT image acquisition, co-registration and
analysis.
A region-of-interest (ROI) (green-yellow rectangle) with ventilation defects was located
using 3He MRI. Following MRI, regional CT was acquired in that specific ROI.
Ventilation defect percent (VDP) was quantified for the whole lung and the CT-derived
ROI and an automated airway tree segmentation algorithm (VIDA) was applied to obtain
airway measurements. Using the carina and trachea as a landmark, the regional CT with
rendered airways was rigidly co-registered with the corresponding MR image to confirm
the spatial relationship between ventilation defects and corresponding airways.
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4.2.5

Statistical Analysis

Pulmonary function tests, MRI and CT measurements were compared between subject
groups using unpaired Student t-tests performed using SPSS 20.0 (IBM, Armonk, NY,
USA).

Linear regression (r2) and Spearman rank correlation coefficients (r) were

performed using GraphPad Prism version 4.00 (Graphpad Software Inc, San Diego, CA,
USA). Results were considered statistically significant when the probability of making a
Type I error was less than 5% (p < 0.05).

4.3

Results

We enrolled 34 subjects including 26 subjects with a clinical diagnosis of asthma and
previous methacholine challenge results consistent with asthma, and 8 healthy volunteers.
Table 4-1 shows subject demographic data, pulmonary function measurements, and
dyspnea scores for the two subgroups, and a subject listing of all data is provided in the
online supplement, Table 4-3S.
Table 4-1 Subject demographic characteristics for asthmatics and healthy volunteers.
Healthy
Asthmatics
(n=8)
(n=26)
Subject Demographics

Age yrs (±SD)
Male/Female
BMI kg/m2 (±SD)

34 (11)
4/4
23 (3)

35 (11)
12/14
25 (5)

Pulmonary Function Tests

FEV1 %pred(±SD)
102 (10)
84 (15)
FVC %pred (±SD)
103 (10)
93 (11)
FEV1/FVC % (±SD)
81 (6)
74 (11)
sRaw cmH2O·s (±SD)
3.0 (0.5)
6.9 (4.7)
FeNO ppb (±SD)
18*
44 (45)
PC20 mg/ml (±SD)
42.3 (19.2)
5.9 (12.3)
Dyspnea Scores
mMRC Score (±SD)
0 (0)
1 (1)
Borg Score (±SD)
0 (0)
0.5 (1)
SD=Standard Deviation, BMI=Body Mass Index, FEV1=Forced Expiratory Volume in 1s,
%pred= Percent Predicted, FVC=Forced Vital Capacity, sRaw=Specific Airway Resistance,
FeNO=Fraction of Exhaled Nitric Oxide, PC20= provocative concentration of methacholine
sufficient to induce a 20% decrease in FEV1, mMRC=modified Medical Research Council.
*
n=1

122

Upon qualitative visual inspection, nine of the 26 asthmatics had no ventilation defects
(ND) and 17 had visually obvious asthma ventilation defects (AD). Figure 4-2 shows
posterior, centre and anterior 3He MRI static ventilation coronal slices (in blue) coregistered to the 1H anatomical MRI (in grey-scale) for a representative healthy volunteer
as well as ND and AD asthmatics with yellow arrows identifying ventilation defects. For
both healthy volunteers and ND asthmatics, 3He gas was homogeneously distributed
throughout the lung whereas in contrast, AD asthmatics had visually obvious ventilation
heterogeneity and ventilation defects. Of the 8 healthy volunteers and 26 asthmatics
evaluated, 2 healthy volunteers and 12 asthmatics underwent imaging across multiple
timepoints ranging from 4 years prior, to 2 years following the study session reported here.
In accordance with the study visit data presented here, both healthy volunteers had no
ventilation defects at their additional timepoint. All asthmatics who underwent multiple
imaging timepoints were AD asthmatics and all of these subjects had ventilation defects at
their additional timepoint and in the same spatial locations. Moreover, for all asthmatic
subjects with repeated imaging measurements (n=12), VDP was not significantly different
(p=0.49) from measurements acquired and reported in this study.
As shown in Table 4-2, AD subjects were significantly older than ND subjects (p=0.01)
with significantly worse FEV1/FVC (p=0.0003), specific airways resistance (sRaw)
(p=0.004), FeNO (p=0.03), PC20 (p=0.008), COV (p=0.046), wall thickness percent
(p=0.02) and lumen area normalized to body surface area (p=0.04), but importantly there
was no mean difference for FEV1 (p=0.08), FVC (p=0.71) or dyspnea (mMRC: p=0.79,
Borg: p=0.12). As compared to healthy subjects, AD subjects had significantly worse
FEV1 (p=0.001), FEV1/FVC (p=0.003), sRaw (p=0.003), PC20 (p<0.0001), COV (p=0.007)
wall area percent (p=0.001), wall thickness percent (p=0.04), and lumen area normalized
to body surface area (p=0.0003), but there was no significant difference for FVC (p=0.06).
ND subjects had significantly worse FVC (p=0.04), PC20 (p=0.02) and wall area percent
(0.03) compared to healthy volunteers, but no significant difference for FEV1 (p=0.09),
FEV1/FVC (p=0.36), sRaw (p=0.36), COV (p=0.11), wall thickness percent (p=0.61) or
lumen area normalized to body surface area (p=0.26).
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Figure 4-2 Hyperpolarized 3He MRI of a representative healthy volunteer and asthmatic
subjects.
3
He MRI gas distribution (in blue) registered to the 1H MRI of the thorax (in grey-scale)
for posterior, centre and anterior coronal slices for a representative healthy volunteer, an
asthmatic with no ventilation defects, and two asthmatics with ventilation defects. Yellow
arrows identify ventilation defects.
Healthy Volunteer: 27 yr old female, FEV1=105%pred, FEV1/FVC=85%, sRaw=2.60
cmH2O·s; Asthmatic 1 No Defects: 23 yr old female, FEV1=82%pred, FEV1/FVC=79%,
sRaw=3.80 cmH2O·s; Asthmatic 2 Defects: 25 yr old female, FEV1=87%pred,
FEV1/FVC=69%, sRaw=5.36 cmH2O·s; Asthmatic 3 Defects: 42 yr old male,
FEV1=72%pred, FEV1/FVC=65%, sRaw=13.85 cmH2O·s.
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Table 4-2 Subject demographic characteristics, pulmonary function, hyperpolarized 3He
MRI and x-ray CT airways measurements for asthmatics and healthy volunteers.
Healthy
(n=8)

Subject Demographics
Age yrs (±SD)
34 (11)
Male/Female
4/4
Pulmonary Function Tests
FEV1 %pred(±SD)
102 (10)
FVC %pred (±SD)
103 (10)
FEV1/FVC % (±SD)
81 (6)
sRaw cmH2O·s
2.96
(±SD)
(0.53)
FeNO ppb (±SD)
18†
PC20 mg/ml (±SD)
42.3
(19.2)
Dyspnea
mMRC Score (±SD) 0.0 (0.0)
Borg Score (±SD)
0.1 (0.2)
3
He MRI
Whole Lung VDP%
1.22
(±SD)
(0.19)
Regional VDP%
0.94
(±SD)¥
(0.28)
Whole Lung COV
0.22
(±SD)
(0.02)
Regional CT¥
WA% (±SD)
62 (2)
WT% (±SD)
24 (4)
LA mm2 (±SD)
18 (3)
LA/BSA mm2/m2
10 (2)
(±SD)

Asthma
(n=26)

Significance of Difference*
(p)
HV vs.
HV vs.
ND vs.
ND
AD
AD

ND
(n=9)

AD
(n=17)

27 (8)
2/7

39 (11)
10/7

0.19
-

0.29
-

0.01
-

91 (13)
92 (10)
84 (7)
3.42(1.22)

81 (14)
94 (11)
69 (10)
8.51(4.95)

0.09
0.04
0.36
0.36

0.001
0.06
0.003
0.003

0.08
0.71
0.0003
0.004

17 (9)‡
14.3(16.8)

60 (50)δ
1.4 (3.9)

0.02

<0.0001

0.03
0.008

0.7 (0.7)
0.2 (0.3)

0.8 (1.0)
0.7 (0.8)

0.02
0.28

0.04
0.047

0.79
0.12

1.31(0.32)

4.26(3.28)

-

-

-

0.95(0.40)

2.35(0.98)

-

-

-

0.23(0.01)

0.26(0.03)

0.11

0.007

0.046

66 (3)
25 (2)
14 (6)
8 (3)

69 (3)
29 (4)
11 (4)
6 (2)

0.03
0.61
0.19
0.26

0.001
0.04
0.002
0.0003

0.08
0.02
0.12
0.04

ND=Asthmatics with No Defects, AD=Asthmatics with Defects, SD=Standard Deviation,
FEV1=Forced Expiratory Volume in 1s, %pred= Percent Predicted, FVC=Forced Vital
Capacity, sRaw=Specific Airway Resistance, FeNO=Fraction of Exhaled Nitric Oxide,
PC20= provocative concentration of methacholine sufficient to induce a 20% decrease in
FEV1, mMRC=modified Medical Research Council, VDP=Ventilation Defect Percent,
COV=Coefficient of Variation, WA%=Wall Area Percent, WT%=Wall Thickness Percent,
LA=Lumen Area, BSA=Body Surface Area. *Significance of difference (p<0.05)
determined using a t-test. †n=1; ‡n=8; δn=13; ¥HV: n=5; ND: n=9; AD: n=9.
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Figure 4-3 shows the correlations for FEV1 and sRaw with whole lung VDP, regional VDP
and wall area percent. FEV1 was significantly correlated with both 3He MRI VDP (whole
lung: r=-0.61, p=0.0002; regional: r=-0.55, p=0.006) and wall area percent (r=-0.49,
p=0.02). In addition, sRaw was significantly correlated with both 3He MRI VDP (whole
lung: r=0.77, p<0.0001; regional: r=0.81, p<0.0001) and wall area percent (r=0.48,
p=0.02). Additionally, FEV1 and sRaw were significantly correlated with whole lung 3He
MRI COV (FEV1: r=-0.49, p=0.003; sRaw: r=0.59, p=0.0003). Figure 4-4 demonstrates
that for all subjects wall area percent was significantly correlated with whole lung (r=0.42,
p=0.046) and regional VDP (r=0.43, p=0.04).

Figure 4-3 Relationships of MRI and CT measurements with FEV1 and airways resistance.
(A) Negative relationship between 3He MRI VDP and FEV1%pred (WL: r=-0.61, r2=0.20,
p=0.0002; RG: r=-0.55, r2=0.26, p=0.006).
(B) Positive relationship between 3He MRI VDP and specific airways resistance (sRaw)
(WL: r=0.77, r2=0.62, p<0.0001; RG: r=0.81, r2=0.75, p<0.0001).
(C) Negative relationship between wall area percent and FEV1%pred (r=-0.49, r2=0.23,
p=0.02).
(D) Positive relationship between wall area percent and specific airways resistance (sRaw)
(r=0.48, r2=0.21, p=0.02).
WL=whole lung, RG=regional, WA%=wall area percent
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Figure 4-4 Relationship between 3He MRI VDP and CT-derived wall area percent (WA%)
WA% was significantly correlated with both whole lung 3He MRI VDP (r =0.42, r2=0.11,
p=0.046) and regional 3He MRI VDP (r =0.43, r2=0.15, p=.04).
Dashed lines represent the 95% confidence intervals of the regression line.

Figure 4-5 shows hyperpolarized 3He MRI ventilation maps for four asthmatics with the
3

He MRI ventilation map in blue co-registered to the CT volume with the airway tree

segmented in yellow. The qualitative spatial relationship between ventilation defects
(yellow arrows) and remodeled airways (white arrows) is shown.

127

Figure 4-5 Spatial relationship between ventilation defects and airways for four
representative asthmatics with ventilation defects.
3
He MRI gas distribution (in blue) registered to the regional CT of the thorax (in greyscale) with the airway tree segmented in yellow. Airway measurements are for the specific
airway (white arrow) spatially related to the ventilation defect (yellow arrow) of interest.
Panel A is a 29 yr old male FEV1=81%pred, regional VDP=5%, wall area=71%, lumen
area=5mm2; Panel B is a 49 yr old male, FEV1=60% pred, regional VDP=3%, wall area
=67%, lumen area=12mm2 ; Panel C is a 25 yr old female, FEV1=87% pred, regional
VDP=2%, wall area =75%, lumen area=5mm2; Panel D is a 58 yr old male, FEV1=73%
2
pred, regional VDP=1%, wall area=70%, lumen area=5mm .

4.4

Discussion

To better understand the structural and clinical determinants of MRI ventilation defects in
asthma, and, in turn, what it might mean for an asthmatic to have ventilation defects, we
evaluated well-established clinical measurements and emerging CT and 3He MRI
measurements of airway structure and function.
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We think that it is interesting that 9/26 (35%) subjects with clinical findings and
methacholine challenge results diagnostic of asthma had a 3He MRI gas distribution that
was qualitatively and quantitatively (VDP and COV) similar to healthy volunteers. It is
important to note that all of the healthy volunteers had a homogenous gas distribution with
no visual or quantitative evidence of ventilation defects, which is in agreement with
previous work at our centre11,41-43 and others.5,7,44 In contrast, and as expected based on
previous investigations,5-9,11,12 the remaining 17/26 (65%) asthmatics had obvious
ventilation abnormalities.

This observation prompted us to ask the question: Are

asthmatics with ventilation defects different than asthmatics without ventilation defects?
The results here suggest that asthmatics with ventilation defects are older, with worse
FEV1/FVC, (but similar FEV1), and greater airways resistance, airway responsiveness, and
airway inflammation/remodeling. Such findings suggest that ventilation defects may
reflect long-term or progressive airway remodeling in patients with a longer history of
disease or perhaps more severe or advanced disease. Regardless, the constellation of
clinical and imaging findings in these asthmatics suggest that more aggressive therapy or
compliance to therapy is required. This is a hypothesis that can be tested in future imaging
studies of older and/or more severe asthmatics.
A number of studies have quantitatively investigated asthma airway structure using CT and
showed that bronchial wall thickness was related to asthma severity, duration of disease
and airflow obstruction.14-22 Similarly, 3He MRI has previously shown that ventilation
defects were related to asthma severity6 and in a preliminary report,45 half of a small group
of asthmatics (7/15) showed no obvious ventilation defects, with significantly different
bronchial wall thickness (but not bronchial wall area) compared to asthmatics with
ventilation defects. Here, we prospectively acquired both MRI and CT within about 30
minutes using the same lung volume and breath-hold manoeuvre to try to mimic the same
airway and parenchyma dimensions using both imaging methods. We must consider that
because 3He gas is itself, highly diffusive and may penetrate even narrowed airways, there
is the possibility that even when bronchial wall thickness and lumen area are abnormal,
some 3He gas ventilation is possible. In support of this explanation, we note the recent
report of indirect or collateral ventilation in COPD that was directly visualized using
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hyperpolarized 3He MRI46 – likely possible only because the timeframe for imaging was
relatively long and 3He gas is highly diffusive.
We also observed that regional CT airway morphology and 3He ventilation defect
measurements were significantly correlated. This important finding suggests that there is
a relationship between airways that are remodeled and/or constricted and ventilation
defects. Previous studies have demonstrated that focal regions of hyperlucency on CT
(likely related to gas trapping) were spatially correlated with 3He MRI ventilation defects28
and bronchoalveolar lavage had higher total and percent neutrophils in areas of the lung
with greater ventilation defects, suggestive of increased inflammation. Although we
observed significant relationships between airway dimensions and defects, these
relationships were modest, perhaps because of the heterogeneity of asthma and the asthma
patients evaluated here, or because of the relatively low dose partial CT region of interest
that was utilized. It is important to acknowledge that in asthma, the airways from the large
bronchi to the alveolar ducts may be involved,47 thus using CT to measure airway
dimensions has limitations because CT cannot spatially resolve the small airways (<2mm)
sufficiently to provide accurate measurements. In addition to small and heterogeneously
distributed ventilation defects, some of the asthmatics evaluated here presented large
wedge shaped defects; these have previously been reported using single photon emission
computed tomography (SPECT) imaging with Technegas25 and are believed to be the result
of segmental airway narrowing. Following MRI-CT registration we were able to identify
and quantify segmental bronchi that were spatially related to ventilation defects. Larger
‘segmental’ ventilation defects may be the result of proximal remodeled sub-segmental
airways feeding these regions of signal void. Unfortunately, due to the limitations of the
spatial resolution of the CT images, we cannot comment on the structure of the smaller
airways distal to the sub-segmental airways quantified here, which may further contribute
to the abnormal gas distributions observed.
Large and temporally persistent 3He ventilation defects, provide excellent targets for
therapy and could potentially guide localized airway treatments such as bronchial
thermoplasty. Although we have focused our attention on ventilation defects, areas of
hyper-intense signal intensity are often observed in asthmatic subjects in conjunction with
ventilation defects. Similar to regions of signal void, to our knowledge, the underlying
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etiology of these regions has not been investigated. We hypothesize that hyper-intense
signal may be due to hyperinflation and note that investigation of these regions is warranted
in asthma.
We recognize and acknowledge that this work was limited by the relatively small number
of subjects evaluated, although we note that this is the single largest prospective study that
directly compared CT and 3He MRI in asthmatics and healthy subjects. Furthermore, the
subjects evaluated here were enrolled from a multi-disciplinary asthma care centre and
therefore they represent a diverse group of asthmatics that have been mainly referred to
improve asthma symptoms and control. As shown in Figure 4-3, there was a single subject
with elevated VDP as compared to the other AD subjects and we confirmed that this 42
year old male had experienced an asthma exacerbation that required hospitalization
approximately 5 months prior to hyperpolarized 3He MRI performed here. This subject’s
asthma was previously well-controlled and the exacerbation was determined to be the result
of sudden cessation of asthma medication. It is important to note that the relationships
presented in Figure 4-3 remain statistically significant when this outlier is removed from
the analysis. Certainly, this is a hypothesis generating study and therefore marginally
significant p-values should be interpreted with caution, and larger studies are required for
more extensive phenotyping and characterization of asthmatics and to test the hypotheses
generated here. We must also acknowledge that our analysis was limited because of the
acquisition of partial CT thoracic volumes.
In summary, our results showed that asthmatics with 3He MRI ventilation abnormalities
were older, with greater airway hyperresponsiveness, and worse measurements of
FEV1/FVC and airways resistance/inflammation as well as abnormally remodeled airways
in comparison to asthmatics without ventilation defects. Hyperpolarized 3He ventilation
abnormalities were spatially and quantitatively related to remodeled airways in asthmatics
providing a better understanding of the etiology of heterogeneous ventilation abnormalities
in asthma and the clinical meaning of these abnormalities in asthmatics with similar FEV1.
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Table 4-3S Subject listing of demographic characteristics, pulmonary function and dyspnea.
Subject

Age
(yrs)

Gender

FEV1
(%pred)

FVC
(%pred)

FEV1/FVC
(%)

021
023
027
030
031
033
034
035
Mean(±SD)

27
39
24
50
26
23
30
50
34(11)

F
M
M
F
F
M
M
F
-

105
86
108
106
97
93
101
117
102(10)

105
95
110
107
90
91
108
118
103(10)

85
72
80
79
93
85
77
79
81(6)

005
006
007
008
010
017
018
020
024
Mean(±SD)

45
23
24
34
30
23
22
23
20
27(8)

F
F
M
M
F
F
F
F
F
-

78
96
81
82
102
112
79
82
108
91(13)

87
91
85
79
101
102
83
91
110
92(10)

72
92
81
84
87
96
82
79
86
84(7)

001
002
003
004
011
012
013
014
015
016
019
022
025
026
028
029
032
Mean(±SD)

49
30
29
49
23
25
37
29
47
53
42
24
58
37
36
41
49
39(11)

F
M
M
F
F
F
M
F
M
M
M
F
M
M
F
M
M
-

69
96
81
59
98
87
77
92
60
104
72
99
73
93
66
75
69
81(14)

94
105
100
75
93
107
77
102
82
104
88
111
99
93
92
95
77
94(11)

59
75
66
63
91
69
81
77
57
77
65
76
56
66
59
63
70
69(10)

IC
RV
TLC
(%pred)
(%pred)
(%pred)
Healthy Volunteers (n=8)
124
107
113
125
182
118
113
179
121
134
75
110
99
109
96
110
99
99
111
102
109
126
88
115
118(11)
118(40)
110(9)
Asthmatics with No Defects (n=9)
124
108
102
107
104
97
86
111
94
110
105
91
135
82
96
128
164
122
90
115
91
104
69
87
138
85
99
114(18)
105(25)
98(10)
Asthmatics with Defects (n=17)
116
144
110
122
108
109
118
115
111
84
130
96
101
113
95
119
98
101
107
135
97
98
96
97
99
115
94
111
82
100
110
144
108
132
90
108
91
121
110
105
107
109
129
165
113
114
136
106
98
98
87
109(13)
117(22)
103(8)

sRaw
(cmH2O·s)

FeNO
(ppb)

PC20
(mg/ml)

mMRC

2.60
2.77
4.00
3.08
3.24
2.18
2.81
3.01
2.96(0.53)

18
-

8.5
54.4
46.1
52.6
49.9
42.3(19.2)

0
0
0
0
0
0
0
0
0(0)

0
0
0.5
0
0
0
0
0
0.1(0.2)

0.0
0.0
2.0
2.0
0.5
0.0
0.5
0.5
0.7(0.8)

4.97
1.50
3.22
2.67
2.25
3.95
5.58
3.80
2.88
3.42(1.22)

8
12
16
21
12
37
17
10
17(9)

2.4
16.9
27.9
55.2
3.4
13.2
0.4
0.3
9.1
14.3(16.8)

2
1
0
0
1
0
0
1
1
0.7(0.7)

0.5
1
0.5
0
0
0
0
0
0
0.2(0.3)

4
7
3
3
2
3
3
2
4
3.4(1.4)

10.20
5.11
19.50
2.93
5.36
10.42
2.64
6.51
4.78
13.85
6.40
8.38
4.33
15.74
13.76
6.31
8.51(4.95)

38
114
116
50
31
18
45
22
40
187
29
69
23
60(50)

0.08
0.2
0.1
0.07
0.2
0.1
0.1
1.3
0.3
16.3
0.1
0.2
1.0
2.6
0.8
0.1
1.0
1.4(3.9)

0
0
1
0
1
1
4
1
0
0
1
0
0
1
1
1
1
0.8(1.0)

1
0
0.5
0
1
0
1
1
0.5
0
0
0
0.5
0.5
3
2
0.5
0.7(0.8)

1
4
3
2
3
3
3
3
4
4
1
3
0
3
3
3
3
2.7(1.1)

Baseline

Borg
Post-MCh

SD=Standard Deviation, FEV1=Forced Expiratory Volume in 1s, %pred= Percent Predicted, FVC=Forced Vital Capacity, IC=Inspiratory
Capacity, RV=Residual Volume, TLC=Total Lung Capacity, sRaw=Specific Airway Resistance, FeNO=Fraction of Exhaled Nitric
Oxide, PC20=provocative concentration of methacholine sufficient to induce a 20% decrease in FEV1, mMRC=modified Medical
Research Council.
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CHAPTER 5
Improving asthma control is the primary treatment goal for asthmatics. Links between
asthma control and ventilation defects have not been ascertained so we endeavoured to
answer the question, “What is the relationship of asthma control with in vivo ventilation
defects quantified and regionally visualized using MRI?”
The contents of this chapter are in preparation to be submitted to the journal Radiology: S
Svenningsen, P Nair, DG McCormack and G Parraga. What do Ventilation Defects Reveal
about Asthma Control? Radiology (To be submitted December 2015).

5

WHAT DO VENTILATION DEFECTS REVEAL ABOUT
ASTHMA CONTROL?

5.1

Introduction

The primary goal of asthma treatment is the achievement and maintenance of disease
control. Unfortunately, approximately 50% of asthmatics remain poorly controlled with
up-to 10% of these patients experiencing severe and life-threatening exacerbations.1 It is
now well-understood that the clinical and pathophysiological characteristics of poorlycontrolled asthma are heterogeneous which makes treatment decisions particularly
complex. Because of this heterogeneity, sensitive and specific disease biomarkers are
required to guide treatment decisions aimed at improving asthma control. Recent studies
using multiple-breath-gas-washout techniques have suggested that poor asthma control
may be related to ventilation heterogeneity.2,3 Although the exact pathophysiological
abnormalities responsible for ventilation heterogeneity are unclear, these may include
regional variations in luminal accumulation of inflammatory cells, mucus, albumin and
fibrin, thickening of the airway walls, smooth muscle hyperplasia and hypertrophy, subepithelial fibrosis and mucus cell metaplasia.
Ventilation heterogeneity measured using the lung clearance index (LCI), was first
described over 65 years ago,4 and has endured as a biomarker of obstructive lung disease.
Ventilation heterogeneity in asthmatics is elevated in comparison to healthy controls,5-7 is
an

independent

determinant

of

airway

hyperresponsiveness,8

improves

with

bronchodilation5,9 and inhaled corticosteroids3,10 and worsens during exacerbations.11
Although this mature body of research strongly supports the notion that LCI is sensitive to
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ventilation heterogeneity in asthma, such measurements cannot localize the site of these
functional abnormalities.
On the other hand ventilation defects may be regionally identified and visualized using
pulmonary imaging methods12,13 including noble gas magnetic resonance imaging (MRI).14
It was previously established that in well-controlled asthmatics, focal MRI ventilation
defects are associated with worse lung function, increased airway inflammation, airway
hyperresponsiveness and greater airway wall thickness.15 Furthermore, MRI ventilation
defects are temporally and spatially persistent,16 worsen in response to bronchoconstriction
and improve following bronchodilation.17
Until now however, the relationship between ventilation defects and asthma control and
exacerbations has not been ascertained. Therefore, the purpose of this small study in severe
asthmatics was to investigate MBNW and MRI measurements of ventilation heterogeneity
to better understand their relationship with asthma control. We hypothesized that MRI
ventilation defects and the lung clearance index would be correlated, and that both would
be biomarkers of poor asthma control. Given the relative lack of therapy options for severe
asthma, this is important because regional ventilation defects and the lung clearance index
provide endpoints that might be helpful in guiding treatment decisions aimed at improving
asthma control.

5.2

Methods

5.2.1

Study Participants and Design

Participants provided written informed consent to a study protocol approved by a local
research ethics board, and the study was compliant with the Personal Information
Protection and Electronic Documents Act (PIPEDA, Canada) and the Health Insurance
Portability and Accountability Act (HIPAA, USA). Patients between 18 and 70 years of
age with a diagnosis of severe asthma, according to the Global Initiative of Asthma (GINA)
treatment step criteria

18

and under the care of a respirologist were recruited from two

academic tertiary care centres (McMaster and Western Universities, Canada).
During a single 2-hour visit, all participants performed pre- and post-bronchodilator
spirometry, MBNW and MRI. Asthma-control and quality-of-life was assessed using the
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Asthma-Control-Questionnaire (ACQ; 7-item version)19 and Standardized-AsthmaQuality-of-Life-Questionnaire (AQLQ(S)),20 respectively. Borg and modified Medical
Research Council dyspnea scores were recorded. Clinical history of severe asthma
exacerbations, emergency department (ED) visits and hospitalizations for respiratory
symptoms were self-reported. As previously defined,21 a severe asthma exacerbation was
a worsening of symptoms requiring treatment with oral or intravenous corticosteroids, OR
a doubling of inhaled corticosteroid (ICS) dose for ≥ 3 days, OR any temporary increase
in the dosage of oral corticosteroids (OCS) for subjects taking maintenance OCS.
Methacholine challenge was performed within 6 months previous to the MRI visit to
determine the provocative concentration resulting in a ≥20% decrease in FEV1 (PC20).

5.2.2

Pulmonary Function Tests and Bronchial Challenge

Spirometry was performed according to American Thoracic Society Guidelines 22 using a
MedGraphics Elite Series plethysmograph (MedGraphics; St. Paul, MN, USA). For postbronchodilator measurements, four 100μg doses of Novo-Salbutamol® HFA (Teva
Novopharm Ltd.; Toronto, ON, Canada) were delivered through a pressurized meter dose
inhaler using an AeroChamber Plus spacer (Trudell Medical International; London, ON,
Canada). All participants were instructed to withhold their short-acting beta-agonists 12
hours prior to their visit (overnight).

5.2.3

Lung Clearance Index

The multiple breath washout manoeuvre was performed using 100% oxygen (O2) for
nitrogen washout and the ndd EasyOne Pro® LAB system (ndd Medical Technologies; AG,
Zurich, Switzerland) equipped with an ultrasonic flow and molar mass sensor. With the
volunteer seated upright and breathing through a mouth piece while wearing nose clips, the
washout phase was initiated after several breaths of room air by switching from room air
to 100% O2 at end expiration. Tidal breathing of 100% O2 was performed until washout
was complete (expired N2 concentration <2.5% of test start). Functional residual capacity
(FRC) was calculated from the cumulative volume of expired N2 divided by the difference
between the end-tidal concentration at the start and end of the washout. The cumulative
expired volume (CEV) was the cumulative volume of expired air during the washout. The
140

lung clearance index (LCI) was the number of FRC lung turnovers required to reach N2
concentration<2.5% of test start and was generated as CEV divided by FRC as previously
described.23 The washout manoeuvre was performed in duplicate and LCI was reported as
the mean of two washout manoeuvres.

5.2.4

Magnetic Resonance Imaging

MRI was performed on a whole body 3.0 Tesla Discovery MR750 (General Electric Health
Care, Milwaukee, WI, USA) system with broadband imaging capability, as previously
described.24 Subjects were instructed to inhale a gas mixture from a 1.0L Tedlar ® bag
(Jensen Inert Products; Coral Springs, FL, USA) from FRC, and image acquisition was
performed in 8-15s under breath-hold conditions. Conventional 1H MRI was performed 5
minutes prior to hyperpolarized 3He MRI and both methods were previously described.24
Quantitative evaluation was performed by a single trained observer (S.S) using custom
semi-automated segmentation software generated using MATLAB R2007b (The
Mathworks Inc.; Natick, MA, USA), as previously described.25 3He MRI ventilation defect
percent (VDP) was generated and defined as the ventilation defect volume normalized to
the thoracic cavity volume.25

5.2.5

Statistical Analysis

Data were tested for normality using the Shapiro-Wilk normality test and when data were
not normal, non-parametric tests were performed. Univariate relationships were evaluated
using linear regressions (r2), Pearson correlations (r) and when the data were not normal,
Spearman correlations (). Paired two-tailed t-tests and Wilcoxon matched-pairs signed
rank tests were used to evaluate the effect of bronchodilator therapy on ventilation
heterogeneity. Unpaired t-tests and Mann-Whitney tests were performed to compare
ventilation heterogeneity in subjects stratified by ACQ (≤2 or >2) and AQLQ scores (≥5
or <5) and previous 6-month exacerbation history (<1 or ≥1). All statistical analyses were
performed using GraphPad Prism version 6.02 (GraphPad Software Inc.; La Jolla, CA,
USA) and results were considered statistically significant when the probability of making
a Type I error was < 5% (p < 0.05).
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5.3

Results

5.3.1

Study Participants

Table 5-1 provides a summary of demographic and asthma characteristics for 18
participants (6 males/12 females, 46±12 years) with severe asthma. The mean duration of
asthma was 31±15 years (range=7-57), pre-bronchodilator FEV1 was 68±24%pred
(range=33-103%pred) and pre-bronchodilator FEV1/FVC was 65±15% (range=35-88%). A
participant listing provided in Table 5-3 (supplement) shows there was abnormal
ventilation heterogeneity (both VDP and LCI) for 13 participants and there was normal
VDP/LCI or normal VDP/abnormal LCI for five subjects.
Table 5-1 Participant demographics and asthma measurements.
Parameter (±SD)
Severe Asthma (n=18)
Pre-bronchodilator
Post-bronchodilator
Age years
46 (12)
Male/Female
6/12
Duration of asthma years
31 (15)
2
BMI kg/m
29 (5)
FEV1 L
2.2 (0.8)
2.5 (0.8)
FEV1 %pred
68 (24)
75 (26)
FVC L
3.5 (1.0)
3.6 (1.0)
FVC %pred
83 (19)
88 (17)
FEV1/FVC %
65 (15)
68 (16)
PC20 mg/mL
1.4 (2.8)*
Lung clearance index
10.5 (3.0)
9.5 (2.6)†
Ventilation defect percent %
12 (11)
8 (8)
SD=standard deviation; BMI=body mass index; FEV1=forced expiratory volume in 1
second; %pred=percent predicted; FVC=forced vital capacity; PC20=methacholine
concentration for 20% decrease in FEV1. *n=5; †n=17
Asthma medications and control parameters are summarized in Table 5-2. A participant
listing of these data is also provided in Table 5-4 (supplement). Despite receiving mediumto-high dose inhaled corticosteroids (ICS) and long-acting beta-agonists (GINA treatment
step 4-5),18 all 18 participants had poorly-controlled disease as evidenced by mean ACQ
score (2.3±0.9, range=1.0-4.3). Eight (44%) participants were prednisone-dependent
(dosage ranging from 2.5 to 50 mg/day). One or more severe asthma exacerbations were
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reported by nine (50%) and 15 (83%) participants in the previous 6- and 12-months
respectively.
Table 5-2 Asthma medication and control.
Severe Asthma (n=18)
Asthma Medications
Inhaled corticosteroid n (%)
18 (100%)
Long-acting β2-agonist n (%)
18 (100%)
Long-acting anticholinergic n (%)
7 (39%)
Oral corticosteroid n (%)
8 (47%)
Leukotriene receptor antagonist n (%)
9 (53%)
Anti-immunoglobulin E n (%)
1 (6%)
Asthma Control
ACQ score*
2.3 (0.9)
AQLQ total score*
4.6 (1.2)
mMRC dyspnea score*
1.3 (1.0)
Borg dyspnea score*
2.5 (2.3)
Severe exacerbation previous 6 months n (%)
9 (50%)
Severe exacerbation previous year n (%)
15 (83%)
ED visit previous 6 months n (%)
1 (6%)
ED visit previous year n (%)
4 (22%)
Hospitalization previous 6 months n (%)
0 (0%)
Hospitalization previous year n (%)
1 (6%)
Values are mean (±SD) except when indicated otherwise. ACQ=asthma control
questionnaire; AQLQ=asthma quality-of-life questionnaire; mMRC=modified Medical
Research Council; ED=emergency department. *n=16

5.3.2

Ventilation Heterogeneity

Figure 5-1 shows pre-bronchodilator coronal 3He MRI ventilation (in blue) co-registered
to 1H anatomical MRI (in grey-scale) for six representative participants. As shown
qualitatively in Figure 5-1, there was a greater number and volume of 3He MRI ventilation
abnormalities in participants with worse ACQ. For example, in subject S17 there was a
relatively homogeneous ventilation pattern, normal LCI and relatively good asthma control
whereas for subjects S16, S06, S13 and S04, there was qualitatively abnormal ventilation
that was concomitant with worse asthma control.
Table 5-1 shows that both VDP (pre-salbutamol=12±11%, post-salbutamol=8±8%,
p=0.008)

and

LCI

(pre-salbutamol=10.5±3.0,

significantly improved following bronchodilation.
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post-salbutamol=9.5±2.6,

p=0.02)

One participant (S12) could not

complete the post-bronchodilator MBNW manoeuvre due to fatigue and was excluded
from this evaluation.

Figure 5-1 Hyperpolarized 3He MRI of representative patients with severe asthma.
Centre coronal slice 3He MRI ventilation in blue co-registered to anatomical 1H MRI in
grey-scale for six representative severe asthmatics.
S07: 55 year-old female,
FEV1=77%pred, ACQ=1.4, LCI=9.7, VDP=2%; S17: 39 year-old female, FEV1=66%pred,
ACQ=1.7, LCI=6.7, VDP=3%; S16: 48 year-old male, FEV1=78%pred, ACQ=2.3, LCI=8.6,
VDP=8%; S06: 45 year-old male, FEV1=34%pred, ACQ=2.7, LCI=11.5, VDP=14%; S13:
56 year-old male, FEV1=34%pred, ACQ=3.1, LCI=17.5, VDP=33%; S04: 60 year-old
female, FEV1=47%pred, ACQ=4.3, LCI=14.0, VDP=35%.
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5.3.3

Ventilation Heterogeneity and Asthma Control

Figure 5-2 shows VDP and LCI in participants stratified by ACQ score (ACQ≤2, n=7 and
ACQ>2, n=9), AQLQ score (AQLQ≥5, n=7 and AQLQ<5, n=9) and by the number of selfreported exacerbations in the past 6 months (exacerbations <1, n=9 and exacerbations ≥1,
n=9). As shown in Figure 5-2A, there was significantly worse VDP (18±13% versus
6±5%; p=0.04), but not LCI (11.2±3.6 versus 9.4±2.4; p=0.3), in the subgroup of
asthmatics with ACQ scores >2. There was also significantly worse VDP (18±13% versus
6±5%; p=0.04), but not LCI (11.4±3.3 versus 9.1±2.6; p=0.2), in the subgroup of
asthmatics with AQLQ scores <5. Figure 5-2C also shows that there was a trend towards
worse VDP (17±13% versus 8±5%; p=0.053), but not LCI (11.2±3.8 versus 9.7±1.8;
p=0.3), in asthmatics reporting ≥1 exacerbation in the past 6-months. There were 15
subjects with exacerbations in the previous 12-months (VDP=13±12%; LCI=10.3±3.2).
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Figure 5-2 Ventilation heterogeneity stratified by ACQ and AQLQ scores and selfreported exacerbations.
A) Significantly worse VDP (>2 ACQ, VDP=18±13%; ≤2 ACQ, VDP=6±5, p=0.04), but
not LCI (>2 ACQ, LCI=11.2±3.6; ACQ≤2, LCI=9.4±2.4, p=0.29) for subjects with
ACQ >2.
B) Significantly worse VDP (AQLQ<5, VDP=18±13; AQLQ≥5, VDP=6±5, p=0.04), but
not LCI (AQLQ<5, LCI=11.4±3.3; AQLQ≥5, LCI= 9.1±2.6, p=0.16), for subjects
with AQLQ total scores <5.
C) There was a trend towards greater VDP (exacerbations ≥1, VDP=17±13%;
exacerbations<1, VDP=8±5%; p=0.053), but not LCI (exacerbations ≥1,
LCI=11.2±3.8 exacerbations<1, LCI= 9.7±1.8; p=0.3), for subjects with ≥1
exacerbation in past 6-months.
Box-and-whiskers plots show minimum, 25th percentile, median, 75th percentile, and
maximum with each individual value superimposed on the graph. += mean. ACQ=asthma
control questionnaire; AQLQ=asthma quality-of-life questionnaire; LCI=lung clearance
index; VDP=ventilation defect percent.
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5.3.4

Relationships

Given the different results for the ACQ and AQLQ subgroups with VDP and LCI
measurements, we also evaluated the bilateral relationships for LCI and VDP and their
post-salbutamol changes. Figure 5-3 qualitatively shows some of these relationships in
individual participants. For example, for subjects S11, S03 and S15, there was significantly
improved VDP, with minimal post-salbutamol change in LCI. In contrast, for subjects
S02, S13 and S05, there was significantly improved LCI with a minimal post-salbutamol
change in VDP. Figure 5-4A shows that there were strong VDP-LCI correlations pre(r=0.86, r2=0.74, p<0.0001) and post-bronchodilator (r=0.93, r2=0.86, p<0.0001). However,
as shown in Figure 5-4B, the post-bronchodilator change in VDP was not correlated with
the post-bronchodilator change in LCI (r=0.44, r2=0.01, p=0.08). As shown in Figure
5-4C and D, VDP (r=0.62, r2=0.38, p=0.01) was correlated with ACQ score and LCI
(r=0.49, r2=0.24, p=0.052) showed a similar trend. VDP and LCI were not related to
AQLQ score (VDP: r=-0.34, r2=0.11, p=0.20; LCI: r=-0.22, r2=0.05, p=0.40) or
exacerbations in the past 6 (VDP: r=0.31, r2=0.02, p=0.21; LCI: r=0.08, r2=0.0001, p=0.77)
and 12-months (VDP: r=0.03, r2=0.003, p=0.92; LCI: r=-0.21, r2=0.06, p=0.41).
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Figure 5-3 Pre- and post-bronchodilator 3He ventilation MRI.
S11: 40 year-old female, ACQ=2.3, ΔLCI=-0.8, ΔVDP=-11%; S03: 61 year-old male,
ACQ=2.1, ΔLCI=-1.4, ΔVDP=-13; S15: 42 year-old male, ACQ=1.4, ΔLCI=0.6, ΔVDP=4%; S02: 67 year-old male, ACQ=NA, ΔLCI=-3.8, ΔVDP=-5%; S13: 56 year-old male,
ACQ=3.1, ΔLCI=-2.1, ΔVDP=-5%; S05: 38 year-old female, ACQ=1.9, ΔLCI=-2.2,
ΔVDP=-1%.

148

Figure 5-4 Relationship for ventilation heterogeneity and asthma control.
A) VDP was significantly correlated with LCI pre- (r=0.86, r2=0.74, p<0.0001,
y=3.1x-20.0) and post-bronchodilator (r=0.93, r2=0.86, p<0.0001).
B) The change in VDP and LCI post-bronchodilator was not correlated (r=0.44,
r2=0.01, p=0.08).
C) VDP was significantly correlated with ACQ (r=0.62, r2=0.38, p=0.01).
D) There was a trend for an LCI–ACQ correlation (r=0.49, r2=0.24, p=0.052).
Dotted lines=95% confidence intervals; ACQ=asthma control questionnaire; LCI=lung
clearance index; VDP=ventilation defect percent.

5.4

Discussion

In an endeavour to answer the question: Are MRI ventilation defects related to asthma
control?, we evaluated MRI and LCI measurements in 18 severe asthmatics. We observed:
1) abnormal VDP and LCI were strongly correlated but there were different responses to
salbutamol, 2) there was significantly worse VDP but not LCI in asthmatics with an ACQ
score >2 and AQLQ score <5, which was supported by a significant VDP-ACQ correlation,
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and, 3) there was a trend towards greater VDP, but not LCI, in asthmatics with ≥1
exacerbation in the past 6-months.
To our knowledge, this is the first direct evaluation of MRI and LCI ventilation
heterogeneity and their relationship with asthma control. Similar to previous imaging17,26
and multiple-breath washout studies27 we observed abnormally heterogeneous ventilation
that improved post-bronchodilator. The strong correlation for LCI and VDP was not
surprising. The fact that there was no relationship for the post-bronchodilator change in
VDP and LCI was not expected, but may be explained by a number of mechanistic
differences in the measurements themselves.
The temporal resolution of both approaches relative to the time constants for lung segment
filling and emptying are important to consider.

For example, inert gas washout

measurements are made over a time-course of many minutes of normal tidal breathing and
based on the time needed to exchange N2 with O2 in lung regions accessible to inhaled gas.
In contrast, MRI ventilation defects are typically measured during a single 8-10s inhalation
breath-hold; hence, inhaled-gas MRI provides a rapid visual snapshot of where the inhaled
gas goes when inhaled from FRC. In the case of airway narrowing or gas trapping that are
both common in severe asthma, long time constants for lung filling and emptying are
expected and this may explain some of the differences for VDP and LCI observed here.
In addition to temporal resolution differences, there may be differences in the apparent
spatial resolution of the MBNW and MRI methods used. In principle, LCI measurements
may be influenced by any or all of the conducting and acinar lung zones.27 For ventilation
MRI, there is somewhat coarse spatial resolution (3x3x15mm) and this may result in an
underestimation of very small ventilation defects. Supporting this notion, subjects S07 and
S14 reported relatively well-controlled disease (ACQ=1.4 and 1.0) but abnormal LCI and
relatively homogeneous MRI ventilation. Another explanation, previously proposed,27
suggests that even small ventilation defects may increase LCI well beyond the upper-limit
of normal, resulting in an overestimation of disease severity. Supporting this view, subject
07 had an abnormal LCI (9.7) and only a single small hypo-ventilated region (VDP=2%).
Importantly, this 55 yr old female was prescribed oral prednisone (7.5mg/day) and ICS
(Budesonide > 1000µg), and was relatively well-controlled (ACQ=1.4). We also observed
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post-bronchodilator imaging improvements in patients in whom LCI did not change, such
as in subject S04. This 60 year old female reported very poor control (ACQ=4.3) and
highly heterogeneous ventilation (VDP=35%; LCI=14.0) despite high-dose OCS
maintenance therapy (prednisone 50mg/day) and ICS (Fluticasone propionate
dose>1000µg). Similar VDP responses have been reported in COPD patients with little or
no bronchodilator reversibility measured using FEV1.28
The most important observation stemming from this study was the finding of significantly
worse VDP in asthmatics with ACQ>2 and AQLQ<5 and a trend toward worse VDP in
asthmatics with more frequent exacerbations. These findings were not observed using LCI
measurements, perhaps because of the small sample size and/or because LCI is a less
sensitive measure of the underlying pathophysiology responsible for asthma control. This
novel imaging result was also supported by a significant relationship for VDP (and a trend
for a significant relation for LCI) with ACQ score.

It is worth noting that a previous

ventilation imaging study using single photon emission computerized tomography
(SPECT), reported no relationship for ACQ score and ventilation.29 This discordant result
may stem from the inherently low spatial resolution of SPECT or small sample size, or
perhaps because the asthmatics in the previous study were well-controlled. Previous
seminal studies point to the clinical importance of airflow obstruction,30 airway
inflammation,31 respiratory system reactance32 and inert-gas washout ventilation
heterogeneity measurements of asthma.2,3 Yet, some of these measurements underestimate
asthma pathophysiology because of their relative insensitivity to the peripheral airway
abnormalities directly responsible for asthma symptoms and control. In view of the
limitations of conventional clinical asthma measurements, we think our results strongly
support the use of pulmonary MRI in clinical research and in the management of severe
asthmatics in whom control is difficult to achieve.
We recognize a number of study limitations including the small number of study
participants. However, pulmonary imaging measurements are quite sensitive and therefore
significant differences may be detected using small sample sizes. Nonetheless, caution
should be exercised in generalizing our results to a general asthma population. We also
acknowledge that asthma patients were recruited from two major tertiary care centres, so
FeNO and sputum inflammometry were not available for the majority of patients. If these
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were available, we could try to tease out the relative contribution of luminal inflammation
to ventilation heterogeneity and asthma control. Furthermore, we did not (for logistical
reasons) evaluate a comparator group of well-controlled asthmatics or asthmatics with
more moderate disease. Because of this, we could not ascertain the relative contribution
of asthma severity to ventilation heterogeneity in this study, but this relationship was
previously explored in well-controlled patients with mild to moderate asthma.15 It is
noteworthy that there was no difference in ventilation heterogeneity for participants
prescribed oral prednisone versus those who were not prednisone-dependent.

Postural

effects should also be considered when comparing MRI and MBNW measurements of
ventilation heterogeneity because imaging was performed supine, whereas MBNW was
performed upright. In one previous study, gas trapping was increased in supine asthmatic
children but this was not the case for MBNW ventilation heterogeneity measurements.33
Regardless, to mitigate and minimize postural effects including atelectasis, imaging was
completed within 5 minutes, limiting the time that patients remained supine, which limits
atelectasis.34
While there is strong evidence that poor asthma control is associated with an increased risk
for future severe asthma events35 and exacerbations,36 biomarkers that identify the source
and regional location of poor control are generally lacking and many are not readily
available except in highly specialized care centres, beyond the reach of the vast majority
of asthma patients. In this context, we note that MBNW biomarkers are more universally
available and previously revealed the efficacy of aerosolized ultrafine steroid particles in a
subset of asthma patients with abnormal acinar airways.10 Moreover, emerging biomarkers
of airway inflammation have been proposed37 and used as therapy targets to significantly
decrease asthma exacerbations.38-40 The results of our study argue for the continued
development and use of novel and conventional ventilation heterogeneity biomarkers and
measurements of asthma.
In conclusion, in a small group of poorly-controlled severe asthmatics, MRI ventilation
defects were significantly worse in the subgroup of patients with worse asthma control and
quality-of-life. Hence, regional ventilation defects may be considered as intermediate
endpoints of asthma that can be used to evaluate therapies in relatively small studies that
target improved asthma control and quality-of-life.
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5.6

Supplementary Material

Table 5-3S Participant listing of demographic and other measurements.
Subject
001
002
003
004
005
006
007
008
009
010
011
012
013
014
015
016
017
018
Mean
(±SD)

Age
(yrs)
34
67
61
60
38
45
55
47
21
45
40
31
56
44
42
48
39
59
46
(12)

Demographics
Sex
BMI
(M/F)
(kg/m2)
F
40
M
28
M
33
F
33
F
30
M
25
F
33
F
30
F
20
F
31
F
29
F
37
M
25
F
27
M
33
M
30
F
22
F
23
12F/
29
6M
(5)

Duration
(yrs)
16
7
7
39
36
44
20
34
18
41
27
28
55
23
28
46
36
57
31
(15)

ACQ
Score
2.1
4.3
1.9
2.7
1.4
2.3
2.7
1.6
2.3
2.0
3.1
1.0
1.4
2.3
1.7
4.3
2.3
(0.9)

AQLQ Scores
Tota
Acti
4.6
4.6
3.2
2.7
5.9
6.0
4.7
4.6
5.0
5.1
5.3
5.3
3.1
3.6
4.0
4.9
4.8
4.7
5.8
5.8
4.2
4.4
5.6
5.6
4.6
5.5
5.5
6.4
6.1
6.2
1.7
2.4
4.6
4.9
(1.2)
(1.2)

Questionnaires and Exacerbation History
Dyspnea Scores
Exacerbations
mMRC
Borg
(n)*
0/2
0/0
0.0
4.0
1/3
3.0
9.0
2/4
1.0
1.0
0/1
1.0
1.0
0/0
1.0
3.0
0/1
2.0
2.0
2/5
2.0
5.0
0/5
0.0
0.5
4/18
1.0
1.0
6/12
2.0
1.0
3/4
2/3
1.0
0.5
0/1
1.0
2.0
0/0
0.0
3.0
0/1
1.0
0.5
5/7
3.0
4.0
4/8
1.3
2.5
9(50%)/
(1.0)
(2.3)
15(83%)

ED visits
(n)*
0/0
0/0
0/0
0/2
0/0
0/0
0/0
1/1
0/0
0/0
0/0
0/3
0/0
0/0
0/0
0/0
0/0
0/1
1(6%)/
4(22%)

Hospitalizations
(n)*
0/0
0/0
0/0
0/0
0/0
0/0
0/0
0/0
0/0
0/0
0/0
0/1
0/0
0/0
0/0
0/0
0/0
0/0
0(0%)/
1(6%)

FEV1
Pre/Post(L)
2.2/2.5
3.1/3.4
2.7/3.4
1.0/0.9
1.4/1.6
1.5/1.6
2.1/2.3
3.0/3.0
3.4/3.5
3.0/3.3
2.1/2.4
0.9/1.4
1.5/1.5
2.9/3.0
2.7/3.1
2.9/3.2
2.2/2.4
1.4/1.6
2.2(0.8)/
2.5(0.8)

Spirometry
FVC
Pre/Post(L)
3.0/3.2
4.8/5.0
5.0/5.8
2.1/2.0
1.7/2.0
3.3/3.4
2.9/3.1
3.7/3.6
3.8/3.7
3.8/3.8
3.3/3.4
2.3/3.1
4.4/4.2
3.8/3.9
4.0/4.4
4.2/4.4
4.0/3.9
1.9/2.7
3.5(1.0)/
3.6(1.0)

FEV1/FVC
Pre/Post(%)
74/80
66/68
54/59
46/46
82/79
44/47
71/76
80/83
88/94
78/86
65/72
42/46
35/37
74/79
67/71
69/72
56/62
71/58
65(15)/
68(16)

Ventilation heterogeneity
LCI
VDP
Pre/Post
Pre/Post(%)
9.5/8.8
12/10
12.6/8.8
11/6
13.4/12.1
30/17
14.0/14.4
35/20
11.5/9.3
7/6
11.5/10.6
14/11
9.7/9.3
2/3
6.3/7.1
2/2
7.0/7.3
1/2
7.4/6.6
4/1
10.6/9.8
18/7
13.4/NA
15/5
17.5/15.5
33/29
7.7/7.3
3/2
9.5/10.1
8/4
8.6/8.2
8/8
6.7/6.1
3/2
11.6/11.0
15/16
10.5(3.0)/
12(11)/
9.5(2.7)
8(8)

SD=standard deviation; M=Male; F=Female; BMI=body mass index; ACQ=asthma control questionnaire; AQLQ=asthma quality-oflife questionnaire; Tota=Total; Acti=Activity; mMRC=modified Medical Research Council; ED=emergency department; FEV1=forced
expiratory volume in 1 second; BD=bronchodilator; FVC=forced vital capacity; LCI=lung clearance index; VDP=ventilation defect
percent. *in previous 6 months/in previous year.
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Table 5-4S Participant listing of asthma medications.
Subject
001
002
003
004
005
006
007
008
009
010
011
012
013
014
015
016
017
018

SABA
Generic
Salbutamol
Salbutamol
Salbutamol
Salbutamol
Salbutamol
Salbutamol
Salbutamol
Salbutamol
Terbutaline
Salbutamol
Salbutamol
Salbutamol
Salbutamol
Salbutamol
Salbutamol
Salbutamol
Salbutamol
Salbutamol

LABA
Generic
Dose(µg/d)
Formoterol
12
Formoterol
24
Formoterol
24
Salmeterol
100
Formoterol
36
Formoterol
20
Formoterol
24
Salmeterol
100
Formoterol
24
Salmeterol
100
Formoterol
24
Salmeterol
100
Salmeterol
100
Formoterol
24
Formoterol
24
Formoterol
24
Formoterol
24
Formoterol
20

LAAC
Generic
--Tiotropium
Tiotropium
-Tiotropium
Tiotropium
----Tiotropium
Tiotropium
----Aclidinium bromide

Dose(µg/d)
--18
18
-18
18
----18
18
----800

ICS
Generic
Budesonide
Budesonide
Budesonide
Fluticasone
Budesonide/Beclometasone
Mometasone furoate/Fluticasone
Budesonide
Fluticasone
Budesonide
Fluticasone
Budesonide/Ciclesonide
Fluticasone/Ciclesonide
Fluticasone
Budesonide
Budesonide
Budesonide/Ciclesonide
Budesonide
Mometasone furoate/Ciclesonide

OCS
Dose(µg/d)
400
800
800
2500
1200/800
800/1000
1600
1000
800
1500
800/800
1000/400
1000
800
1200
800/800
800
800/800

Generic
Prednisone
Prednisone
Prednisone
Prednisone
Prednisone
-Prednisone
---Prednisone
Prednisone
-------

Dose(mg/d)
4
12.5
20
50
2.5
-7.5
---7.5
3
-------

LTRA
Generic
Dose(mg/d)
----Montelukast
10
Montelukast
10
--Montelukast
10
--Montelukast
10
Montelukast
10
Montelukast
10
Montelukast
10
Montelukast
10
--------Montelukast
10
---

Anti-IgE
Generic
Dose(mg)
------------------------------Omalizumab
150
-----

SABA=Short-acting beta-agonist; LABA=Long-acting beta-agonist; LAAC=Long-acting anticholinergics; ICS=Inhaled
Corticosteroids; OCS=Oral corticosteroids; LTRA=Leukotriene Receptor Antagonists; Anti-IgE=Anti-immunoglobulin E.
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CHAPTER 6
6

Conclusions and Future Directions

The final chapter of this thesis revisits our rationale and research objectives and provides
a summary of the important findings and conclusions of Chapters 2-5. Subsequently, study
specific limitations, general limitations and potential solutions are presented. Finally, a
roadmap for future studies in asthma motivated by the work presented in this thesis will be
outlined.

6.1

Overview of Rationale and Research Questions

The forced expiratory volume in one second (FEV1) currently plays an important role in
the diagnosis and management of asthma; and it is also universally used as a primary
endpoint of lung function in the majority of asthma clinical trials.1,2 However, FEV1 is a
global measurement made at the mouth that cannot be used to ascertain regional lung
function and it is relatively insensitive to subtle changes and peripheral airway pathology
in asthma.3 For decades, the concept of regionally heterogeneous airway abnormalities in
asthma has been acknowledged. This regional heterogeneity was first noted in cadavers
using post mortem ex vivo gross sections and histology.4 Shortly after, single-breath and
multiple-breath washout studies in living patients were also indicative of ventilation
heterogeneity in asthma, but due to the limitations of this technique, the regional site of
functional abnormalities could not be ascertained.5 Accordingly, beyond specialized
academic centres, it has been difficult to investigate asthmatics based on the suggested
regional nature of their underlying pathology. There has therefore been an urgent need for
non-invasive and quantitative imaging methods to regionally evaluate asthma.
In response to this demand, numerous imaging methods have been developed and are
currently available to non-invasively evaluate asthma regionally,6 however, they are not all
well-suited for serial and longitudinal investigations. While CT is widely available and
provides high spatial and temporal resolution images of lung structure7,8 and function,9 it
is burdened by radiation exposure, a particular concern when evaluating asthmatic children
and young adults. Similarly, nuclear medicine methods are burdened by ionizing radiation
exposure and are further limited by relatively poor spatial resolution.10-12
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In contrast, functional MRI using hyperpolarized 3He and 129Xe is not limited by radiation
exposure.

The recent development of this approach has demonstrated promise for

functional imaging of asthma13 as it provides an opportunity to visualize, with high spatial
and temporal resolution, those areas of the lung that participate in gas distribution and those
that do not.

In healthy young adults, inhalation of hyperpolarized gas results in

homogeneous signal suggesting that all areas of the lung are participating equally in
ventilation.14-17 In contrast, characteristic ventilation defects are observed in asthma,
corresponding to areas of the lung that are not ventilated within the time-course of a breathhold scan.13,18-27 Previous work using this technique provides a strong foundation for its
use in asthma research and patient care; however, a major drawback is that the clinical and
physiological meaning of MRI-derived ventilation defects is poorly understood.
Furthermore, the heterogeneity of asthma is under appreciated by the medical community.
Regardless of the gas used for imaging, a clear understanding of ventilation defects is
absolutely necessary prior to the clinical translation of hyperpolarized gas imaging
methods. Therefore, in spite of the well-demonstrated potential for pulmonary imaging to
provide a better understanding of the regional aspects of asthma, it currently takes on an
insignificant role in asthma clinical care and treatment evaluation and guidance.
Accordingly, the overarching objective of this thesis was to develop and apply novel
pulmonary imaging methods to better understand asthma and to provide a foundation for
functional imaging to guide clinical decisions and therapy in patients with asthma. The
specific research questions investigated here included: 1) Do the different properties of
129

Xe and 3He gas result in significant differences in 129Xe compared to 3He gas distribution

before and after bronchodilator administration in well-controlled asthmatics? (CHAPTER
2); 2) Can the inherent temporal and spatial pulmonary function information provided by
hyperpolarized 3He MRI be used to visualize and quantify temporally persistent and
intermittent ventilation defects as potential targets for therapy? (CHAPTER 3); 3) Are
asthmatics with 3He MRI ventilation defects different from asthmatics without ventilation
defects with respect their airway structure and standard clinical measurements of disease?
(CHAPTER 4) and, 4) What is the relationship of asthma control with ventilation defects
quantified and regionally visualized using 3He MRI? (CHAPTER 5).
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6.2

Summary and Conclusions

In Chapter 2, we quantitatively compared hyperpolarized 3He and

129

Xe MRI in a small

group of seven asthmatics before and after salbutamol inhalation. Prior to salbutamol
inhalation, 129Xe VDP (8±5%) was significantly greater than 3He VDP (6±5%, p=0.003).
Post-salbutamol, there was a significant improvement in both 129Xe (5±4%, p<0.0001) and
3

He (4±3%, p=0.001) VDP, but the improvement in 129Xe VDP was significantly greater

(p=0.008). For a single asthmatic, a sub-segmental 129Xe MRI ventilation defect that was
visible only prior to salbutamol inhalation but not visible using 3He MRI was spatially
related to a remodeled airway (WA%=78%, LA=2.9 mm2). These results indicate that
hyperpolarized

129

Xe MRI may help reveal ventilation abnormalities prior to

bronchodilation that are not observed using hyperpolarized 3He MRI.
In Chapter 3, we exploited the temporal and spatial information inherent to 3He MRI to
generate pulmonary ventilation temporal-spatial maps that could be used to measure,
optimize and guide asthma therapy. In this proof-of-concept study, seven asthmatics
underwent spirometry and 3He MRI on three occasions, each 5±2 days apart. A registration
and segmentation pipeline was developed to generate temporal-spatial pulmonary function
maps.

This enabled the regional mapping of temporally persistent and intermittent

ventilation defects that were normalized to the 1H MRI thoracic cavity volume to generate
VDPP and VDPI. Persistent and intermittent ventilation defects were identified and were
strongly correlated with FEV1/FVC (VDPP: r=-0.87, p=0.01; VDPI: r=-0.96, p=0.0008).
These findings suggest that temporal-spatial pulmonary maps generated from 3He MRI can
be used to quantify temporally persistent and intermittent ventilation defects as asthma
intermediate endpoints and targets for therapy.
In Chapter 4, we evaluated well-established clinical as well as 3He MRI and x-ray CT
airway measurements in eight healthy and 26 asthmatic subjects to better understand the
determinants of 3He MRI ventilation defects in asthma. Prior to broncho-provocation, 17
asthmatics (17/26=65%) had visually obvious evidence of ventilation defects and nine
asthmatics had no ventilation defects (9/26=35%). Asthmatics with defects were older
(p=0.01) with worse FEV1/FVC (p=0.0003), airways resistance (p=0.004), FeNO (p=0.03),
lower PC20 (p=0.008), and wall thickness percent (p=0.02), compared to asthmatics without
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defects. We also identified a moderate correlation for wall area percent with VDP (r=0.43,
p=0.04). These results indicate that asthmatics with 3He MRI ventilation defects are older
with significantly worse airway hyperresponsiveness, inflammation and airway
remodeling in comparison to asthmatics without defects; and that hyperpolarized 3He
ventilation abnormalities are spatially and quantitatively related to abnormally remodeled
airways.
In Chapter 5, we evaluated MBNW and MRI measurements of ventilation heterogeneity
and their relationship with asthma control in 18 severe asthmatics. Mean VDP was
12±11% and LCI was 10.5±3.0 with both VDP (p=0.008) and LCI (p=0.02) improving
post-bronchodilator. While VDP was strongly correlated with LCI (r=0.86, p<0.0001), the
post-bronchodilator change in VDP and LCI was not correlated (p=0.08). There was
significantly worse VDP but not LCI in asthmatics with ACQ >2 (p=0.04) and AQLQ<5
(p=0.04). Notably, VDP (but not LCI, p=0.052) was correlated with ACQ score (r=0.62,
p=0.01). MRI ventilation defects were significantly worse in severe asthma patients with
poor asthma control and poor quality-of-life. This is important, because as an intermediate
endpoint, ventilation defects may be used to target therapy to improve clinically-important
asthma outcomes.
In summary, we have provided: 1) evidence that hyperpolarized

129

Xe MRI may be more

sensitive than 3He MRI to ventilation abnormalities; 2) a new method to quantify
temporally persistent and intermittent ventilation defects that may be used as intermediate
endpoints and targets for therapy; 3) evidence that asthmatics with 3He ventilation defects
are older with significantly worse airway hyperresponsiveness, inflammation and airway
remodeling in comparison to asthmatics without defects; and, 4) evidence that ventilation
defects are significantly worse in severe asthmatics with poor asthma control and poor
quality-of-life.

6.3

Limitations

In this section, some of the most significant limitations of the studies presented in Chapters
2-5 are discussed. It should be noted that a description of the study specific limitations are
also presented within the discussion section of the respective Chapters. In addition to
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Chapter specific limitations, this section includes a description of general limitations
common to Chapters 2-5.

6.3.1

Study Specific Limitations

Hyperpolarized 3He and
(Chapter 2)

129

Xe MRI: Differences in Asthma before Bronchodilation

In the study presented in Chapter 2, thoracic CTs were not contemporaneously acquired
and this limited our ability to investigate the relationship between lung structure and
function. However, for two of the seven asthmatics evaluated, partial thoracic CTs were
acquired approximately one year before 3He and

129

Xe MRI. In a single asthmatic, we

observed a large wedge shaped ventilation defect at baseline using 129Xe MRI but not using
3

He MRI; the defect was spatially related to a partially obstructed airway.

This

serendipitous finding led us to hypothesize that 3He gas may penetrate lung regions through
partially obstructed airways that

129

Xe gas cannot access during a short breath-hold scan.

Unfortunately, without whole lung thoracic CTs for all seven subjects we were unable to
further investigate, and statistically evaluate, the relationship between abnormal airway
pathophysiology and the differences between 3He and 129Xe gas distribution.
Another limitation was that ventilation abnormalities, quantified as VDP, for the small
group of mild-to-moderate asthmatics with well-controlled disease evaluated in this study
were not large. The mean pre-salbutamol VDP was low as compared to a previous study
of asthma,22 but importantly was higher than previously reported values observed for
healthy volunteers of a similar age.22 Accordingly, the differences in 3He and

129

Xe

ventilation defects reported here might be a conservative estimate of the differences that
would be observed in a larger group of asthmatics with a range of disease severity. Ideally,
a range of mild, moderate and severe asthmatics would have been evaluated to ascertain if
the differences observed between the two gases were dependent on disease severity.
Similarly, we were unable to ascertain the clinical relevance of the improvement in both
3

He and

129

Xe VDP following salbutamol inhalation. This endeavor was not possible as

clinically-relevant measurements such as dyspnea or exercise capacity were not collected
at the time of study. Importantly, however, the smallest detectable difference (SDD),
defined as the smallest difference that can be measured with prospectively determined
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confidence not due to measurement error (variability) has been previously calculated for
3

He MRI and the mean change in the 3He (0.11L) and 129Xe MRI (0.14L) ventilation defect

volume measured in this study was greater than the SDD (0.05L).28 Although the SDD is
not a measure of clinical relevance, this confirms that the changes detected were not due
to measurement variability. In future attempts to determine the clinical relevance of the
changes detected using 3He and 129Xe MRI, we will evaluate the degree of dyspnea and/or
exercise capacity in study participants.
Pulmonary Functional Magnetic Resonance Imaging: Asthma Temporal-Spatial Maps
(Chapter 3)
In the longitudinal study presented in Chapter 3, we did not obtain well-established clinical
measurements of asthma or x-ray CT, and therefore questions regarding the clinical
relevance of our data could not be investigated. Importantly, between visits we observed
qualitative regional differences in the distribution of 3He gas within the lung. These
temporal differences, termed “intermittent defects” were quantified and visualized using
the temporal-spatial pulmonary function maps. Unfortunately, we were unable to ascertain
whether these asthmatics experienced symptomatic worsening over the two weeks that
could be attributed to their variable ventilation heterogeneity. Furthermore, it would have
been important to investigate the differences in CT-derived airway morphology for airways
spatially related to intermittent defects, persistent defects and persistently-ventilated lung
regions.
The maps generated in this study captured the week-to-week lung function variability in a
small group of seven asthmatics. Previous work by de Lange and colleagues have
demonstrated that the persistence of ventilation defects in asthma decreases with time.20
Accordingly, it would be very important to evaluate these subjects over a longer period of
time to determine whether the variability captured over a short two-week period is
representative of the ventilation variability over longer periods of time, in the absence of
an exacerbation. Before these temporal abnormalities are used as therapy targets or as an
intermediate endpoint, this concept will first need to be investigated.
Another limitation of this study is that we currently do not know what “type” of ventilation
defect, if any, is the best target for localized airway treatment in asthma. For example, in
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addition to the persistent and intermittent ventilation defects identified in this study,
dynamic ROI that respond to broncho-provocation (methacholine/exercise) or
bronchodilation (salbutamol) could potentially be excellent targets for localized treatment.
It is important to note however that this study provided proof-of-concept results; with this
segmentation and registration pipeline, the methodology can subsequently be uniquely
tailored to probe a wide variety of ventilation defect behaviours over time or in response
to treatment. For example, the pipeline has been subsequently tailored to regionally
quantify and visualize the temporal behaviour of ventilation defects in cystic fibrosis
patients who underwent 3He MRI on two occasions over four years.29
As a technical limitation, the temporal-spatial pulmonary function maps are susceptible to
image registration errors that can have an effect on map interpretation. Scan-to-scan
variability/differences in lung volume and patient position in the MRI scanner, particularly
patient tilting, make registration across visits particularly challenging. Rotations out of
plane are particularly cumbersome since our voxels have anisotropic dimensions (3.125
mm x 3.125 mm, slice thickness 15 mm). However, despite this limitation, we were able
to achieve sufficient registrations between visits. We do acknowledge, however, that there
were a few regions identified along the periphery of the maps with intermittent ventilation
that may be attributed purely to mismatches in image registration. However, these
occurrences were acknowledged and represent a very small percentage of the overall
thoracic cavity volume.
What are Ventilation Defects in Asthma? (Chapter 4)
In the study presented in Chapter 4, we evaluated a relatively broad range of asthmatics
who were not enrolled based on disease severity or symptoms. Importantly, however, they
were patients from an interdisciplinary (Allergy and Respirology) asthma care centre, were
between 18 and 60 years of age and had a physician diagnosis of asthma and a positive
methacholine challenge within the past five years. The strength of this study would have
been considerably improved if at least severity was documented based on the GINA
treatment step score. Furthermore, it would have been advantageous to quantify asthma
control using one of the many asthma control questionnaires. Unfortunately, the GINA
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step score and asthma control questionnaires were not utilized in the asthma care clinic,
nor the research study, and therefore could not be evaluated in this study.
Another limitation of this study was the use of partial thoracic CTs that reduced the number
of airways that could be quantified. However, we strongly believe that whenever possible,
lower dose partial CTs should be acquired and be used to quantify airway morphology in
young subjects, in whom the benefit-risk ratio does not support more extensive CT
imaging. In spite of the partial and lower dose CT volume, we were able to generate
quantitative information and showed there was a significant relationship between CT
airway measurements and 3He MRI overall, and for specific defects and airways in certain
cases.
What do Ventilation Defects Reveal about Asthma Control? (Chapter 5)
In the study presented in Chapter 5, we evaluated severe asthmatics who were poorly
controlled but we did not include a control group of patients with less severe asthma but
with the same degree of poor asthma control. Accordingly, we could not ascertain the
relative contribution of asthma severity and asthma control to ventilation defects. In other
words, we could not address the important question, "Is the same ventilation heterogeneity
observed in milder asthmatics who are poorly controlled?" Future studies are necessary to
investigate this important question.
Another limitation of this study was that MRI and MBNW measurements of ventilation
heterogeneity were obtained in different positions, introducing the potential for postural
effects. Imaging was performed supine, whereas MBNW was performed upright and this
may have influenced the strength of the demonstrated relationships between MRI and
MBNW measurements of ventilation heterogeneity. From previous experience, we have
observed that MBNW measurements of ventilation heterogeneity are significantly worse
when performed supine as compared to when performed upright. Regardless, we took
necessary steps to mitigate and minimize potential postural effects in this study.
Specifically, imaging was completed within five minutes to limit the time that the patients
had to remain supine, which has been shown to limit atelectasis.30
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6.3.2

General Limitations

One limitation to the studies presented in Chapters 2-5 was the small number of subjects
evaluated, therefore, caution should be exercised in generalizing these results to the broader
asthma population. Importantly, however, hyperpolarized gas MRI measurements are
quite sensitive and therefore, as demonstrated in these studies and many others, significant
differences may be detected using small sample sizes. Moreover, at the time of study
initiation for the majority of these investigations, there was little prior MRI data in asthma
available to help generate power calculations and so these were not performed. Regardless,
future studies should aim to evaluate larger groups of asthmatics to confirm the results
observed in these studies.
Pertinent to both Chapters 2 and 4, we acknowledge that the quantitative measurement of
ventilation heterogeneity employed here, the COV, is likely affected by partial volumes
inherent to both 3He and

129

Xe MR images. Errors induced by partial volumes have the

potential to influence the accuracy of the COV estimations reported in Chapters 2 and 4.
Our objective was not to develop a novel quantitative metric to evaluate ventilation
heterogeneity; instead, a previously published method developed by Tzeng and colleagues
was adopted.27 Edge and/or partial volume effects can be visualized in the cluster and COV
maps of ventilation (Figure 2-1). With respect to Chapter 2, in accordance with Tzeng and
colleagues, we made the assumption that the elevated COV values observed toward the
edges cancel out when images are compared, as this effect is present both pre- and postsalbutamol.27 Therefore, although we acknowledge that edge and/or partial volume effects
likely influence our COV maps, this does not influence or alter our overall conclusions
which interrogated relative change.
In Chapters 2-5 our attention was directed towards ventilation defects; however, it is wellunderstood that ventilation visualized using hyperpolarized gas MRI is not binary. The
studies presented in this thesis have overlooked the potential clinical significance of lung
regions in asthma that have signal hyper-intensity. Many of the asthmatics evaluated in
these studies have had a very heterogeneous MRI gas distribution with regions of hyperintense signal intensity in addition to ventilation defects. We are interested in these regions
of hyper-intense signal intensity and the physiological mechanisms that may cause them.
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These regions may be due to hyperinflation and therefore may indicate underlying
structural abnormalities within the asthmatic lung.

The same semi-automated

segmentation image analysis software employed in these studies to quantify VDP can be
used to quantify the gradation of signal intensity observed in hyperpolarized gas MR
images.28 This analysis method segments static ventilation images using a k-means
clustering algorithm that classifies voxel signal intensity values into five clusters and is
therefore able to quantify hyper-intense signal regions. In future studies, it will be
important to investigate these regions in addition to ventilation defects.
Another important limitation to this work in general is the limited 3He access, and the high
cost of 3He gas that has thus far restricted translation of this imaging method beyond
specialized MR physics centres. As previously discussed, this shortage is forcing the noble
gas MRI community to transition to 129Xe gas, a less expensive and more readily available
contrast agent. While both 3He and 129Xe MRI were acquired within a five-minute period
for the study presented in Chapter 2, the remaining study designs (Chapters 3-5) did not
include 129Xe MRI. In Chapter 2, significantly greater 129Xe as compared to 3He ventilation
defects were observed in asthma, suggesting that 129Xe gas may be more sensitive to airway
abnormalities than 3He gas. Although this increased sensitivity is advantageous moving
forward, the observed difference suggests that our findings presented in Chapters 3-5 using
3

He gas may not be a direct reflection of what would be observed using

129

Xe gas. For

example, in Chapter 4 we observed that 65% of well-controlled asthmatics had 3He
ventilation defects.

If this study were to be repeated using

129

Xe MRI, one might

hypothesize that ventilation defects would be visually obvious in nearly 100% of the same
asthmatics. Similarly, in Chapter 3, one might hypothesize that 129Xe MRI temporal-spatial
pulmonary function maps of the same asthmatics would have increased intermittent and
persistent ventilation defects. Regardless of this speculation, future 129Xe MRI studies are
required to validate the results presented here using 3He MRI. Moreover, future research
and potential clinical applications of noble gas MRI will most definitely utilize 129Xe gas.
In accordance with this trajectory, relevant studies that are currently underway at the
Robarts Research Institute are now using 129Xe MRI.
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6.4

Future Directions

6.4.1

Functional MRI of Ventilation in Asthma: Sensitivity, Specificity
and Comparison with FEV1

Our results presented in Chapters 4 and 5 indicate that asthmatics with worse MRI
ventilation, but not FEV1, have worse asthma control, greater airways resistance and
greater airway hyperresponsiveness. These results strongly support the notion that MRI
ventilation defects may be more sensitive than FEV1 to structural and functional changes
in the asthmatic lung. Moreover, it is well-understood that FEV1 is relatively insensitive
to structural and functional changes in the small airways <2mm.31 Taken together, the
work presented in this thesis and previous work of others using hyperpolarized 3He and
129

Xe MRI provides a strong foundation for the use of MRI in asthma research and clinical

care. To accelerate clinical translation and regulatory approval of hyperpolarized gas MRI,
studies must be performed to validate MRI-derived measurements of ventilation against
clinical gold-standards, such as FEV1.
We have performed preliminary analysis in a small proof-of-concept study in which
spirometry, hyperpolarized 3He MRI and a methacholine challenge were performed in a
single visit. We wanted to evaluate and compare the performance of FEV1 and 3He MRI
VDP to discriminate:
1. Patients with a clinical diagnosis of asthma from healthy volunteers
2. Patients with and without bronchial hyperresponsiveness
We speculated that MRI ventilation defects may be a more accurate predictor of asthma
and bronchial hyperresponsiveness than FEV1. Preliminary data was obtained for 34
subjects (Asthma: n=25, Healthy: n=9) who performed spirometry, hyperpolarized 3He
MRI, and a methacholine challenge during a single study visit.

Receiver-operating

characteristic (ROC) curves were used to characterize the performance of FEV1 and MRI
VDP as predictors of asthma and bronchial hyperresponsiveness (Figure 6-1). Optimum
diagnostic cut-offs were determined according to the maximum Youden’s index value
(J=sensitivity+specificity-1) and the corresponding sensitivity, specificity, positive and
negative likelihood ratios were calculated.
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As shown in Figure 6-1, similar to FEV1, MRI measurements of ventilation discriminated:
1) patients with a clinical diagnosis of asthma from healthy volunteers (AUCFEV1=0.82,
p=0.006; AUCMRI

VDP=0.79,

hyperresponsiveness

p=0.01); and 2) patients with and without bronchial

(AUCFEV1=0.83,

p=0.0009;

AUCMRI

VDP=0.88,

p=0.0002).

Importantly, estimated likelihood ratios suggested that the most accurate diagnosis of
asthma and bronchial hyperresponsiveness was established using 3He MRI, not FEV1.
These preliminary results validated functional MRI against FEV1, a clinically-accepted
measurement of asthma, and this is a necessary step towards clinical translation and
regulatory approval. As demonstrated in Chapter 2 of this thesis,

129

Xe MRI is more

sensitive to ventilation abnormalities in asthma than 3He MRI. Accordingly, next steps
require a similar but larger scale validation study of 129Xe MRI in asthma.

Figure 6-1 Performance of FEV1 and 3He MRI VDP as predictors of asthma (left plot)
and bronchial hyperresponsiveness (right plot).
Receiver-operating characteristic curves show the sensitivity, specificity and area under
the curve for FEV1 (solid black line) and 3He MRI VDP (broken blue line).
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6.4.2

Efficacy of Functional MRI Guided Bronchial Thermoplasty

We now have an understanding of the underlying structural determinants of regional
ventilation defects observed using MRI in asthma. The proof-of-concept results presented
in Chapter 4 strongly support the notion that MRI ventilation defects are directly related to
abnormally remodeled airways that are regionally heterogeneous in the asthmatic lung.
Therefore, we speculate that abnormally remodeled airways, proximal to MRI ventilation
defects, may be excellent targets for localized asthma treatment. In a similar fashion,
normally functioning airways, proximal to well or normally-ventilated lung regions could
be avoided during localized treatment. Current asthma treatments aim to treat all accessible
airways.
Bronchial thermoplasty (BT), an established localized asthma treatment, aims to
permanently reduce smooth muscle mass in the lobar and segmental bronchi with the goal
of improving symptoms and asthma control.32 To date, the effectiveness and safety of BT
has been evaluated in four clinical trials,33-36 and this work has demonstrated persistent
improvement in asthma control, quality-of-life and fewer exacerbations following
treatment in some patients. Despite its demonstrated safety and efficacy, BT is a timeconsuming procedure. The current conventional whole-lung treatment approach targets all
accessible airways throughout the lungs during three bronchoscopy sessions, each
separated by approximately three weeks. Accordingly, the treatment assumes that all
airways in the asthmatic lung are homogeneously remodeled, which may result in treatment
of normally functioning airways. If a personalized, image-guided treatment approach were
to be adopted that targeted only abnormally functioning airways, treatment time, cost and
adverse effects might be reduced while patient outcomes may be improved.
In a study currently underway, we aim to use pulmonary functional MRI to guide BT
treatment, evaluate BT treatment response and to generate new knowledge required to
better understand airway-targeted therapy in severe asthma. All participants will have
severe asthma and will undergo up to three pre-therapy MRIs to evaluate ventilation
reproducibility and post-prednisone effects, and there will also be two longitudinal posttherapy MRIs to evaluate treatment effect. All participants will be randomized to MRIdirected or conventional BT and we will measure airway function and treatment response
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using conventional and imaging tests as well as questionnaires that capture how well
asthma is controlled and how patients are feeling.
For those participants randomized to the MRI-directed treatment arm, patient-specific BT
treatment plans will be developed to identify specific airways to be targeted during a singlesession BT treatment procedure. Briefly, low-dose thoracic CT will be used to generate a
detailed three-dimensional model of the airway tree. Following CT, all subjects will
undergo further MR imaging following methacholine challenge or salbutamol inhalation.
As shown for a representative subject in Figure 6-2, the post-challenge MRI will be coregistered to the low-dose CT with airway rendering to enable spatial comparisons between
ventilation defects and airways. Patient-specific treatment plans will identify target
airways, prioritized in order of importance and grouped by lobe to be targeted. Airways
demonstrating dynamic or static bronchoconstriction will be targeted based on their spatial
proximity to ventilation defects.

Figure 6-2 Spatial relationship between 3He MRI ventilation (blue), ventilation defects
(green) and airways (yellow) for a representative subject with severe asthma three days
prior to BT while on 50 mg of prednisone.
3
He MRI registered to the CT of the thorax (in grey-scale) with the airways segmented in
yellow to identify airways demonstrating dynamic bronchoconstriction following
methacholine challenge to be targeted for treatment based on their spatial proximity to
ventilation defects.
This study will address the following research questions:
1) Do regional ventilation defects resolve following BT?
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2) What is the relationship between ventilation defects and patient outcomes following
BT?
3) Can MRI-guided BT treatment to specific abnormal airways result in improved
asthma control and quality-of-life?
4) Are patient outcomes related to image-guided BT significantly different than those
achieved using the conventional treatment approach?
5) Can MRI identify characteristic ventilation defects that predict BT response?
One functional MRI study, evaluating seven severe asthmatics, has provided promising
preliminary evidence supporting the notion that MRI ventilation defects decrease after BT
treatment.37 Our study will be the first to evaluate the effect of a localized airway
intervention on regional ventilation visualized using MRI in asthma. The use of functional
MRI in this context will provide a better understanding of BT treatment, providing a
foundation of knowledge for studies aimed at assessing the ability of imaging methods to
guide localized treatment to only abnormally-functioning airways. We hypothesize that
treatment of only specific abnormal airways, proximal to MRI ventilation defects, will
result in improved MRI gas distribution, airway hyperresponsiveness, asthma control and
quality-of-life that is not significantly different from patients in the conventional therapy
group. We also hypothesize that improved ventilation will be related to improvements in
well-established clinical measurements of asthma.

6.4.3

Imaging
Exercise-induced
and
Methacholine-induced
Bronchoconstriction using Hyperpolarized Gas MRI: Same
Ventilation Defects or Not?

Airway hyperresponsiveness is a universal defining feature of asthma.38 It is currently
measured clinically to aid in the diagnosis and management of asthma, and is often
employed in clinical trials to evaluate the effectiveness of novel asthma therapies. Airway
hyperresponsiveness can be assessed using both direct and indirect stimuli which induce
bronchoconstriction via different mechanistic pathways; however, these differences are
poorly understood.39 A better understanding of airway hyper-responsiveness and the
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mechanisms that contribute to this process in asthma is required to achieve better patient
outcomes.
3

He MRI has been used to visualize regionally heterogeneous ventilation in response to

both exercise-23 and methacholine-induced22,23 bronchoconstriction, suggesting that not all
airways respond to provocation equally.

However, the spatial relationship between

exercise- and methacholine-induced ventilation defects has not been investigated in the
same asthmatics. In other words, it is currently unknown if the same airways in asthma
respond in a similar manner to both indirect and direct stimuli. It has been hypothesized
that clinical assessments of airway hyperresponsiveness induced by indirect methods
correlate better with the clinical features of asthma.40 This hypothesis has not been tested
using MRI, therefore it is unknown whether indirect or direct stimuli induced ventilation
defects correlate more strongly with the clinical features of asthma. If non-invasive
imaging measurements are going to be used as intermediate endpoints in clinical trials of
new therapies, we think future MRI studies should investigate these concepts.
By acquiring pulmonary CT and well-established clinical measurements of asthma in
addition to performing MRI following both exercise and methacholine challenge in the
same asthmatics, the following research questions can be addressed:
1) Are MRI ventilation defects observed in the same focal lung regions following
exercise- and methacholine-induced bronchoconstriction in asthma?
2) Are exercise- or methacholine-induced MRI ventilation defects more strongly
correlated with well-established clinical measurements of asthma?
3) Are CT-derived measurements of airway structure different for those airways
proximal to ventilation defects observed following methacholine and exercise
induced bronchoconstriction?
Comparative imaging studies have the potential to provide a better understanding of the
underlying mechanisms involved in airway hyperresponsiveness, and in turn provide a
better understanding of potential treatment targets in asthma. So far at our centre, four
asthmatics have undergone MR imaging prior to and following both exercise- and
methacholine-induced bronchoconstriction.
asthmatics is shown in Figure 6-3.

Imaging results from one of the four

Preliminary data suggests that exercise and
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methacholine-induced bronchoconstriction will induce a similar decrease in wellestablished clinical measurements of asthma; however, visually obvious regional
differences in gas distribution will be observed using MRI that cannot be detected by
spirometry.

Figure 6-3 Representative coronal centre slice hyperpolarized 3He MRI of an asthmatic
subject at baseline and following both methacholine and exercise-induced
bronchoconstriction.
3
He MRI gas distribution (in blue) registered to the 1H MRI of the thorax (in grey-scale).
Ventilation abnormalities are present at baseline that become worse following
methacholine- and exercise-induced bronchoconstriction.

6.4.4

Functional MRI of Asthma: Alternative Approaches

It is well-established that direct visualization of the lung airspaces using functional MRI is
important and that it and provides numerous advantages over clinically available tools.
Motivating the work presented in Chapter 2, 3He MRI is not well-suited to be a widely
available clinical tool due to the limited availability of 3He gas.41 This roadblock has
initiated further development of

129

Xe MRI and oxygen enhanced MRI,42 as well as

motivated the need for alternative approaches to visualize lung function using nonpolarized inhaled gases and 1H MRI. These emerging methods come with tradeoffs
regarding cost, access and importantly, image quality.
Fluorine-19 (19F) MRI of the lungs uses inert fluorinated gases (e.g. tetrafluoromethane
(CF4), sulfur hexafluoride (SF6), perfluoropropane (C3F8 or PFP)) and may offer
comparable regional lung function information to hyperpolarized gas MRI, but at a much
lower cost.43-46 This approach to functional lung imaging has the advantage of using gases
that are inexpensive, abundant and do not need to be polarized prior to their use. Halaweish
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and colleagues have been the first to apply this approach in patients with asthma,
demonstrating its sensitivity to ventilation defects in two subjects.44
Free-breathing pulmonary 1H MRI is another approach currently being developed with the
ability to evaluate lung function.47-50 Fourier decomposition of the 1H signal intensity
acquired during tidal breathing was introduced by Bauman and colleagues to generate
ventilation and perfusion images.47 This unique approach does not require a contrast agent
and can be implemented on the majority of clinical scanners without the requirement for
specialized multi-nuclear hardware; however, it is limited by cumbersome post-processing.
Unlike 19F MRI, this approach has not yet been evaluated in patients with asthma.
With these promising alternative functional MRI approaches in the pipeline, future studies
are required to investigate their utility in the asthmatic population. Specifically, initial
investigations should be focused towards direct qualitative and quantitative comparisons
of ventilation abnormalities derived from these alternative approaches with those identified
using hyperpolarized gas MRI.

Such proof-of-concept demonstrations are currently

underway in COPD51 and should be emulated in asthma. One major advantage of these
alternative functional MRI approaches is their direct translational ability as they can be
implemented in most medical imaging centres with access to a clinical MRI scanner. This
advantage is fundamentally important, making these alternative functional MRI
approaches more likely to find a place in the clinical setting.

6.5

Significance and Impact

Even though it is well-understood that FEV1 does not reflect the regional nature of asthma,
the assessment of novel therapies and disease management continues to depend on this
global metric. Using hyperpolarized gas MRI, heterogeneous ventilation defects are
observed and the regional, patient-specific nature of asthma can be safely and noninvasively visualized – providing information that is not available using alternative clinical
methods.

This thesis significantly advances our understanding of the structural

determinants of MRI ventilation defects identified in asthma and what it means clinically
to be an asthmatic with ventilation defects. The studies presented in this thesis provide
strong evidence that ventilation defects in asthma are not random, but are heterogeneously
distributed in the lungs, spatially related to airway abnormalities and are related to worse
176

clinical characteristics of asthma including airway hyperresponsiveness, airway
inflammation, airflow obstruction and disease control. It is also now well-understood that
129

Xe MRI is more sensitive to airway abnormalities in asthma than 3He MRI, which is

important for future clinical translation of this imaging method beyond specialized
academic centres.
This thesis confirms that regional ventilation defects are a clinically relevant imagingbased biomarker of asthma and provides a foundation of knowledge supporting the need
for clinical integration of functional MRI.

Armed with this understanding, there is

enormous potential for MRI ventilation defects to be used as intermediate endpoints of
asthma that can be used to evaluate novel treatments and to better inform treatment
decisions. Furthermore, the development of novel asthma treatments may be directed
towards focal ventilation defects. Hence, there is the potential for functional MRI to guide
validated localized airway treatments, such as bronchial thermoplasty, to abnormal airways
that lead to ventilation defects. These advances in our understanding of asthma may very
likely impact asthma management and how new treatment will be developed and evaluated.
By “seeing” asthma and how it regionally responds to treatment and provocation, and how
it changes over time, there is increased potential for more effective treatments, reduced
treatment time, and improved patient outcomes.
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Imaging of Asthma: Pre- and Post-Salbutamol. London Imaging Discovery Day,
London, Ontario, Canada (06/12)
7. S Svenningsen*, M Kirby, D Starr, HO Coxson, NAM Paterson, DG McCormack
and G Parraga. Asthma Airway Morphology and Hyperpolarized 3He Magnetic
Resonance Imaging Ventilation Defects. London Healthy Research Day, London,
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205
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